

From: Hamud, Fozia
Sent: Sunday, April 18, 2004 8:10 AM
To: STIC-Biotech/ChemLib
Subject: sequence search for 09/989725

Kindly search SEQ ID NO:417 of 09/989725 against commercial and interference data bases. Thanks.

Fozia Hamud
Patent Examiner
Art Unit 1647
Remsen: Room 4D64
Mail Box Remsen: 4C70
272-0884

Searcher: _____
Phone: _____
Location: _____
Date Picked Up: *4/19/04*
Date Completed: *4/20/04*
Searcher Prep/Review: _____
Clerical: _____
Online time: _____

TYPE OF SEARCH: /
NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)
STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: *104*
WWW/Internet: _____
Other (specify): _____



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 119643

TO: Fozia Hamud
Location: REM/4D64/4C70
Art Unit: 1647
Tuesday, April 20, 2004

Case Serial Number: 09/989725

From: Edward Hart
Location: Biotech-Chem Library
REM-1A55
Phone: 571-272-2512

edward.hart@uspto.gov

Search Notes

Examiner Hamud,

Here are the results of the search you requested.

Please feel free to contact me if you have any questions.

Edward Hart

GenCore version 5.1.6
 Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2004, 01:40:55 ; Search time 692 Seconds

(without alignments)

10608.217 Million cell updates/sec

Title: US-09-989-725-417

Perfect score: 1728

Sequence: 1 cagccggtcacaggctgt.....aaatttttggaaaatcaa 1728

Scoring table: IDENTITY_NUC
 GAPOP 10.0 , Gapext 1.0

Searched: 3373863 seqs, 2124093041 residues

Total number of hits satisfying chosen parameters:

6747726

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database : N_Geneseq_29Jan04:*

1: GeneseqN1980s:*

2: GeneseqN1990s:*

3: GeneseqN2000s:*

4: GeneseqN2001s:*

5: GeneseqN2002s:*

6: GeneseqN2003s:*

7: GeneseqN2003s:*

8: GeneseqN2003s:*

9: GeneseqN2003s:*

10: GeneseqN2004s:*

ALIGNMENTS

RESULT 1
 AAZ65108 standard; cDNA; 1728 BP.
 ID AAZ65108
 XX AC
 XX DT
 05-APR-2000 (first entry)

XX
 DB Membrane-bound protein PRO1375 encoding cDNA.
 KW Membrane-bound polypeptide; PRO Polypeptide; LDL receptor; TIE ligand;
 KW Pharmaceutical; receptor immunoadhesin; gene mapping; SS.
 XX
 OS Homo sapiens.
 XX
 PN WO953088-A2.
 XX
 PD 09-DEC-1999.
 XX
 PR 02-JUN-1999; 99WO-US012252.

PR 02-JUN-1999; 99US-0081607P.
 PR 02-JUN-1998; 98US-0081609P.
 PR 02-JUN-1998; 98US-0081759P.
 PR 03-JUN-1998; 98US-0081827P.
 PR 04-JUN-1998; 98US-008021P.
 PR 04-JUN-1998; 98US-008025P.
 PR 04-JUN-1998; 98US-008028P.
 PR 04-JUN-1998; 98US-008029P.
 PR 04-JUN-1998; 98US-008030P.
 PR 04-JUN-1998; 98US-008033P.
 PR 04-JUN-1998; 98US-008036P.
 PR 04-JUN-1998; 98US-008032P.
 PR 05-JUN-1998; 98US-008167P.
 PR 05-JUN-1998; 98US-008020P.
 PR 05-JUN-1998; 98US-008212P.
 PR 05-JUN-1998; 98US-008217P.
 PR 09-JUN-1998; 98US-008365P.
 PR 10-JUN-1998; 98US-008722P.
 PR 10-JUN-1998; 98US-0088330P.
 PR 10-JUN-1998; 98US-0088734P.
 PR 10-JUN-1998; 98US-0088738P.
 PR 10-JUN-1998; 98US-0088740P.
 PR 10-JUN-1998; 98US-0088741P.
 PR 10-JUN-1998; 98US-0088742P.
 PR 10-JUN-1998; 98US-0088810P.
 PR 10-JUN-1998; 98US-0088811P.

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	100.0	1728	3	AAZ65108		AAZ65108 Membrane-bound protein PRO1375 encoding cDNA.
2	100.0	1728	4	AAC91568		AAC91568 Human PRO
3	100.0	1728	4	AAT30062		AAT30062 Human cDNA
4	100.0	1728	5	AAC91485		AAC91485 Human PRO
5	100.0	1728	5	AAF44254		AAF44254 Human PRO
6	100.0	1728	7	ABX77979		ABX77979 Human PRO
7	100.0	1728	7	ABX80391		ABX80391 Novel human cDNA
8	100.0	1728	7	ACB69297		ACB69297 Human sec cDNA
9	100.0	1728	7	ABX90368		ABX90368 Human sec cDNA
10	100.0	1728	7	ABX64214		ABX64214 cDNA enco
11	100.0	1728	7	ACB64436		ACB64436 Novel human cDNA enco
12	100.0	1728	7	ACB58005		ACB58005 cDNA enco
13	100.0	1728	7	ABX80895		ABX80895 Human sec cDNA enco
14	100.0	1728	7	ACD44404		ACD44404 cDNA enco
15	100.0	1728	7	ABX79575		ABX79575 Human sec cDNA
16	100.0	1728	7	ACB93596		ACB93596 Novel human cDNA
17	100.0	1728	7	ABX81278		ABX81278 Novel human cDNA
18	100.0	1728	7	ACA91094		ACA91094 Novel human cDNA
19	100.0	1728	7	ABX17178		ABX17178 Human PRO
20	100.0	1728	8	ACB68033		ACB68033 Novel human cDNA
21	100.0	1728	8	ACB88482		ACB88482 Human sec cDNA enco
22	100.0	1728	8	ACD81989		ACD81989 cDNA enco
23	100.0	1728	8	ADA37928		ADA37928 Human cDNA

PR	10-JUN-1998;	98US-0088824P.	04-AUG-1998;	94US-0095325P.
PR	10-JUN-1998;	98US-0088825P.	PR	10-AUG-1998;
PR	10-JUN-1998;	98US-0088826P.	PR	10-AUG-1998;
PR	11-JUN-1998;	98US-0088858P.	PR	10-AUG-1998;
PR	11-JUN-1998;	98US-0088861P.	PR	11-AUG-1998;
PR	11-JUN-1998;	98US-0088863P.	PR	11-AUG-1998;
PR	11-JUN-1998;	98US-0088876P.	PR	12-AUG-1998;
PR	12-JUN-1998;	98US-0089090P.	PR	12-AUG-1998;
PR	12-JUN-1998;	98US-0089105P.	PR	17-AUG-1998;
PR	16-JUN-1998;	98US-0089440P.	PR	17-AUG-1998;
PR	16-JUN-1998;	98US-0089512P.	PR	17-AUG-1998;
PR	16-JUN-1998;	98US-0089514P.	PR	17-AUG-1998;
PR	17-JUN-1998;	98US-0089532P.	PR	17-AUG-1998;
PR	17-JUN-1998;	98US-0089538P.	PR	17-AUG-1998;
PR	17-JUN-1998;	98US-0089905P.	PR	17-AUG-1998;
PR	17-JUN-1998;	98US-0089938P.	PR	17-AUG-1998;
PR	17-JUN-1998;	98US-00899440P.	PR	17-AUG-1998;
PR	17-JUN-1998;	98US-00899447P.	PR	17-AUG-1998;
PR	19-JUN-1998;	98US-0089947P.	PR	19-AUG-1998;
PR	19-JUN-1998;	98US-0089948P.	PR	20-AUG-1998;
PR	19-JUN-1998;	98US-0089953P.	PR	18-AUG-1998;
PR	18-JUN-1998;	98US-0089901P.	PR	18-AUG-1998;
PR	18-JUN-1998;	98US-0089907P.	PR	18-AUG-1998;
PR	22-JUN-1998;	98US-0089908P.	PR	18-AUG-1998;
PR	22-JUN-1998;	98US-00899147P.	PR	19-AUG-1998;
PR	23-JUN-1998;	98US-00899147P.	PR	19-AUG-1998;
PR	24-JUN-1998;	98US-0089946P.	PR	24-AUG-1998;
PR	22-JUN-1998;	98US-0090252P.	PR	26-AUG-1998;
PR	22-JUN-1998;	98US-0090254P.	PR	26-AUG-1998;
PR	23-JUN-1998;	98US-0090349P.	PR	26-AUG-1998;
PR	23-JUN-1998;	98US-0090355P.	PR	26-AUG-1998;
PR	24-JUN-1998;	98US-0090429P.	PR	26-AUG-1998;
PR	24-JUN-1998;	98US-0090431P.	PR	26-AUG-1998;
PR	24-JUN-1998;	98US-0090435P.	PR	26-AUG-1998;
PR	24-JUN-1998;	98US-0090444P.	PR	26-AUG-1998;
PR	24-JUN-1998;	98US-0090445P.	PR	26-AUG-1998;
PR	24-JUN-1998;	98US-0090461P.	PR	26-AUG-1998;
PR	24-JUN-1998;	98US-0090472P.	PR	31-AUG-1998;
PR	24-JUN-1998;	98US-0090535P.	PR	16-SEP-1998;
PR	24-JUN-1998;	98US-0090538P.	PR	12-JAN-1999;
PR	24-JUN-1998;	98US-0090540P.	XX	99US-0115563P.
PR	25-JUN-1998;	98US-0090547P.	XX	99US-0115563P.
PR	25-JUN-1998;	98US-0090676P.	PA	PA
PR	25-JUN-1998;	98US-0090678P.	PA	PA
PR	25-JUN-1998;	98US-0090688P.	PA	PA
PR	25-JUN-1998;	98US-0090690P.	PA	PA
PR	01-JUL-1998;	98US-0090691P.	PA	PA
PR	02-JUL-1998;	98US-0091478P.	PA	PA
PR	02-JUL-1998;	98US-0091486P.	PA	PA
PR	02-JUL-1998;	98US-0091519P.	PA	PA
PR	02-JUL-1998;	98US-0091544P.	PA	PA
PR	02-JUL-1998;	98US-0091626P.	PA	PA
PR	02-JUL-1998;	98US-0091628P.	PA	PA
PR	02-JUL-1998;	98US-0091633P.	PA	PA
PR	02-JUL-1998;	98US-0091646P.	PA	PA
PR	07-JUL-1998;	98US-0091978P.	PA	PA
PR	07-JUL-1998;	98US-0091982P.	PA	PA
PR	09-JUL-1998;	98US-0092182P.	PA	PA
PR	10-JUL-1998;	98US-0092472P.	PA	PA
PR	30-JUL-1998;	98US-009339P.	PA	PA
PR	30-JUL-1998;	98US-0094651P.	PA	PA
PR	04-AUG-1998;	98US-0095282P.	PA	PA
PR	04-AUG-1998;	98US-0095301P.	PA	PA
PR	04-AUG-1998;	98US-0095302P.	PA	PA
PR	04-AUG-1998;	98US-0095316P.	PA	PA
PR	04-AUG-1998;	1. CAGCCGGTCTCAAGCTGTC.	PA	PA
PR	04-AUG-1998;	Query Match 100.0%;	PA	PA
PR	Best Local Similarity 100.0%;	PA	PA	
PR	Matches 1728; Conservative 0	PA	PA	
PR	Sequence 1728 BP; 438 A; 360 C	PA	PA	

Db	601	CAACGGCTGAAACAGGTAGAATATGCCAACGGCAGGCTGGAGCTCAAGTCAGAGCA	660	
QY	661	GCGAAAGTCTGTTTGACCGGGATGTGCTTCAGCTAATGGGAATGATTCAAGGT	720	
Db	661	GCGDAGGTGTTGGGGATGGGATGTTGCTCACTTGGATGATTCAAGGT	720	
QY	721	GACTAGAAGAAACGGGAGAACCTGGAAAGAACCTGCTGGTTCTAGTAACTGGATGATTCAAGGT	780	
Db	721	GACTAGAAGAAACGGGAGAACCTGGAAAGAACCTGCTGGTTCTAGTAACTGGATGATTCAAGGT	780	
QY	781	TAAATACCTTGTGATTTCACCATGTTGAACTTGCGGAGATTCACAGGAAACACT	840	
Db	781	TAAATACCTTGTGATTTCACCATGTTGAACTTGCGGAGATTCACAGGAAACACT	840	
QY	841	TGCTTGATTTTTCTCTGTAAACGPAATAATAGACAATTTAAAGGACACAGCTC	900	
Db	841	TGCTTGATTTTTCTCTGTAAACGPAATAATAGACAATTTAAAGGACACAGCTC	900	
QY	901	AAAGTCACCCATAAGTGTTCCTTACCTTGACTCTTAACTATAATAATCTGCCT	960	
Db	901	AAAGTCACCCATAAGTGTTCCTTACCTTGACTCTTAACTATAATAATCTGCCT	960	
QY	961	GTAAATTATCTGAAGTCCTTACCTGGAAACAGCACTCTCTTACCAACATAGTTT	1020	
Db	961	GTAAATTATCTGAAGTCCTTACCTGGAAACAGCACTCTCTTACCAACATAGTTT	1020	
QY	1021	AACCTGACTTTCAAGATAATTTCAGGGTTTGTGTGTGTGTGTGTGTGTGT	1080	
Db	1021	AACCTGACTTTCAAGATAATTTCAGGGTTTGTGTGTGTGTGTGTGTGTGT	1080	
QY	1081	TTCGGGGAGAGGGGGATGCTGGGGAGGGTAAACAACTTTCAAGTCACCTTA	1140	
Db	1081	TTCGGGGAGAGGGGGATGCTGGGGAGGGTAAACAACTTTCAAGTCACCTTA	1140	
QY	1141	CRAAACAAACTTTGTAAATAAGACCTTACCCCTTCACTTTCAGTTTCATTTGC	1200	
Db	1141	CRAAACAAACTTTGTAAATAAGACCTTACCCCTTCACTTTCAGTTTCATTTGC	1200	
QY	1201	AGTGTAGGCGCTCATAAAGCTCACTCACTCATGGCTGTTCTGACTGACTGTT	1260	
Db	1201	AGTGTAGGCGCTCATAAAGCTCACTCACTCATGGCTGTTCTGACTGACTGTT	1260	
QY	1261	ATCTGGGATCTGTCTGACTTTACTCTAAAGCTAAATGGCTGGTGGCT	1320	
Db	1261	ATCTGGGATCTGTCTGACTTTACTCTAAAGCTAAATGGCTGGTGGCT	1320	
QY	1321	TTCGACAAAAAGAGATTTCTCATGACTGTGATCTGATGCAATCTAGAAC	1380	
Db	1321	TTCGACAAAAAGAGATTTCTCATGACTGTGATCTGATGCAATCTAGAAC	1380	
QY	1381	AAACTGGCCATTGCTGACTTTACTCTAAAGCTAAATGCTGGTGGCTGCTT	1440	
Db	1381	AAACTGGCCATTGCTGACTTTACTCTAAAGCTAAATGCTGGTGGCTGCTT	1440	
QY	1441	ACATCATCTCTGACTCTGACTCTGACTCTGACTCTGACTCTGACTCTGACT	1500	
Db	1441	ACATCATCTCTGACTCTGACTCTGACTCTGACTCTGACTCTGACTCTGACT	1500	
QY	1501	ATTTATTTAAACCCAGCTCCCTGATGATAATAATACACATTTGTCAGATTC	1560	
Db	1501	ATTTATTTAAACCCAGCTCCCTGATGATAATAATACACATTTGTCAGATTC	1560	
QY	1561	GGTCGTTGTTGAGGGCTGTTGAGCTCAATATGGAGCTTGAACTAGGGCTGG	1620	
Db	1561	GGTCGTTGTTGAGGGCTGTTGAGCTCAATATGGAGCTTGAACTAGGGCTGG	1620	
QY	1621	GGTGTGGCTGCTCTGGAAATGTTGAACTTGGATTTGGCTTCTTCTTCC	1680	
Db	1621	GGTGTGGCTGCTCTGGAAATGTTGAACTTGGATTTGGCTTCTTCTTCC	1680	
QY	1681	TATCTCCCTTGGAAATGTTGAACTTGGATTTGGCTTCTTCTTCC	1728	
Db	1681	TATCTCCCTTGGAAATGTTGAACTTGGATTTGGCTTCTTCTTCC	1728	

(GETH) GENENTECH INC.

RESULT 4
 AAC1485 standard; cDNA; 1728 bp.
 XX
 AAC1485;
 AC
 XX
 DT 21-MAR-2001 (first entry)
 XX
 DE Human PRO1375 cDNA.
 XX
 Human; PRO; antiinflammatory; dermatological; antiarthritic;
 KW antirheumatic; cardiotonic; antianemic; immunosuppressive; antithyroid;
 KW antidiabetic; nootropic; neuroprotective; hepatotropic; virucide;
 KW antiallergic; antilasthma; immune related disorder;
 KW hepatopathy; autoimmune disease; allergy; ss.
 XX
 Homo sapiens.
 XX
 WO200073452-A2.

PD 07-DEC-2000.

XX

XX

XX

XX

XX

02-JUN-2000; 2000WO-US015264.

PR 02-JUN-1999;

PR 02-JUL-1999;

The present sequence is one of thirty three nucleic acids encoding PRO polypeptides. The PRO polypeptides, anti-PRO antibodies, agonists and antagonists are useful for treating and diagnosing immune related disorders such as systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis, idiopathic inflammatory myopathies, Sjögren's syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal disease, demyelinating diseases of the central and peripheral nervous systems (such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barre syndrome, and chronic inflammatory demyelinating polyradiculoneuropathy), hepatobiliary diseases (such as infectious, autoinflammatory chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis and sclerosing cholangitis), inflammatory bowel disease, gluten-sensitive enteropathy and Whipple's disease, autoimmune or immune-mediated skin diseases (such as bullous skin diseases, erythema multiforme, contact dermatitis, psoriasis), allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticarial, immunological diseases of the lung (such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis), transplantation associated diseases including graft rejection and graft-versus-host diseases

Sequence 1728 BP: 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;

Query Match 100.0%; Score 1728; DB 5; Length 1728;

Best Local Similarity 100.0%; Pred. No. 0; Matches 1728; Conservative 0; Indels 0; Gaps 0;

Qy	1	CAGCGCCCTCCAAAGCCTGCTGCCCTGACCTCTGAGCCCTGAGCCGCCGAGCC	60	Db	1	CAGCGGGCTCCAAAGCCTGCTGCCCTGACCTCTGAGCCGCCGAGCC	60	Qy	61	GCTGCGGCGGGCTCCGCGCTCGCGAGCGCTGGCGGCCGAGCGCTGGCGGCCGAGCC	120	Db	61	GCTGCGGCGGCCTCAAGCTGCTGCCCTGAGCCGCCGAGCGCTGGCGGCCGAGCC	120	Qy	121	AGGCCTTTCGCTTCTGCTCTGCTCTGCTCTGCTCTGCTCTGCTCTGCT	180	Db	121	AGGCCTTTCGCTTCTGCTCTGCTCTGCTCTGCTCTGCTCTGCTCTGCT	180	Qy	181	GCTGGCGAGCTGTCAGGCCCTGAGAATTGCGGATTCGCTGTAATGATCTG	240	Db	181	GCTGGCGAGCTGTCAGGCCCTGAGAATTGCGGATTCGCTGTAATGATCTG	240	Qy	241	CCCTCCCTATAAGAAAATTCTGGCATATTATAAGAACATCTCGAAAGATG	300	Db	241	CCCTCCCTATAAGAAAATTCTGGCATATTATAAGAACATCTCGAAAGATG	300	Qy	301	TGATTCGCTTCATGTCAGGGCTGCTGTGAGGCTACATG	360	Db	301	TGATTCGCTTCATGTCAGGGCTGCTGTGAGGCTACATG	360	Qy	361	TCTACAGCTGTAATGCAAAATAGAAAGAAAGCTCTGTCACAATCAAGGTTACATTAT	420	Db	361	TCTACAGCTGTAATGCAAAATAGAAAGAAAGCTCTGTCACAATCAAGGTTACATTAT	420	Qy	421	AATTATTCCTCATTTGGCCCTTCATCTTGATGTTATCTACTCTGGTGA	480	Db	421	AATTATTCCTCATTTGGCCCTTCATCTTGATGTTATCTACTCTGGTGA	480	Qy	481	GCCCCATCTGAAAGGGCCCTCTTGGCATGCACTTGATGAGGCTACATG	540	Db	481	GCCCCATCTGAAAGGGCCCTCTTGGCATGCACTTGATGAGGCTACATG	540	Qy	541	TGGGATACAGGCTTTCGAAATGCAAGCAGTGGCTCCGAGTCAGC	600	Db	541	TGGGATACAGGCTTTCGAAATGCAAGCAGTGGCTCCGAGTCAGC	600	Qy	601	CAACGTGCTGAACTGGAGAAATGCAAGCAGTCAGTCAAAGCA	660	Db	601	CAACGTGCTGAACTGGAGAAATGCAAGCAGTCAGTCAAAGCA	660
----	---	---	----	----	---	--	----	----	----	--	-----	----	----	--	-----	----	-----	--	-----	----	-----	--	-----	----	-----	--	-----	----	-----	--	-----	----	-----	--	-----	----	-----	--	-----	----	-----	--	-----	----	-----	--	-----	----	-----	---	-----	----	-----	---	-----	----	-----	--	-----	----	-----	--	-----	----	-----	--	-----	----	-----	--	-----	----	-----	--	-----	----	-----	--	-----	----	-----	--	-----	----	-----	--	-----

Qy	661	GGGAAGTGTGCTTGTACCTGGGATGTTGACCTCAGCTAATGGAAATTGAAATTCAAGGT	720	Db	661	GGGAAGTGTGCTTGTACCTGGGATGTTGACCTCAGCTAATGGAAATTCAAGGT	720
Qy	721	GACTGAAGAAACAGGAGCACTGAAAGAAGCTGACTGCTGGTTTCTGGCTTCATT	780	Db	721	GACTGAAGAAACAGGAGCACTGAAAGAAGCTGACTGCTGGTTTCTGGCTTCATT	780
Qy	781	TTAAATACCTGTTGATTCACCAACTGTTGCTGAAGATTCAAACCTGAAAGAAACT	840	Db	781	TTAAATACCTGTTGATTCACCAACTGTTGCTGAAGATTCAAACCTGAAAGAAACT	840
Qy	841	TGCCTGATTTTCTPCTGTTAACGTTAAATAGAGACATTTTAAAGCAACAGTC	900	Db	841	TGCCTGATTTTCTPCTGTTAACGTTAAATAGAGACATTTTAAAGCAACAGTC	900
Qy	901	GTAAATTAACTGAACTCTTACCTAAATTAATTCGCTTACTAAATAATAATTCGCT	960	Db	901	GTAAATTAACTGAACTCTTACCTAAATTAATTCGCTTACTAAATAATAATTCGCT	960
Qy	961	GTAAATTAACTGAACTCTTACCTGAAACAGCACTCTCCTTACCACTAGTTT	1020	Db	961	GTAAATTAACTGAACTCTTACCTGAAACAGCACTCTCCTTACCACTAGTTT	1020
Qy	1021	AACCTGACTTCAGATAATTTCGGTTTCTGCTTGTGTTTGTGTTTGTGTTTGT	1080	Db	1021	AACCTGACTTCAGATAATTTCGGTTTCTGCTTGTGTTTGTGTTTGTGTTTGT	1080
Qy	1081	TTGGTGGGAGGGAGGGATGCTGGAAAGTGTAAACACTTTCAAGTCCTTA	1140	Db	1081	TTGGTGGGAGGGAGGGATGCTGGAAAGTGTAAACACTTTCAAGTCCTTA	1140
Qy	1141	CTAAACAAACTTTGAAATAGACCTTACCTTCTATTTGCACTTCAATTATTTG	1200	Db	1141	CTAAACAAACTTTGAAATAGACCTTACCTTCTATTTGCACTTCAATTATTTG	1200
Qy	1201	AGTGTAGCCAGCCTCAAGCTGACTTCACTATTGACTGTACTGTT	1260	Db	1201	AGTGTAGCCAGCCTCAAGCTGACTTCACTATTGACTGTACTGTT	1260
Qy	1261	ATCGGGTATCTGGCTGCTGCACTTCATGACTGATGCTGCTGCTGCTG	1320	Db	1261	ATCGGGTATCTGGCTGCTGCACTTCATGACTGATGCTGCTGCTGCTG	1320
Qy	1321	TTTCACAAAAAGCAGATTTCCTCATGACTGATGCTGCTGCTGCTGCTG	1380	Db	1321	TTTCACAAAAAGCAGATTTCCTCATGACTGATGCTGCTGCTGCTGCTG	1380
Qy	1381	AAACTGGCATTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1440	Db	1381	AAACTGGCATTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1440
Qy	1441	ACTCATCTCTGACTGATGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1500	Db	1441	ACTCATCTCTGACTGATGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1500
Qy	1501	ATTTATTTAAACCAAGCCTCCCTGGATATATAACATTTGCACTTTC	1560	Db	1501	ATTTATTTAAACCAAGCCTCCCTGGATATATAACATTTGCACTTTC	1560
Qy	1561	CGGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1620	Db	1561	CGGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1620
Qy	1621	GGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1680	Db	1621	GGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1680
Qy	1681	TATGCTCTTGTAAATGTAACATAAAATAATTGAAACATCAA	1728	Db	1681	TATGCTCTTGTAAATGTAACATAAAATAATTGAAACATCAA	1728
Qy	1728	TATGCTCTTGTAAATGTAACATAAAATAATTGAAACATCAA	1728	Db	1728	TATGCTCTTGTAAATGTAACATAAAATAATTGAAACATCAA	1728

CC and protein sequence can be used for tissue typing and in treating
CC cancer. Anti-PRO antibodies can be used in diagnostic assays. AAP44270 to
CC AAP4470 represent PCR primers and hybridisation probes used in the
CC isolation of human PRO sequences. AAP44087 to AAP44269 and AAP5154 to
CC AAB61300 represent human PRO polynucleotide and protein sequences given
CC in the exemplification of the present invention.

Qy	901	AAAGTCAGCCATAAAGTCTTTCCATTGNGACTTTACTAATAAAAATAATCTGCC	960	PN	US2003027163-A1.
Db	901	AAAGTCAGCCATAAAGTCTTTCCATTGNGACTTTACTAATAAAAATAATCTGCC	960	XX	XX
Qy	961	GTAATATCTGAAGCTTACCTGGAAAGCCTCTTCAACATAGTTT	1020	PR	15-NOV-2001; 2001US-00997666.
Db	961	GTAATATCTGAAGCTTACCTGGAAAGCCTCTTCAACATAGTTT	1020	PR	16-JUN-1997;
Qy	961	GTAATATCTGAAGCTTACCTGGAAAGCCTCTTCAACATAGTTT	1020	PR	17-OCT-1997;
Db	961	GTAATATCTGAAGCTTACCTGGAAAGCCTCTTCAACATAGTTT	1020	PR	05-NOV-1997;
Qy	1021	AACCTGAACTTAAAGATAATTTCAGGTTTGTGTGTGTGTGT	1080	PR	12-NOV-1997;
Db	1021	AACCTGAACTTAAAGATAATTTCAGGTTTGTGTGTGTGTGT	1080	PR	13-NOV-1997;
Qy	1021	AACCTGAACTTAAAGATAATTTCAGGTTTGTGTGTGTGT	1080	PR	24-NOV-1997;
Db	1021	AACCTGAACTTAAAGATAATTTCAGGTTTGTGTGTGTGT	1080	PR	25-FEB-1998;
Qy	1081	TGGTGGAGGGGAGCTGGAAAGGGTAAACACTTTCAAGTCACTTA	1140	PR	20-MAR-1998;
Db	1081	TGGTGGAGGGGAGCTGGAAAGGGTAAACACTTTCAAGTCACTTA	1140	PR	28-APR-1998;
Qy	1141	CTAACAAACACTTTGTAATGACCTTACCTCTATTATTTGC	1200	PR	07-MAY-1998;
Db	1141	CTAACAAACACTTTGTAATGACCTTACCTCTATTATTTGC	1200	PR	28-JAY-1998;
Qy	1201	AGTGTGACCGACCTCATCAAAGCTCATCTACTCATTTGACTT	1260	PR	02-JUN-1998;
Db	1201	AGTGTGACCGACCTCATCAAAGCTCATCTACTCATTTGACTT	1260	PR	02-JUN-1998;
Qy	1261	ATCTGGGATTCGCTGCTGCTGACTTGTAAATGCCCTGGCC	1320	PR	03-JUN-1998;
Db	1261	ATCTGGGATTCGCTGCTGACTTGTAAATGCCCTGGCC	1320	PR	04-JUN-1998;
Qy	1321	TTCACAAAAGGAGATTCTCATGACTGCTGACTTGTAAAGAA	1380	PR	04-JUN-1998;
Db	1321	TTCACAAAAGGAGATTCTCATGACTGCTGACTTGTAAAGAA	1380	PR	04-JUN-1998;
Qy	1381	AAACTGGGATTTGCTACTTACTCTAAAGACTAAACAATGCTTG	1440	PR	04-JUN-1998;
Db	1381	AACTGGGATTTGCTACTTACTCTAAAGACTAAACAATGCTTG	1440	PR	04-JUN-1998;
Qy	1441	ACTCATCTCTGACTCTTAAAGCAAACTCTAAAGCTGAACTTC	1500	PR	05-JUN-1998;
Db	1441	ACTCATCTCTGACTCTTAAAGCAAACTCTAAAGCTGAACTTC	1500	PR	05-JUN-1998;
Qy	1501	ATTTATTTAACCCAGCCCTCGATGATAATAATACATTTGCACTTC	1560	PR	05-JUN-1998;
Db	1501	ATTTATTTAACCCAGCCCTCGATGATAATAATACATTTGCACTTC	1560	PR	05-JUN-1998;
Qy	1561	CGGTGCGTGTGAGGGCGCTGTTGAGCTCCAATATGCGACTTGG	1620	PR	06-JUN-1998;
Db	1561	CGGTGCGTGTGAGGGCGCTGTTGAGCTCCAATATGCGACTTGG	1620	PR	06-JUN-1998;
Qy	1621	GGTGTGCGTGTGAGGGCGCTGTTGAGCTCCAATATGCGACTTGG	1680	PR	07-JUN-1998;
Db	1621	GGTGTGCGTGTGAGGGCGCTGTTGAGCTCCAATATGCGACTTGG	1680	PR	07-JUN-1998;
Qy	1681	TATTCCTTTGGAAATTAAACATAAAATAATTGGAAACATCA	1728	PR	08-JUN-1998;
Db	1681	TATTCCTTTGGAAATTAAACATAAAATAATTGGAAACATCA	1728	PR	08-JUN-1998;
Qy	1728	ABX77979 standard; cDNA; 1728 bp.		PR	08-JUN-1998;
XX				PR	12-JUN-1998;
AC				PR	22-JUN-1998;
XX				PR	22-JUN-1998;
DT	14-APR-2003	(first entry)		PR	23-JUN-1998;
XX				PR	23-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Homo sapiens.			PR	24-JUN-1998;
OS				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
ABX77979				PR	24-JUN-1998;
ABX77979;				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DT	14-APR-2003	(first entry)		PR	24-JUN-1998;
XX				PR	24-JUN-1998;
DE	Human PRO polymucleotide #32.			PR	24-JUN-1998;
XX				PR	24-JUN-1998;
AC				PR	24-JUN-1998;
XX					

IPR	24-JUN-1998	98US-00905579P-
IPR	25-JUN-1998	98US-0090576P-
IPR	25-JUN-1998	98US-0090578P-
IPR	25-JUN-1998	98US-0090590P-
IPR	25-JUN-1998	98US-0090594P-
IPR	25-JUN-1998	98US-0090595P-
IPR	26-JUN-1998	98US-0090562P-
IPR	26-JUN-1998	98US-0090633P-
IPR	01-JUL-1998	98US-0091260P-
IPR	01-JUL-1998	98US-0091454P-
IPR	02-JUL-1998	98US-0091478P-
IPR	02-JUL-1998	98US-0091519P-
IPR	02-JUL-1998	98US-0091626P-
IPR	02-JUL-1998	98US-0091728P-
IPR	02-JUL-1998	98US-0091633P-
IPR	02-JUL-1998	98US-0091446P-
IPR	02-JUL-1998	98US-0091673P-
IPR	07-JUL-1998	98US-0091778P-
IPR	07-JUL-1998	98US-0091828P-
IPR	09-JUL-1998	98US-0092182P-
IPR	10-JUL-1998	98US-0092472P-
IPR	20-JUL-1998	98US-0093313P-
IPR	30-JUL-1998	98US-0094511P-
IPR	04-AUG-1998	98US-0095222P-
IPR	04-AUG-1998	98US-0095285P-
IPR	04-AUG-1998	98US-0095311P-
IPR	04-AUG-1998	98US-0095312P-
IPR	04-AUG-1998	98US-0095318P-
IPR	04-AUG-1998	98US-0095321P-
IPR	10-AUG-1998	98US-0095315P-
IPR	10-AUG-1998	98US-0095916P-
IPR	10-AUG-1998	98US-0096012P-
IPR	11-AUG-1998	98US-0096113P-
IPR	11-AUG-1998	98US-0096146P-
IPR	12-AUG-1998	98US-0096329P-
IPR	17-AUG-1998	98US-0096717P-
IPR	17-AUG-1998	98US-0096766P-
IPR	17-AUG-1998	98US-0096768P-
IPR	17-AUG-1998	98US-0096773P-
IPR	17-AUG-1998	98US-0096771P-
IPR	17-AUG-1998	98US-0096637P-
IPR	17-AUG-1998	98US-0096781P-
IPR	17-AUG-1998	98US-0096834P-
IPR	17-AUG-1998	98US-0096835P-
IPR	17-AUG-1998	98US-0096837P-
IPR	18-AUG-1998	98US-0096849P-
IPR	18-AUG-1998	98US-0096930P-
IPR	18-AUG-1998	98US-0097141P-
IPR	24-AUG-1998	98US-0097248P-
IPR	26-AUG-1998	98US-0097661P-
IPR	26-AUG-1998	98US-0097952P-
IPR	26-AUG-1998	98US-0097954P-
IPR	31-AUG-1998	98US-0097971P-
IPR	16-SEP-1998	98US-0097974P-
IPR	26-AUG-1998	98US-0097977P-
IPR	16-SEP-1998	98US-01000634P-
IPR	17-SEP-1998	98US-01000855P-
IPR	17-SEP-1998	98US-0097986P-
IPR	16-AUG-1998	98US-0098044P-
IPR	22-DEC-1998	98WO-US01132508-
IPR	05-JAN-1999	99WO-US001016

PR	08-MAR-1999;	99WO-US005028;
PR	12-MAR-1999;	99WO-US012252P;
PR	02-JUN-1999;	99WO-US012252P;
PR	23-JUN-1999;	99US-0141032P;
PR	07-JUL-1999;	99US-0144745P;
PR	20-JUL-1999;	99US-0144751P;
PR	26-JUL-1999;	99US-0145698P;
PR	28-JUL-1999;	99US-0146226P;
PR	17-AUG-1999;	99US-0149396P;
PR	15-SEP-1999;	99WO-US0210509;
PR	15-SEP-1999;	99WO-US0211547;
PR	08-OCT-1999;	99US-0158663P;
PR	30-NOV-1999;	99WO-US028313;
PR	01-DEC-1999;	99WO-US028310;
PR	01-DEC-1999;	99WO-US028634;
PR	16-DEC-1999;	99WO-US028635;
PR	20-DEC-1999;	99WO-US030911;
PR	05-JAN-2000;	2000WO-US000219;
PR	06-JAN-2000;	2000WO-US000376;
PR	11-FEB-2000;	2000WO-US0003565;
PR	18-FEB-2000;	2000WO-US044341;
PR	22-FEB-2000;	2000WO-US004411;
PR	24-FEB-2000;	2000WO-US004914;
PR	24-FEB-2000;	2000WO-US005004;
PR	02-MAR-2000;	2000WO-US005841;
PR	10-MAR-2000;	2000WO-US006319;
PR	15-MAR-2000;	2000WO-US006984;
PR	20-MAR-2000;	2000WO-US007377;
PR	30-MAR-2000;	2000WO-US008439;
PR	15-MAY-2000;	2000WO-US013358;
PR	17-MAY-2000;	2000WO-US013705;
PR	22-MAY-2000;	2000WO-US014042;
PR	30-MAY-2000;	2000WO-US014941;
PR	02-JUN-2000;	2000WO-US015664;
PR	23-JUN-2000;	2000US-US013637;
PR	28-JUL-2000;	2000WO-US020710;
PR	11-AUG-2000;	2000WO-US0202321;
PR	23-AUG-2000;	2000WO-US023522;
PR	24-AUG-2000;	2000WO-US023328;
PR	07-SEP-2000;	2000US-US0230978P.

QY	421 AATTATCTCTCCATTTCGGCCTTCACTCTGACTGGTATCTACTCTGTTGA 480	Db	1501 ATTATTTAACCAAGCTCCCTGGATTGATAATAACATTGTCAAGCATTTTC 1560
Db	421 AATTATCTCTCCATTTCGGCCTTCACTCTGACTGGTATCTACTCTGTTGA 480	Qy	1561 CGGTCTGTGGTGAAGGCASGTGTTGAGCTCCAATATGCGAGTTGAACTAGGCTGG 1620
QY	481 GCCCATATCTGAAAGGGCCTCTTCGACATGACAGTGATAGATGATAT 540	Db	1561 CGGTCTGTGGTGAAGGCAGTGGTGTGTTGAGCTCCAATATGCGAGTTGAACTAGGCTGG 1620
Db	481 GCCCATATCTGAAAGGGCCTCTTCGACATGACAGTGATAGATGATAT 540	Qy	1621 CGGTCTGTGGTGAAGGCAGTGGTGTGTTGAGCTCCAATATGCGAGTTGAACTAGGCTGG 1680
QY	541 TGGGATTAACCAAGCGCTTGTGACATGACAGTGATAGATGATAT 540	Db	1621 CGGTCTGTGGTGAAGGCAGTGGTGTGTTGAGCTCCAATATGCGAGTTGAACTAGGCTGG 1680
Db	541 TGGGATTAACCAAGCGCTTGTGACATGACAGTGATAGATGATAT 540	Qy	1681 TATGCCCTTTGAGTGAACATAATAATAATTGAAACATCAA 1728
QY	601 CAACGGCTGAAACAGGTAGAAATATGCCAACAGCAGCTTAAGTCAAAGCA 660	Db	1681 TATGCCCTTTGAGTGAACATAATAATAATTGAAACATCAA 1728
Db	601 CAACGGCTGAAACAGGTAGAAATATGCCAACAGCAGCTTAAGTCAAAGCA 660	Qy	661 GCGAAAGCTGTCTTGGCCATGTTGACCTGGATGGAAATGGTCAAGGT 720
Db	661 GCGAAAGCTGTCTTGGCCATGTTGACCTGGATGGAAATGGTCAAGGT 720	Db	ABX80391 ID: ABX80391 standard; DNA; 1728 BP.
QY	721 GACTGAAAGAAACGGAGACAACACTGGAAAGAACTGACTGCTGCTGCTTTCATT 780	Qy	XX AC ABX80391;
Db	721 GACTGAAAGAAACGGAGACAACACTGGAAAGAACTGACTGCTGCTGCTTTCATT 780	Db	XX DT 28-APR-2003 (first entry)
QY	781 TTAACTCTGTGATTCAACACTGCTGGCGAAGATTCAACTGGAAACAACT 840	Db	XX DE Novel human secreted or transmembrane protein PRO1385 DNA.
Db	781 TTAACTCTGTGATTCAACACTGCTGGCGAAGATTCAACTGGAAACAACT 840	Qy	XX Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
QY	841 TGCTGTGATTTTTCTGTGATTCAACACTGCTGGCGAAGATTCAACTGGAAACAACT 900	Db	XX KW cardiac insufficiency disorder; cancer; tumour; immune response;
Db	841 TGCTGTGATTTTTCTGTGATTCAACACTGCTGGCGAAGATTCAACTGGAAACAACT 900	Qy	XX KW adrenal cortical capillary endothelial growth; c-fos induction;
QY	901 AAAGTCAGGCAATAAGTGTCTTCTATTGTGACTTTACTATAAAATCTGCT 960	Db	XX KW vascular endothelial growth factor inhibition; VEGF inhibition;
Db	901 AAAGTCAGGCAATAAGTGTCTTCTATTGTGACTTTACTATAAAATCTGCT 960	Qy	XX KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
QY	961 GTAAATTCTGTGAGTCCTTACCTGGACAGCAAGCTCTTTTACCAACATACTTT 1020	Db	XX KW retinal neurons cell survival; rod photoreceptor cell survival;
Db	961 GTAAATTCTGTGAGTCCTTACCTGGACAGCAAGCTCTTTTACCAACATACTTT 1020	Qy	XX KW mammalian kidney mesangial cell proliferation; Berger disease;
QY	1021 AACATGACTTTCAAGATAATTTCAGGGTTTGTGTGTTTGTGTGTT 1080	Db	XX KW dermatis; herpetiformis; Crohn's disease; chondrocyte proliferation;
Db	1021 AACATGACTTTCAAGATAATTTCAGGGTTTGTGTGTTTGTGTGTT 1080	Qy	XX KW chondrocyte proliferation; sports injury; arthritis; gene; ds.
QY	1081 TTGGTGGAGAGGGAGGGATGCTGGAAAGCTGGTAAACAACCTTTCAAGTCACTTA 1140	Db	XX Homo sapiens.
Db	1081 TTGGTGGAGAGGGAGGGATGCTGGAAAGCTGGTAAACAACCTTTCAAGTCACTTA 1140	Qy	XX US2002132252-A1.
QY	1141 CTAAACAAACTTTGTAAATAGACCTTACCTCTTCAAGTCACCTTA 1200	Db	XX PD 19-SEP-2002.
Db	1141 CTAAACAAACTTTGTAAATAGACCTTACCTCTTCAAGTCACCTTA 1200	Qy	XX PR 14-NOV-2001; 2001US-00930442.
QY	1201 AGTGTGGCAGGCCTCATGAAAGGCTGACTTCACTTTGCACTGACTTT 1260	Db	XX PR 16-JUN-1997; 97US-0049787P.
Db	1201 AGTGTGGCAGGCCTCATGAAAGGCTGACTTCACTTTGCACTGACTTT 1260	Qy	XX PR 17-OCT-1997; 97US-0052250P.
QY	1261 ATCTGGGATCTGTGACTTCATGACTTCATGACTTCATGACTTCATGACTTC 1320	Db	XX PR 05-NOV-1997; 97US-0050069.
Db	1261 ATCTGGGATCTGTGACTTCATGACTTCATGACTTCATGACTTCATGACTTC 1320	Qy	XX PR 12-NOV-1997; 97US-006186P.
QY	1321 TTTCACAAAAGGAGATTTCTTCATGACTTCATGACTTCATGACTTCATGACTTC 1380	Db	XX PR 13-NOV-1997; 97US-006311P.
Db	1321 TTTCACAAAAGGAGATTTCTTCATGACTTCATGACTTCATGACTTCATGACTTC 1380	Qy	XX PR 24-NOV-1997; 97US-006770P.
QY	1381 AAACCTGGCAATTGCTGACTTTACTCTAAAGACTAAACATAAGCTTGTGTTGCTT 1440	Db	XX PR 25-FEB-1998; 98US-0075945P.
Db	1381 AAACCTGGCAATTGCTGACTTTACTCTAAAGACTAAACATAAGCTTGTGTTGCTT 1440	Qy	XX PR 20-MAR-1998; 98US-0078910P.
QY	1441 ACTCATCTCTGACCTTAAAGCAAACTGCTGACTTCATGACTTCATGACTTC 1500	Db	XX PR 28-APR-1998; 98US-0083322P.
Db	1441 ACTCATCTCTGACCTTAAAGCAAACTGCTGACTTCATGACTTCATGACTTC 1500	Qy	XX PR 07-MAY-1998; 98US-0084600P.
QY	1501 ATTATTTAAACCAAGCTCCCTGGATTGATAATAACATTTGAGATTTC 1560	Db	XX PR 28-MAY-1998; 98US-008106P.
Qy	1501 ATTATTTAAACCAAGCTCCCTGGATTGATAATAACATTTGAGATTTC 1560	Db	XX PR 02-JUN-1998; 98US-0081607P.
Qy	1501 ATTATTTAAACCAAGCTCCCTGGATTGATAATAACATTTGAGATTTC 1560	Qy	XX PR 02-JUN-1998; 98US-0081202P.
Qy	1501 ATTATTTAAACCAAGCTCCCTGGATTGATAATAACATTTGAGATTTC 1560	Db	XX PR 04-JUN-1998; 98US-0081212P.
Qy	1501 ATTATTTAAACCAAGCTCCCTGGATTGATAATAACATTTGAGATTTC 1560	Qy	XX PR 05-JUN-1998; 98US-0081217P.
Qy	1501 ATTATTTAAACCAAGCTCCCTGGATTGATAATAACATTTGAGATTTC 1560	Db	XX PR 09-JUN-1998; 98US-0081655P.

WPI: 2003-247083/24.
P-PSDB; ABUS179.

Novel isolated PRO polypeptides e.g. PRO826, PRO1068, PRO1184, PRO13 and PRO1375, which stimulate proliferation of stimulated T-lymphocytes and are therapeutically useful for enhancing immune response and in cancer treatments.

Claim 3: Fig 301; 648pp; English.

Db	3611	TCTAGGCTGTGAATCAAATGTCAACATCAAGGTtACCAATT	420	QY	1501	ATTTTATTAAACCCAAAGCCTCCCTGGATTGATAATAACATTGTCAGCATTTC	1560
	421	AATTATCCTCCATTGCCCCTACTCTGTACAGGTATATCTGTTGA	480	Db	1501	ATTTTATTAAACCCAAAGCCTCCCTGGATTGATAATAACATTGTCAGCATTTC	1560
	421	AATTATCCTCCATTGCCCCTACTCTGTACAGGTATATCTGTTGA	480	QY	1551	CGGTGCTGTGAGAGGCTTGTGAGCTTGAATATGTGAGCTTGAGCTGG	1620
	481	GCCCATCTGAAGGCCCTTGGACATGAGTGTATAAGAGTATGATA	540	Db	1551	CGGTGCTGTGAGAGGCTTGTGAGCTTGAATATGTGAGCTTGAGCTGG	1620
	481	GCCCATCTGAAGGCCCTTGGACATGAGTGTATAAGAGTATGATA	540	QY	1621	GGTTGTGGTGCCTCTTGAGGTAAACATTATGGATAACTGCCTTTCTCC	1680
	541	TGGGATCAACAGCCTTTCAAATGCAACAGTGTAGTCAGC	600	Db	1621	GGTTGTGGTGCCTCTTGAGGTAAACATTATGGATAACTGCCTTTCTCC	1680
	541	TGGGATCAACAGCCTTTCAAATGCAACAGTGTAGTCAGC	600	QY	1681	TATGTCCTCTTGGATAACTGCCTTTTGAAACATCAA	1728
	601	CAACGTGCTAACAGGTAAATATGCAACAGCAGGGTGAAGTCCAAGAGCA	660	Db	1681	TATGTCCTCTTGGATAACTGCCTTTTGAAACATCAA	1728
	601	CAACGTGCTAACAGGTAAATATGCAACAGCAGGGTGAAGTCCAAGAGCA	660	QY	1501	ATTTTATTAAACCCAAAGCCTCCCTGGATTGATAATAACATTGTCAGCATTTC	1560
	661	GCGAAGTCTGTCTTGAACGGCATGTTCTAGTATTGGAAATGAACTT	720	Db	1501	ATTTTATTAAACCCAAAGCCTCCCTGGATTGATAATAACATTGTCAGCATTTC	1560
	661	GCGAAGTCTGTCTTGAACGGCATGTTCTAGTATTGGAAATGAACTT	720	QY	1551	ACAA69297 standard; cDNA; 1728 BP.	XX
	721	GACTGAAAGAACAGGGACAACAGGGACAACAGGGACAACAGGGACA	780	Db	1551	ACAA69297;	XX
	721	GACTGAAAGAACAGGGACAACAGGGACAACAGGGACAACAGGGACA	780	QY	1621	DT 26-JUN-2003 (first entry)	DE
	781	TAAATACCTGGTGTGTTACCAACTGTTGCTGGAAAGATTCAAAACT	840	Db	1621	Human cDNA encoding secreted/transmembrane protein PRO1375.	XX
	781	TAAATACCTGGTGTGTTACCAACTGTTGCTGGAAAGATTCAAAACT	840	QY	1621	KW Human; se; gene; PRO; secreted protein; transmembrane protein;	XX
	841	TGCTGTGATTTTCTCTGTTAAGGTAAATAGAGACATTTAAGGAACT	900	Db	1621	KW cardiac insufficiency disorder; angiogenesis; wound healing;	XX
	841	TGCTGTGATTTTCTCTGTTAAGGAACTTAAAGGAAATGAACTGAGTC	900	QY	1621	KW cancerous tumour; immune response;	XX
	901	AAAGTCAGCCAAATAGTCTTCTTCTATTTGACTTTTAAATAATCTGCT	960	Db	1621	KW retinitis pigmentosa; age-related macular degeneration; AMD;	XX
	901	AAAGTCAGCCAAATAGTCTTCTTCTATTTGACTTTTAAATAATCTGCT	960	QY	1621	KW kidney disorder; Berger disease; nephropathy; dermatitis; herpetiformis;	XX
	961	GTAAATTATCTGGTGTCTTACCTGGACAGCACTCTTCAACATAGTT	1020	Db	1621	KW Crohn's disease; sports injury; arthritis.	XX
	961	GTAAATTATCTGGTGTCTTACCTGGACAGCACTCTTCAACATAGTT	1020	QY	1621	OS Homo sapiens.	OS
	1021	AACTGACTTCAGATAATTTCAGGTTTTCTGGTTGTTCT	1080	Db	1621	XX	XX
	1021	AACTGACTTCAGATAATTTCAGGTTTTCTGGTTGTTCT	1080	QY	1621	US2003032023-A1.	PN
	1081	TTCGGTGGAGGGAGGGATGCCAGGTAAACATTTCAGTCACITTA	1140	Db	1621	US2003032023-A1.	XX
	1081	TTCGGTGGAGGGAGGGATGCCAGGTAAACATTTCAGTCACITTA	1140	QY	1621	PD 13-FEB-2003.	PD
	1081	TTCGGTGGAGGGAGGGATGCCAGGTAAACATTTCAGTCACITTA	1140	Db	1621	PP 14-NCV-2001; 2001US-00990711.	PP
	1141	CTAAACAAACTTGTAAATAGACCTTACCTCTTATGCTTATGTTG	1200	QY	1621	PR 16-JUN-1997;	PR
	1141	CTAAACAAACTTGTAAATAGACCTTACCTCTTATGCTTATGTTG	1200	Db	1621	PR 17-OCT-1997;	PR
	1141	CTAAACAAACTTGTAAATAGACCTTACCTCTTATGCTTATGTTG	1200	QY	1621	PR 05-NOV-1997;	PR
	1201	AGTGAGGAGCCTTAAGAACAGCTGAACTTACTGACTGTTGACTGTAT	1260	Db	1621	PR 12-NOV-1997;	PR
	1201	AGTGAGGAGCCTTAAGAACAGCTGAACTTACTGACTGTTGACTGTAT	1260	QY	1621	PR 13-NOV-1997;	PR
	1261	ATCTGGGTATCTGTGTGCTGACTTCTATGGTAAACGGCATCTAAATGCT	1320	Db	1621	PR 24-NOV-1997;	PR
	1261	ATCTGGGTATCTGTGTGCTGACTTCTATGGTAAACGGCATCTAAATGCT	1320	QY	1621	PR 25-FEB-1998;	PR
	1321	TTCACAAAGAGGATTTCTCATCAAGAGCTGTTACTCATGGTGTGTTG	1380	Db	1621	PR 20-MAR-1998;	PR
	1321	TTCACAAAGAGGATTTCTCATCAAGAGCTGTTACTCATGGTGTGTTG	1380	QY	1621	PR 07-MAY-1998;	PR
	1381	AAACTGGCCATTCTGTTACTTACTTACATAGCTTCTGCTGCT	1440	Db	1621	PR 28-MAY-1998;	PR
	1381	AAACTGGCCATTCTGTTACTTACTTACATAGCTTCTGCTGCT	1440	QY	1621	PR 04-JUN-1998;	PR
	1381	AAACTGGCCATTCTGTTACTTACTTACATAGCTTCTGCTGCT	1440	Db	1621	PR 04-JUN-1998;	PR
	1381	AAACTGGCCATTCTGTTACTTACTTACATAGCTTCTGCTGCT	1440	QY	1621	PR 04-JUN-1998;	PR
	1441	ACTCATCTCTGTTACTTACATAGCTTCTGCTGCT	1440	Db	1621	PR 05-JUN-1998;	PR
	1441	ACTCATCTCTGTTACTTACATAGCTTCTGCTGCT	1440	QY	1621	PR 05-JUN-1998;	PR
	1441	ACTCATCTCTGTTACTTACATAGCTTCTGCTGCT	1440	Db	1621	PR 05-JUN-1998;	PR
	1441	ACTCATCTCTGTTACTTACATAGCTTCTGCTGCT	1440	QY	1621	PR 05-JUN-1998;	PR

98US-0088742P.	PR	12-AUG-1998;	98US-0096329P.	PR	17-AUG-1998;
98US-0088810P.	PR	17-AUG-1998;	98US-0096757P.	PR	17-AUG-1998;
98US-0088824P.	PR	98US-0096766P.	98US-0096768P.	PR	17-AUG-1998;
98US-0088825P.	PR	98US-0096773P.	98US-0096791P.	PR	17-AUG-1998;
98US-0088858P.	PR	98US-0096867P.	98US-0096867P.	PR	17-AUG-1998;
98US-0088867P.	PR	98US-0096875P.	98US-0096891P.	PR	17-AUG-1998;
98US-0088875P.	PR	98US-0096894P.	98US-0096894P.	PR	17-AUG-1998;
98US-0089440P.	PR	98US-0089512P.	98US-0096895P.	PR	17-AUG-1998;
98US-0089512P.	PR	98US-0089514P.	98US-0096897P.	PR	17-AUG-1998;
98US-0089514P.	PR	98US-0089518P.	98US-0096949P.	PR	18-AUG-1998;
98US-0089518P.	PR	98US-0089530P.	98US-0096950P.	PR	18-AUG-1998;
98US-0089530P.	PR	98US-0089538P.	98US-0096959P.	PR	18-AUG-1998;
98US-0089538P.	PR	98US-0089598P.	98US-0096960P.	PR	18-AUG-1998;
98US-0089598P.	PR	98US-0089600P.	98US-0096960P.	PR	18-AUG-1998;
98US-0089600P.	PR	98US-0089633P.	98US-0097141P.	PR	17-AUG-1998;
98US-0089633P.	PR	98US-0089801P.	98US-009718P.	PR	17-AUG-1998;
98US-0089801P.	PR	98US-0089907P.	98US-0097161P.	PR	18-AUG-1998;
98US-0089907P.	PR	98US-0089908P.	98US-0097198P.	PR	18-AUG-1998;
98US-0089908P.	PR	98US-0089947P.	98US-0097195P.	PR	18-AUG-1998;
98US-0089947P.	PR	98US-0089948P.	98US-0097155P.	PR	18-AUG-1998;
98US-0089948P.	PR	98US-0089952P.	98US-0097171P.	PR	18-AUG-1998;
98US-0089952P.	PR	98US-0090246P.	98US-0097174P.	PR	18-AUG-1998;
98US-0090246P.	PR	98US-0090252P.	98US-0097178P.	PR	18-AUG-1998;
98US-0090252P.	PR	98US-0090254P.	98US-0097179P.	PR	18-AUG-1998;
98US-0090254P.	PR	98US-0090349P.	98US-0097186P.	PR	18-AUG-1998;
98US-0090349P.	PR	98US-0090355P.	98US-0098014P.	PR	18-AUG-1998;
98US-0090355P.	PR	98US-0090429P.	98US-009825P.	PR	18-AUG-1998;
98US-0090429P.	PR	98US-0090431P.	98US-010634P.	PR	18-AUG-1998;
98US-0090431P.	PR	98US-0090435P.	98US-0109330P.	PR	18-AUG-1998;
98US-0090435P.	PR	98US-0090444P.	98US-0109589P.	PR	18-AUG-1998;
98US-0090444P.	PR	98US-0090445P.	98US-0109437P.	PR	18-AUG-1998;
98US-0090445P.	PR	98US-0090472P.	98US-011141P.	PR	07-OCT-1998;
98US-0090472P.	PR	98US-0090535P.	98US-0124252P.	PR	01-DEC-1998;
98US-0090535P.	PR	98US-0090540P.	98US-0125108P.	PR	01-DEC-1998;
98US-0090540P.	PR	98US-0090542P.	98US-013296P.	PR	01-DEC-1998;
98US-0090542P.	PR	98US-0090557P.	98US-0139906P.	PR	05-JAN-1999;
98US-0090557P.	PR	98US-0090676P.	98US-01400106P.	PR	08-MAR-1999;
98US-0090676P.	PR	98US-0090678P.	98US-0140528P.	PR	08-MAR-1999;
98US-0090678P.	PR	98US-0090690P.	98US-0123957P.	PR	12-MAR-1999;
98US-0090690P.	PR	98US-0090694P.	98US-0124252P.	PR	02-JUN-1999;
98US-0090694P.	PR	98US-0090695P.	98US-0141037P.	PR	23-JUN-1999;
98US-0090695P.	PR	98US-0090697P.	98US-0143048P.	PR	07-JUL-1999;
98US-0090697P.	PR	98US-0090700P.	98US-014758P.	PR	20-JUL-1999;
98US-0090700P.	PR	98US-0090702P.	99US-014698P.	PR	26-JUL-1999;
98US-0090702P.	PR	98US-0090704P.	99US-0146222P.	PR	28-JUL-1999;
98US-0090704P.	PR	98US-0090706P.	99US-0149396P.	PR	17-AUG-1999;
98US-0090706P.	PR	98US-0090698P.	99US-01090P.	PR	15-SEP-1999;
98US-0090698P.	PR	98US-0091360P.	99US-015147P.	PR	15-SEP-1999;
98US-0091360P.	PR	98US-0091544P.	99US-0158663P.	PR	08-OCT-1999;
98US-0091544P.	PR	98US-0091478P.	99US-01698313.	PR	30-NOV-1999;
98US-0091478P.	PR	98US-0091519P.	99US-016222P.	PR	01-DIC-1999;
98US-0091519P.	PR	98US-0091626P.	99US-0149396P.	PR	17-AUG-1999;
98US-0091626P.	PR	98US-0091638P.	99US-01090P.	PR	15-SEP-1999;
98US-0091638P.	PR	98US-0091640P.	99US-015095.	PR	16-DEC-1999;
98US-0091640P.	PR	98US-0091646P.	99US-0150911.	PR	20-DEC-1999;
98US-0091646P.	PR	98US-0091673P.	99US-01500219.	PR	05-JAN-2000;
98US-0091673P.	PR	98US-0091798P.	20000W-US000376.	PR	06-JAN-2000;
98US-0091798P.	PR	98US-0091826P.	20000W-US034565.	PR	11-FEB-2000;
98US-0091826P.	PR	98US-0092182P.	20000W-US04341.	PR	18-FEB-2000;
98US-0092182P.	PR	98US-0092472P.	20000W-US007377.	PR	20-MAR-2000;
98US-0092472P.	PR	98US-0093339P.	20000W-US008439.	PR	30-MAR-2000;
98US-0093339P.	PR	98US-0094651P.	20000W-US03358.	PR	15-MAY-2000;
98US-0094651P.	PR	98US-0095282P.	20000W-US005841.	PR	02-MAR-2000;
98US-0095282P.	PR	98US-0095325P.	20000W-US06319.	PR	10-MAR-2000;
98US-0095325P.	PR	98US-0095301P.	20000W-US06884.	PR	15-MAR-2000;
98US-0095301P.	PR	98US-0095302P.	20000W-US04414.	PR	20-MAR-2000;
98US-0095302P.	PR	98US-009518P.	20000W-US04914.	PR	24-FEB-2000;
98US-009518P.	PR	98US-0095339P.	20000W-US005004.	PR	24-FEB-2000;
98US-0095339P.	PR	98US-009514P.	20000W-US00219.	PR	05-JAN-2000;
98US-009514P.	PR	98US-009517P.	20000W-US00376.	PR	06-JAN-2000;
98US-009517P.	PR	98US-009519P.	20000W-US034565.	PR	11-FEB-2000;
98US-009519P.	PR	98US-009516P.	20000W-US04341.	PR	18-FEB-2000;
98US-009516P.	PR	98US-009518P.	20000W-US007377.	PR	20-MAR-2000;
98US-009518P.	PR	98US-009514P.	20000W-US008439.	PR	30-MAR-2000;
98US-009514P.	PR	98US-009516P.	20000W-US03358.	PR	15-MAY-2000;
98US-009516P.	PR	98US-009518P.	20000W-US03705.	PR	17-MAY-2000;
98US-009518P.	PR	98US-009519P.	20000W-US014042.	PR	22-MAY-2000;
98US-009519P.	PR	98US-009512P.	20000W-US014941.	PR	30-MAY-2000;
98US-009512P.	PR	98US-009513P.	20000W-US05264.	PR	02-JUN-2000;
98US-009513P.	PR	98US-009514P.	20000W-US0213637P.	PR	28-JUL-2000;
98US-009514P.	PR	98US-009516P.	20000W-US050710.	PR	28-JUL-2000;

PR	05-NOV-1997;	97W0-US020069-
PR	12-NOV-1997;	97W0-006186P-
PR	13-NOV-1997;	97W0-00653110P-
PR	24-NOV-1997;	97W0-0066770P-
PR	25-FEB-1998;	98W0-007945P-
PR	20-MAR-1998;	98W0-0079910P-
PR	28-APR-1998;	98W0-0083322P-
PR	07-MAY-1998;	98W0-0084000P-
PR	28-MAY-1998;	98W0-0087016P-
PR	02-JUN-1998;	98W0-0087607P-
PR	02-JUN-1998;	98W0-0087609P-
PR	02-JUN-1998;	98W0-0087759P-
PR	03-JUN-1998;	98W0-0087827P-
PR	04-JUN-1998;	98W0-0088212P-
PR	04-JUN-1998;	98W0-0088025P-
PR	05-JUN-1998;	98W0-0088167P-
PR	05-JUN-1998;	98W0-0088202P-
PR	05-JUN-1998;	98W0-0088228P-
PR	05-JUN-1998;	98W0-0088229P-
PR	04-JUN-1998;	98W0-0088230P-
PR	04-JUN-1998;	98W0-0088303P-
PR	04-JUN-1998;	98W0-0088326P-
PR	05-JUN-1998;	98W0-0088347P-
PR	05-JUN-1998;	98W0-0088349P-
PR	05-JUN-1998;	98W0-0088355P-
PR	05-JUN-1998;	98W0-0088357P-
PR	10-JUN-1998;	98W0-0088373P-
PR	10-JUN-1998;	98W0-0088378P-
PR	10-JUN-1998;	98W0-0088420P-
PR	10-JUN-1998;	98W0-0088422P-
PR	10-JUN-1998;	98W0-0088427P-
PR	10-JUN-1998;	98W0-0088428P-
PR	11-JUN-1998;	98W0-0088426P-
PR	11-JUN-1998;	98W0-0088458P-
PR	11-JUN-1998;	98W0-0088461P-
PR	11-JUN-1998;	98W0-0088476P-
PR	12-JUN-1998;	98W0-0088477P-
PR	12-JUN-1998;	98W0-0089105P-
PR	16-JUN-1998;	98W0-0089440P-
PR	16-JUN-1998;	98W0-0089512P-
PR	16-JUN-1998;	98W0-0089514P-
PR	17-JUN-1998;	98W0-0089515P-
PR	17-JUN-1998;	98W0-0089538P-
PR	17-JUN-1998;	98W0-0089598P-
PR	17-JUN-1998;	98W0-0089599P-
PR	17-JUN-1998;	98W0-0089599P-
PR	17-JUN-1998;	98W0-0089600P-
PR	17-JUN-1998;	98W0-0089653P-
PR	18-JUN-1998;	98W0-0089811P-
PR	18-JUN-1998;	98W0-0089907P-
PR	18-JUN-1998;	99W0-US00528-
PR	02-JUN-1999;	99W0-US012252
PR	15-SEP-1998;	99W0-US019430
PR	17-SEP-1998;	99W0-US019437
PR	07-OCT-1998;	99W0-US021141
PR	07-DEC-1998;	99W0-US021508
PR	05-JAN-1999;	99W0-US000376-
PR	01-DEC-1999;	99W0-US02834-
PR	08-MAR-1999;	99W0-US00528-
PR	16-SEP-1999;	99W0-US020095
PR	15-SEP-1999;	99W0-US021547
PR	15-SEP-1999;	99W0-US021547
PR	03-NOV-1999;	99W0-US028113
PR	01-DEC-1999;	99W0-US028301-
PR	18-FEB-2000;	2000W0-US003365-
PR	22-FEB-2000;	2000W0-US004441-
PR	24-FEB-2000;	2000W0-US004914-
PR	05-JAN-2000;	2000W0-US005004-
PR	02-MAR-2000;	2000W0-US005841-
PR	10-MAR-2000;	2000W0-US06319-
PR	15-MAR-2000;	2000W0-US06584-
PR	20-MAR-2000;	2000W0-US00727-

30-MAR-2000; 2000WKO-US008439.
 15-MAY-2000; 2000WKO-US013585.
 17-MAY-2000; 2000WKO-US013587.
 22-MAY-2000; 2000WKO-US014042.
 30-MAY-2000; 2000WKO-US14941.
 02-JUN-2000; 2000WKO-US015264.
 28-JUL-2000; 2000WKO-US020710.
 11-AUG-2000; 2000WKO-US020321.
 23-AUG-2000; 2000WKO-US235252.
 24-AUG-2000; 2000WKO-US030328.
 08-NOV-2000; 2000WKO-US0303928.
 01-DEC-2000; 2000WKO-US032678.
 28-FEB-2001; 2001WKO-US065450.
 01-JUN-2001; 2001WKO-US017840.
 20-JUN-2001; 2001WKO-US19692.
 29-JUN-2001; 2001WKO-US021066.
 09-JUL-2001; 2001WKO-US021755.
 28-AUG-2001; 2001WKO-US0211952.
 (GETH) GENENTECH INC.
 Ashkenazi AJ, Baker KB, Bot
 Ferrara N, Fong S, Gerber H
 Grimaldi JC, Gurney AL, Kli
 Roy MA, Stewart TA,
 Thomas D
 Zhang Z;
 WPI; 2003-288106/28.
 P-PSDE; ABE0609.
 New transmembrane polypeptide
 polypeptides, useful in gene
 chromosome markers, or in gene
 Claim 2; FIG 299; 650pp; Engl
 The invention discloses isolates
 comprising a sequence without
 encoding them. The polypeptides
 specifically bind to the PRO
 molecule to a cell expressing
 one biological activity of a
 polynucleotides are also useful
 identification, as chromosome
 polypeptides are useful as mo
 and the isolated nucleic acid
 those markers. The PRO polype
 tissue typing. Anti-PRO antib
 PRO, and in affinity purification
 natural sources. The sequence
 genes encoding, the primers a
 polynucleotides of the invent
 is also available in electron
 seqdata.uspto.gov/sequence.ht
 Sequence 1728 BP; 438 A; 360
 ISQ
 Query Match 100.0%
 Best Local Similarity 100.0%
 Matches 1728; Conservative 0
 QY 1 CAGCCGGCTTCAGCCCTT
 DDB 1 CAGCCGGCTTCAGCCCTT
 QY 61 GATCGGGGGGCTCCGGGT
 DB 61 GTCGCGGGGGCTCCGGGT
 QY 121 AGGCCTCTCTGGCTTCGGTT
 DB 1 AGGCCTCTCTGGCTTCGGTT

PR	04-JUN-1998	98US-0088029P.
PR	04-JUN-1998	98US-0088030P.
PR	04-JUN-1998	98US-0088033P.
PR	04-JUN-1998	98US-0088326P.
PR	05-JUN-1998	98US-0088167P.
PR	05-JUN-1998	98US-0088202P.
PR	05-JUN-1998	98US-0088212P.
PR	05-JUN-1998	98US-0088217P.
PR	09-JUN-1998	98US-0088655P.
PR	10-JUN-1998	98US-0088134P.
PR	10-JUN-1998	98US-0088138P.
PR	10-JUN-1998	98US-0088142P.
PR	10-JUN-1998	98US-0088181P.
PR	10-JUN-1998	98US-0088824P.
PR	10-JUN-1998	98US-0088826P.
PR	11-JUN-1998	98US-0088858P.
PR	11-JUN-1998	98US-0088861P.
PR	11-JUN-1998	98US-0088876P.
PR	12-JUN-1998	98US-0088890P.
PR	16-JUN-1998	98US-0088944P.
PR	16-JUN-1998	98US-0088951P.
PR	16-JUN-1998	98US-0088954P.
PR	17-JUN-1998	98US-0088953P.
PR	17-JUN-1998	98US-0088960P.
PR	17-JUN-1998	98US-0088961P.
PR	17-JUN-1998	98US-0088962P.
PR	17-JUN-1998	98US-0088967P.
PR	17-JUN-1998	98US-0088970P.
PR	17-JUN-1998	98US-0088979P.
PR	17-JUN-1998	98US-0088980P.
PR	17-JUN-1998	98WNO-US019330.
PR	17-SEP-1998	98WNO-US019437.
PR	07-OCT-1998	98WNO-US021141.
PR	01-DEC-1998	98WNO-US028108.
PR	05-FEB-1999	99WNO-US000106.
PR	08-MAR-1999	99WNO-US005028.
PR	02-FEB-1999	99WNO-US012252.
PR	15-SEP-1999	99WNO-US021090.
PR	15-SEP-1999	99WNO-US021547.
PR	30-NOV-1999	99WNO-US028131.
PR	01-DEC-1999	99WNO-US023031.
PR	01-DEC-1999	99WNO-US028634.
PR	16-DEC-1999	99WNO-US030414.
PR	24-FEB-2000	2000WU-US004914.
PR	24-FEB-2000	2000WU-US036911.
PR	06-JAN-2000	2000WU-US000376.
PR	06-JAN-2000	2000WU-US000376.
PR	11-FEB-2000	2000WU-US003565.
PR	18-FEB-2000	2000WU-US004341.
PR	22-FEB-2000	2000WU-US004414.
PR	24-FEB-2000	2000WU-US005095.
PR	15-MAY-2000	2000WU-US005377.
PR	15-MAY-2000	2000WU-US013705.
PR	17-MAY-2000	2000WU-US014042.
PR	22-MAY-2000	2000WU-US014941.
PR	30-MAY-2000	2000WU-US030552.
PR	02-JUN-2000	2000WU-US015264.
PR	11-AUG-2000	2000WU-US020710.
PR	23-AUG-2000	2000WU-US025522.
PR	24-AUG-2000	2000WU-US029338.
PR	08-NOV-2000	2000WU-US030552.
PR	01-DEC-2000	2000WU-US036768.
PR	28-FEB-2001	2001WU-US005520.
PR	01-JUN-2001	2001WU-US017800.
PR	29-JUN-2001	2001WU-US021066.
PR	09-JUL-2001	2001WU-US021735.

PR XX	28-AUG-2001; 2001US-00941992.
(GETH) GENENTECH LTD.	
XX	Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Baton DL, Godowski PJ;
PI	Ferrara N, Fong S, Gerber H, Gerritsen MB, Goddard A, Godowski PJ;
PI	Grimaldi JC, Gurley AL, Klijav-in JV, Napier MA, Pan J, Paoni NF;
PI	Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI	Zhang Z;
XX	WPI; 2003-102117/09.
DR	P-SDDB; ABU1991.
XX	Novel secreted and transmembrane polypeptide for modulating biological activity of cell expressing the polypeptide, identifying agonists or antagonists of polypeptide, and as molecular weight markers.
XX	Claim 2: Fig 29; 64pp; English.
PS	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
XX	The present invention relates to the isolation of novel human PRO polypeptides, and the polynucleotide sequences encoding them. The PRO polypeptides are secreted and transmembrane Proteins. The PRO polypeptides are useful for detecting other PRO polypeptides, for linking biactive molecules to cells expressing PRO polypeptides, for modulating biological activities of cells expressing PRO polypeptides, and for for identifying agonists or antagonists of polynucleotide sequences for encoding PRO polypeptides useful as hybridisation probes, in the preparation of PRO polypeptides, for generating transgenic animals or knockout animals, to construct hybridisation probes for mapping the gene which encodes the PRO polypeptide, and for the genetic analysis of individuals with genetic disorders, in gene therapy, for chromosome identification, as chromosome markers, and for generating probes for PCR, Northern analysis, Southern analysis and Western analysis. The present sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent was obtained in electronic format directly from the USPTO web site at seqdata.uspto.gov/patentDBntry.html
SQ	Query Match 100.0%; Score 1728; DB 7; Length 1728; Best Local Similarity 100.0%; Pred. No. 0; Matches 1728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	1 CAGGGGCCCAACCTGTGCCCTGAGCTGAGCTGAGCCCTGAGCTGAGGCC 60
Db	1 CAGGGGCCCAACCTGTGCCCTGAGCTGAGCTGAGCTGAGCTGAGGCC 60
Qy	61 GGTCCCCGGGGCTGGGGCTGGAAACCCTGGGCCCCAGCGATGGGACCCCTGTGGGG 120
Db	61 GGTCGGGGGGCTGGGGCTGGAAACCCTGGGCCCCAGCGATGGGACCCCTGTGGGG 120
Qy	121 AGGCCTCTCTGGCTTGGCTCTCTGAGCTGCTGGGCCCTTGCTGTGTCT 180
Db	121 AGGCCTCTCTGGCTTGGCTCTCTGAGCTGCTGGGCCCTTGCTGTGTCT 180
Qy	181 GCTGGGGCAGGTGTGAGCCGCCATTGAGGAATTTCGAGATGTAATGTTACTG 240
Db	181 GCTGGGGCAGCTGTGAGCCGCCATTGAGGAATTTCGAGATGTAATGTTACTG 240
Qy	241 CCCCTCCCTATAAAGAAAATTCTGGCCATATTATAAAGAACATCTCAAGAAATGG 300
Db	241 CCCCTCCCTATAAAGAAAATTCTGGCCATATTATAAAGAACATCTCAAGAAATGG 300
Qy	361 TCTAGCTGTGAACTCAAATPATGAAAGAAAGCTGTCAAAATGAGGTACCAATTAT 420
Db	361 TCTAGCTGTGAACTCAAATPATGAAAGAGCTGTCAAAATGAGGTACCAATTAT 420
Qy	421 AATTATCTTCCTCCATTGTGGCCCTTACTCTGTGACATGTATCTACTGTGTA 480

Db	601	CAACGTGCTGAACAGGTAAATGCACAGCAGGGCTGAGGTCAAAGGCCAAGGCA 660	
Qy	661	GCGAAGTGTCTTTGCTTGCTGGCATGTTGCTCTAGTAATTGGATTGAAATTCAAGGT 720	RESULT 12 ACA58005 standard; cDNA; 1728 BP.
Db	661	GCGAAGTGTCTTTGCTTGCTGGCATGTTGCTCTAGTAATTGGATTGAAATTCAAGGT 720	ID XX
Qy	721	GAATGAAAGAACAGGAGAACACTGGAAAGACTGAGCTGGGTTGCTGGGTTTATT 780	AC AC58005;
Db	721	GAATGAAAGAACAGGAGAACACTGGAAAGACTGAGCTGGGTTGCTGGGTTTATT 780	XX DT 09-JUN-2003 (first entry)
Qy	781	TAAATACCTTGTGATTCACTTACCAACTGGAAAGATTCAAACCTGGAAAGAAACT 840	XX DE cDNA encoding human neoplasia inhibiting PRO polypeptide PRO1375.
Db	781	TAAATACCTTGTGATTCACTTACCAACTGGAAAGATTCAAACCTGGAAAGAAACT 840	XX KW Human; BS; gene; tumour; cancer; neoplasia; liver cancer; sarcoma;
Qy	841	TGCTTGTATTTTTCTTTTAACGTTAAATAGAGACATTTTAAAGCACACACTC 900	KW KW breast cancer; ovarian cancer; renal cancer; colorectal cancer; melanoma;
Db	841	TGCTTGTATTTTCTTTTAACGTTAAATAGAGACATTTTAAAGCACACACTC 900	KW KW uterine cancer; prostate cancer; lung cancer; bladder cancer; leukaemia;
Qy	901	AAAGTCAGCCATAATGGTCCTTCTTGTACTTTGACTTTACTAAATAATTCGCT 960	KW KW gastric cancer; pancreatic cancer; vulva cancer; thyroid cancer;
Db	901	AAAGTCAGCCATAATGGTCCTTCTTGTACTTTGACTTTACTAAATAATTCGCT 960	KW KW central nervous system cancer; hepatic carcinoma; glioblastoma;
Qy	961	GTAATTTATCTTGAAGTCCTTTACCGAACACTCTCTTTACACATAGTTT 1020	KW KW neuronal disorder; glial disorder; astrocytic disorder;
Db	961	GTAATTTATCTTGAAGTCCTTTACCGAACACTCTCTTTACACATAGTTT 1020	KW KW hypothalamic disorder; glandular disorder; macrophagal disorder;
Qy	1021	AACTTGACTTTCAAGATAATTTCAGGTTTCTTGTGTGTGTGTGTGTGT 1080	KW KW epithelial disorder; stromal disorder; blastocoelic disorder;
Db	1021	AACTTGACTTTCAAGATAATTTCAGGTTTCTTGTGTGTGTGTGTGTGT 1080	KW KW inflammatory disorder; angiogenic disorder; immunologic disorder.
Qy	1081	TTCGGGAGAGGGAGGGATGCTGGAGTGCTTAAACATTTCAGTCACCTTA 1140	XX OS Homo sapiens.
Db	1081	TTCGGGAGAGGGAGGGATGCTGGAGTGCTTAAACATTTCAGTCACCTTA 1140	XX OS US2002192209-A1.
Qy	1141	CTAAACAAAATTGTAATAAGACTCTACCTTCACTTTGAGTTTCAATTATTTGC 1200	XX PN US2002192209-A1.
Db	1141	CTAAACAAAATTGTAATAAGACTCTACCTTCACTTTGAGTTTCAATTATTTGC 1200	XX PR 17-SEP-1998; 97US-0059114P.
Qy	1201	AGTGTAGCCCGCTTCATCAAGAGCTGAGTTACTCATTTGACTTTGCACTGTATT 1260	PR 27-MAR-1998; 98US-0079689P.
Db	1201	AGTGTAGCCCGCTTCATCAAGAGCTGAGTTACTCATTTGACTTTGCACTGTATT 1260	PR 30-MAR-1998; 98US-0079620P.
Qy	1261	ATCTGGTATCTGGCTGTGGCACTCATGGTAACCGATTAATGCTGGTGGCT 1320	PR 24-APR-1998; 98US-0083999P.
Db	1261	ATCTGGTATCTGGCTGTGGCACTCATGGTAACCGATTAATGCTGGTGGCT 1320	PR 29-APR-1998; 98US-0083345P.
Qy	1321	TTTCACAAAAAGCGATTTCTTCACTGACTGTGATGCTGATGCAATGCTAAC 1380	PR 12-MAY-1998; 98US-0085149P.
Db	1321	TTTCACAAAAAGCGATTTCTTCACTGACTGTGATGCTGATGCAATGCTAAC 1380	PR 02-JUN-1998; 98US-0087607P.
Qy	1381	AAACTGGCCATTGTTAGTTTACTTAAAGACTAAACATAGCTTGGCTGTGGCTT 1440	PR 11-JUN-1998; 98US-0088858P.
Db	1381	AAACTGGCCATTGTTAGTTTACTTAAAGACTAAACATAGCTTGGCTGTGGCTT 1440	PR 25-JUN-1998; 98US-0090691P.
Qy	1501	ATTTATTTAAACCAAGCTCCCTGGATTGATAATATACACATTGCTGCTGCTT 1560	PR 17-AUG-1998; 98US-0096691P.
Db	1501	ATTTATTTAAACCAAGCTCCCTGGATTGATAATATACACATTGCTGCTGCTT 1560	PR 29-SEP-1998; 98US-0096894P.
Qy	1441	ACTCATCTCTGACCTTAAAGACAAATCCCTAAGGACTTGCACTTGCAATANAA 1500	PR 10-SEP-1998; 98US-0099803P.
Db	1441	ACTCATCTCTGACCTTAAAGACAAATCCCTAAGGACTTGCACTTGCAATANAA 1500	PR 11-NOV-1998; 98WO-US0-18824.
Qy	1561	CGGTGTGGTGGAGCCAGCTGGCTTGTGAGCTCCATTATGGCACTTGTGACTGGCTT 1620	PR 14-SEP-1998; 98US-0100263P.
Db	1561	CGGTGTGGTGGAGCCAGCTGGCTTGTGAGCTCCATTATGGCACTTGTGACTGGCTT 1620	PR 15-SEP-1998; 98US-0100390P.
Qy	1621	GGTTGGGGCCUTTCCTGAAAGGTAAACCTTATGGATAACTGCTCTTTCTCC 1680	PR 23-SEP-1998; 98US-010476P.
Db	1621	GGTTGGGGCCUTTCCTGAAAGGTAAACCTTATGGATAACTGCTCTTTCTCC 1680	PR 10-NOV-1998; 98US-010783P.
Qy	1621	GGTTGGGGCCUTTCCTGAAAGGTAAACCTTATGGATAACTGCTCTTTCTCC 1680	PR 18-NOV-1998; 98US-0108849P.
Db	1621	GGTTGGGGCCUTTCCTGAAAGGTAAACCTTATGGATAACTGCTCTTTCTCC 1680	PR 19-NOV-1998; 98US-0108997.
Qy	1621	GGTTGGGGCCUTTCCTGAAAGGTAAACCTTATGGATAACTGCTCTTTCTCC 1680	PR 15-DEC-1998; 98US-0114240P.
Db	1621	GGTTGGGGCCUTTCCTGAAAGGTAAACCTTATGGATAACTGCTCTTTCTCC 1680	PR 22-DEC-1998; 98US-0128517.
Qy	1501	ATTTATTTAAACCAAGCTCCCTGGATTGATAATATACACATTGCTGCTGCTT 1560	PR 22-DEC-1998; 98US-0128429I.
Db	1501	ATTTATTTAAACCAAGCTCCCTGGATTGATAATATACACATTGCTGCTGCTT 1560	PR 05-JAN-1999; 99WO-US000106.
Qy	1441	ACTCATCTCTGACCTTAAAGACAAATCCCTAAGGACTTGCACTTGCAATANAA 1500	PR 27-APR-1999; 99US-011554P.
Db	1441	ACTCATCTCTGACCTTAAAGACAAATCCCTAAGGACTTGCACTTGCAATANAA 1500	PR 12-JUN-1999; 99US-011558P.
Qy	1561	TATGTCCTCTTGGAACTAACATAAAATTTGAAACATCAA 1728	PR 20-JUN-1999; 99US-0116133P.
Db	1561	TATGTCCTCTTGGAACTAACATAAAATTTGAAACATCAA 1728	PR 08-MAR-1999; 99WO-US005028.
Qy	1681	TATGTCCTCTTGGAACTAACATAAAATTTGAAACATCAA 1728	PR 09-MAR-1999; 99US-0124618P.
Db	1681	TATGTCCTCTTGGAACTAACATAAAATTTGAAACATCAA 1728	PR 12-APR-1999; 99US-00284429I.
Qy	1681	TATGTCCTCTTGGAACTAACATAAAATTTGAAACATCAA 1728	PR 20-JUL-1999; 99US-014758P.
Db	1681	TATGTCCTCTTGGAACTAACATAAAATTTGAAACATCAA 1728	PR 25-AUG-1999; 99US-00380137.

421	AATTATCCTCCATTGGGCTTCACTTCGTAATGGTATTTACTCTGTGTTGA	480	Qy	1561	CGGTCCTGGTGGAGGCCAGCTGTTGAGCTCAAATATGCGAGCTTGAACTAGGCCTGG	1620
481	GCCCATACTGAAAGGGCCTCTTGGACATGAGCTGATAAGGTGATGATAT	540	Db	1561	CGGTCCTGGTGGAGGCCAGCTGTTGAGCTCAAATATGCGAGCTTGAACTAGGCCTGG	1620
481	GCCCATACTGAAAGGGCCTCTTGGACATGAGCTGATAAGGTGATGATAT	540	Qy	1621	GTTTGTGGTGGCCCTCTGAAAGGCTAACATTATTGATAACTGGCTTTTTCTCC	1680
481	TGGGATATAACGCCCTTTGAAATGACAACGATGCTGAGTCAGTGTGATGATAT	540	Db	1621	GTTTGTGGTGGCCCTCTGAAAGGCTAACATTATTGATAACTGGCTTTTTCTCC	1680
541	TGGGATATAACGCCCTTTGAAATGACAACGATGCTGAGTCAGTGTGATGATAT	540	Qy	1681	TATGTCCTCTGAAATGATAAATATTGAAACATAA	1728
541	TGGGATATAACGCCCTTTGAAATGACAACGATGCTGAGTCAGTGTGATGAC	600	Db	1681	TATGTCCTCTGAAATGATAAATATTGAAACATAA	1728
601	CACGTGTGAAGGTTGAATGCAAGGCGTGGAGCTCAAGTCAGTCAGAGCA	660	Qy	1681	TATGTCCTCTGAAATGATAAATATTGAAACATAA	1728
601	CAACGTGTGAAGGTTGAATGCAAGGCGTGGAGCTCAAGTCAGTCAGAGCA	660	Db	1681	TATGTCCTCTGAAATGATAAATATTGAAACATAA	1728
651	GCGAAAGTGTGCTTTGACGGGATGTTGCTTCAGTAATTGGAAATTGAAAGGT	720	Qy	1681	TATGTCCTCTGAAATGATAAATATTGAAACATAA	1728
661	GCGAAAGTGTGCTTTGACGGCATTGTCAGTAATTGGAAATTGAAAGGT	720	Db	1681	TATGTCCTCTGAAATGATAAATATTGAAACATAA	1728
721	GACTAGAAGAACAGGGAGAACAGTGACTGCTGAGCTGCTGGTTCAATT	780	XX	XX		
721	GACTAGAAGAACAGGGAGAACAGTGACTGCTGAGCTGCTGGTTCAATT	780	DT	10-SEP-2003	(first entry)	
781	TTAATACCTTGTGATTCAACCAACTCTGTCGCGGAAGATTCAAAATCTG	840	DE	CDNA	encoding human PRO1375 polypeptide.	
781	TTAATACCTTGTGATTCAACCAACTCTGTCGCGGAAGATTCAAAATCTG	840	XX	XX		
781	TTAATACCTTGTGATTCAACCAACTCTGTCGCGGAAGATTCAAAATCTG	840	KW	Human; PRO polypeptide; secreted protein; transmembrane protein;		
781	TTAATACCTTGTGATTCAACCAACTCTGTCGCGGAAGATTCAAAATCTG	840	KW	genetic disorder; antibacterial; immunosuppressive; transgenic;		
841	TGCTTGATTTTTCTGTTAACGTTAAAGACATTTAAAGCAGACGCT	900	XX	XX		
841	TGCTTGATTTTTCTGTTAACGTTAAAGACATTTAAAGCAGACGCT	900	OS	OS		
901	AAACTCAGCCAATAAGTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT	960	XX	XX		
901	AAACTCAGCCAATAAGTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT	960	PN	US2002127576-A1.		
961	GTAATTATCTTGAAAGTCTTACCTGSAACAGCACCTCTCTTACATAGTT	1020	XX	XX		
961	GTAATTATCTTGAAAGTCTTACCTGSAACAGCACCTCTCTTACATAGTT	1020	PR	16-JUN-1997;		
961	GTAATTATCTTGAAAGTCTTACCTGSAACAGCACCTCTCTTACATAGTT	1020	PR	17-OCT-1997;		
1021	AACTTGACTTCAAGATAATTTCAGGTTTGTGTTGTTGTTGTTGTT	1080	PR	05-NOV-1997;	97W0-US020069.	
1021	AACTTGACTTCAAGATAATTTCAGGTTTGTGTTGTTGTTGTTGTT	1080	PR	12-NOV-1997;	97US-0065186P.	
1021	AACTTGACTTCAAGATAATTTCAGGTTTGTGTTGTTGTTGTTGTT	1080	PR	13-NOV-1997;	97US-016511P.	
1081	TTGGTGGAGGAGGGAGATGCTGGAAGCTAACACTTTTCAACTCACTTA	1140	PR	24-NOV-1997;	97US-0066770P.	
1081	TTGGTGGAGGAGGGAGATGCTGGAAGCTAACACTTTTCAACTCACTTA	1140	PR	25-FEB-1998;	98US-0075345P.	
1081	TTGGTGGAGGAGGGAGATGCTGGAAGCTAACACTTTTCAACTCACTTA	1140	PR	20-MAR-1998;	98US-007810P.	
1141	CTAAACAAACTTTGTAAATAGACCTTACCTCTATTCTGAGTTTATTTGC	1200	PR	07-MAY-1998;	98US-0083322P.	
1141	CTAAACAAACTTTGTAAATAGACCTTACCTCTATTCTGAGTTTATTTGC	1200	PR	28-MAY-1998;	98US-008400P.	
1141	CTAAACAAACTTTGTAAATAGACCTTACCTCTATTCTGAGTTTATTTGC	1200	PR	02-JUN-1998;	98US-0087106P.	
1141	CTAAACAAACTTTGTAAATAGACCTTACCTCTATTCTGAGTTTATTTGC	1200	PR	02-JUN-1998;	98US-0087007P.	
1201	AGTGTAGCCGAGCTCATTAAGGAGCTTACCTTCAAGCTGTTGTTGTT	1260	PR	02-JUN-1998;	98US-0087009P.	
1201	AGTGTAGCCGAGCTCATTAAGGAGCTTACCTTCAAGCTGTTGTTGTT	1260	PR	04-JUN-1998;	98US-0087159P.	
1261	ATCTGGGTATCTGTGTTGCTGACTCTATGTTGACTTCACTGTTGTTG	1320	PR	03-JUN-1998;	98US-0087247P.	
1261	ATCTGGGTATCTGTGTTGCTGACTCTATGTTGACTTCACTGTTGTTG	1320	PR	04-JUN-1998;	98US-0088021P.	
1381	AAACTGGCATTGCTAGTTACTCTAAGGAGCTTACCTTCAAGCTGTTG	1440	PR	04-JUN-1998;	98US-0088333P.	
1381	AAACTGGCATTGCTAGTTACTCTAAGGAGCTTACCTTCAAGCTGTTG	1440	PR	10-JUN-1998;	98US-0088326P.	
1381	AAACTGGCATTGCTAGTTACTCTAAGGAGCTTACCTTCAAGCTGTTG	1440	PR	10-JUN-1998;	98US-0088318P.	
1381	AAACTGGCATTGCTAGTTACTCTAAGGAGCTTACCTTCAAGCTGTTG	1440	PR	10-JUN-1998;	98US-0088428P.	
1441	ACTCATCTCTAGACCTTAAAGGACAAATCCPAGGACTTGTGAACTTGC	1500	PR	05-JUN-1998;	98US-008810P.	
1441	ACTCATCTCTAGACCTTAAAGGACAAATCCPAGGACTTGTGAACTTGC	1500	PR	10-JUN-1998;	98US-008817P.	
1501	ATTTTATTTAAACCAAGCTCCCTGGATTGATAATATACACATTGTGCA	1560	PR	10-JUN-1998;	98US-008824P.	
1501	ATTTTATTTAAACCAAGCTCCCTGGATTGATAATATACACATTGTGCA	1560	PR	11-JUN-1998;	98US-008826P.	
1501	ATTTTATTTAAACCAAGCTCCCTGGATTGATAATATACACATTGTGCA	1560	PR	11-JUN-1998;	98US-008831P.	
1501	ATTTTATTTAAACCAAGCTCCCTGGATTGATAATATACACATTGTGCA	1560	PR	11-JUN-1998;	98US-008876P.	

XX The present invention relates to the isolation of novel human PRO polypeptides, and the polynucleotide sequences encoding them. The PRO polypeptides are secreted and transmembrane proteins. The PRO polypeptides are useful for detecting other PRO polypeptides, for linking PRO polypeptides to cells expressing PRO polypeptides, for modulating biological activities of cells expressing PRO polypeptides, and for identifying agonists or antagonists of cells expressing PRO polypeptides. The polynucleotide sequences encoding PRO polypeptides are useful as hybridisation probes, in the preparation of PRO polypeptides, for generating transgenic animals or knockout animals, to construct hybridisation probes for mapping the gene which encodes the PRO polypeptide, and for the genetic analysis of individuals with genetic disorders, in gene therapy, for chromosome identification, as chromosome markers, and for generating probes for PCR, Southern analysis, and Western analysis. The present sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent was obtained in electronic format directly from the USPTO web site at seqdata.uspto.gov/pst/pseqidentry.html

PR 98US-0089105P.
 12-JUN-1998; 98US-0089441P.
 16-JUN-1998; 98US-0089512P.
 16-JUN-1998; 98US-0089514P.
 17-JUN-1998; 98US-0089532P.
 17-JUN-1998; 98US-0089534P.
 17-JUN-1998; 98US-0089588P.
 17-JUN-1998; 98US-0089590P.
 17-JUN-1998; 98US-0089633P.
 18-JUN-1998; 98US-0089801P.
 18-JUN-1998; 98US-0089901P.
 18-JUN-1998; 98US-0089906P.
 16-SEP-1998; 98WO-US019330.
 17-SEP-1998; 98WO-US019437.
 17-OCT-1998; 98WO-US021141.
 01-DEC-1998; 98WO-US025108.
 05-JAN-1999; 99WO-US000106.
 08-MAR-1999; 99WO-US005038.
 02-JUN-1999; 99WO-US012222.
 15-SEP-1999; 99WO-US021090.
 15-SEP-1999; 99WO-US021547.
 30-NOV-1999; 99WO-US028313.
 01-DEC-1999; 99WO-US028301.
 01-DEC-1999; 99WO-US028634.
 16-DEC-1999; 99WO-US030051.
 20-DEC-1999; 99WO-US030911.
 06-JAN-2000; 2000WO-US000219.
 06-JAN-2000; 2000WO-US000316.
 11-FEB-2000; 2000WO-US000355.
 18-FEB-2000; 2000WO-US004341.
 22-FEB-2000; 2000WO-US004414.
 24-FEB-2000; 2000WO-US005004.
 02-MAR-2000; 2000WO-US005841.
 10-MAR-2000; 2000WO-US006319.
 15-MAR-2000; 2000WO-US006884.
 20-MAR-2000; 2000WO-US007377.
 30-MAR-2000; 2000WO-US008439.
 15-MAY-2000; 2000WO-US013355.
 17-MAY-2000; 2000WO-US013705.
 22-MAY-2000; 2000WO-US014042.
 30-MAY-2000; 2000WO-US014941.
 02-JUN-2000; 2000WO-US015264.
 28-JUL-2000; 2000WO-US020710.
 11-AUG-2000; 2000WO-US022031.
 23-AUG-2000; 2000WO-US023328.
 24-AUG-2000; 2000WO-US023522.
 04-NOV-2000; 2000WO-US030932.
 01-DEC-2000; 2000WO-US032678.
 28-FEB-2001; 2001WO-US006520.
 01-JUN-2001; 2001WO-US017800.
 20-JUN-2001; 2001WO-US019691.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 28-AUG-2001; 2001US-US00941932.

PA (GETH) GENENTECH INC.
 PR Novel isolated PRO polypeptides e.g., PRO896, PRO1058, PRO1184, PRO1346 and PRO1375, which stimulate proliferation of stimulated T-lymphocytes and are therapeutically useful for enhancing immune responses.

XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL, Godowski PJ, Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Grimaldi JC, Gurley AL, Kjaviv JI, Nairi MA, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D, Watanabe CR, Williams PM, Wood WI, Zhang Z, WPI; 2003-340824/32. P-PSDB; ABO26022.

PA 481 GCCATACTGAGAGGGCCCTTTGGACATGGAAATATGGACAGAGTGTGAAAGCTCAAGTCAGAGGCA 540
 PR 601 CAACTGTGAAAGCTCAAGTCAGAGGCA 660
 PR 601 CAACGCTGCTGAAGGGCCCTTTGGACATGGAAATATGGACAGAGTGTGAAAGCTCAAGTCAGAGGCA 660
 PR 661 GCGAAAGCTGCTTGTGCTGAGGGATGTTCTCAGTAATGGAAATGAACTCAAGT 720
 PR 661 GCGAAAGCTGCTTGTGCTGAGGGATGTTCTCAGTAATGGAAATGAACTCAAGT 720

QY	721	GAATGAGAAACGGGAGAACCTGGAAAGAACTGACTGGTTTGTGGGTTCAATT	780	XX	ABX79575;
Db	721	GAATGAGAAACGGGAGAACCTGGAAAGAACTGACTGGTTTGTGGGTTCAATT	780	XX	AC
Db	781	TAAATACCTTGTGATTCAACCAACTTGCGGAATTCAAACTGGAAAGAAACT	840	XX	XX
QY	781	TAAATACCTTGTGATTCAACCAACTTGCGGAATTCAAACTGGAAAGAAACT	840	XX	DT 17-APR-2003 (first entry)
Db	841	TGCTTGATTTTTTCTGTGTAACGTAATAATAGAGACATTTTAAAAGACAGCTC	900	KW	Human secreted/transmembrane protein cDNA, #168.
QY	841	TGCTTGATTTTTTCTGTGTAACGTAATAATAGAGACATTTTAAAAGACAGCTC	900	KW	Human; gene; s; PRO; secreted; transmembrane; signal peptide;
Db	841	TGCTTGATTTTTTCTGTGTAACGTAATAATAGAGACATTTTAAAAGACAGCTC	900	KW	pharmaceutical; diagnostic; biosensor; bioreactor; tumour; therapeutic;
QY	901	AAAGTCACCCAAATAAGCTTTCCATTATGACTTTAATTAATCTGCCT	960	KW	colon cancer; lung cancer; breast cancer; gene therapy.
Db	901	AAAGTCACCCAAATAAGCTTTCCATTATGACTTTAATTAATCTGCCT	960	XX	Home sapiens.
QY	961	GTAATATTCCTGAACTGCTTACCTGGAAAGCCTCTTTTACCCACATAGTTT	1020	OS	XX
Db	961	GTAATATTCCTGAACTGCTTACCTGGAAAGCCTCTTTTACCCACATAGTTT	1020	XX	XX
QY	1021	AACCTGACTTTCAAGATAATTTCAGGGTTTGTGTTGTTGTT	1080	PR	16-JUN-1997;
Db	1021	AACCTGACTTTCAAGATAATTTCAGGGTTTGTGTTGTTGTT	1080	PR	17-OCT-1997;
QY	1081	TGGTAGGAGAGGGGAGGAGGAGCTGGAAAGCTGTTAACACTTTCAAGTCACTTA	1140	PR	05-NOV-1997;
Db	1081	TGGTAGGAGAGGGGAGGAGCTGGAAAGCTGTTAACACTTTCAAGTCACTTA	1140	PR	12-NOV-1997;
QY	1141	CATAAACAACCTTTGTAATAAGACCTTAACTCTTATTCAGTTTCATTTGC	1200	PR	13-NOV-1997;
Db	1141	CATAAACAACCTTTGTAATAAGACCTTAACTCTTATTCAGTTTCATTTGC	1200	PR	14-NOV-1997;
QY	1201	AGCTTAGGAGCCTCATCAAAGAGCTCACTTCACTTGAATTGCACTTGACTGTT	1260	PR	25-FEB-1998;
Db	1201	AGCTTAGGAGCCTCATCAAAGAGCTCACTTCACTTGAATTGCACTTGACTGTT	1260	PR	20-MAR-1998;
QY	1261	ATCTGGGATCTGCTGCTGACTGACTCTGACTCTGACTCTGACTCTGACTCTG	1320	PR	28-APR-1998;
Db	1261	ATCTGGGATCTGCTGCTGACTCTGACTCTGACTCTGACTCTGACTCTG	1320	PR	07-MAY-1998;
QY	1321	TTCACAAAAAGGAGATTTCCTCATGACTGATSTCTGATGCAATGATCTAGAAC	1380	PR	28-MAY-1998;
Db	1321	TTCACAAAAAGGAGATTTCCTCATGACTGATSTCTGATGCAATGATCTAGAAC	1380	PR	08-JUN-1998;
QY	1381	AAACTGGCCATTGCTGACTTACTCTAAAGACTAAACATAGCTTGTGCTGCTT	1440	PR	04-JUN-1998;
Db	1381	AACTGGCCATTGCTGACTTACTCTAAAGACTAAACATAGCTTGTGCTGCTT	1440	PR	05-JUN-1998;
QY	1441	ACATCATCTGACTGACTCTTAAAGCAAAATCTAAAGAACTGGACACTGCTGAA	1500	PR	05-JUN-1998;
Db	1441	ACATCATCTGACTGACTCTTAAAGCAAAATCTAAAGAACTGGACACTGCTGAA	1500	PR	05-JUN-1998;
QY	1501	ATTTATTTAACCCAGCCCTGCTGATCTGAAATATACACATTGTCAGCATTC	1560	PR	09-JUN-1998;
Db	1501	ATTTATTTAACCCAGCCCTGCTGATCTGAAATATACACATTGTCAGCATTC	1560	PR	11-JUN-1998;
QY	1561	GGTCGTGCTGAGGGAGCTGGTGGACTCAATATGCACTGCTGAACTGGCTGG	1620	PR	11-JUN-1998;
Db	1561	GGTCGTGCTGAGGGAGCTGGTGGACTCAATATGCACTGCTGAACTGGCTGG	1620	PR	12-JUN-1998;
QY	1621	GGTGCCTTGGAAAGGTCAACATAAAATTTGGAAACTGGCTTTC	1680	PR	12-JUN-1998;
Db	1621	GGTGCCTTGGAAAGGTCAACATAAAATTTGGAAACTGGCTTTC	1680	PR	16-SEP-1998;
QY	1681	TATGCCCTTGGAAAGGTCAACATAAAATTTGGAAACTGGCTTTC	1728	PR	17-JUN-1998;
Db	1681	TATGCCCTTGGAAAGGTCAACATAAAATTTGGAAACTGGCTTTC	1728	PR	17-JUN-1998;
RESULT 15					
ABX79575					
ID ABX79575 standard; cDNA; 1728 BP.					

PRR	05-JAN-1999;	99W0-US000106.
PRR	08-MAR-1999;	99W0-US005028.
PRR	02-JUN-1999;	99W0-US012552.
PRR	15-SEP-1999;	99W0-US024090.
PRR	15-NOV-1999;	99W0-US025457.
PRR	30-NOV-1999;	99W0-US023313.
PRR	01-DEC-1999;	99W0-US028031.
PRR	01-DEC-1999;	99W0-US026364.
PRR	16-DEC-1999;	99W0-US030095.
PRR	20-DEC-1999;	99W0-US030911.
PRR	05-JAN-2000;	2000W0-US000219.
PRR	05-JAN-2000;	2000W0-US000376.
PRR	11-FEB-2000;	2000W0-US003565.
PRR	18-FEB-2000;	2000W0-US003431.
PRR	22-FEB-2000;	2000W0-US004414.
PRR	24-FEB-2000;	2000W0-US004114.
PRR	02-MAR-2000;	2000W0-US005004.
PRR	10-MAR-2000;	2000W0-US005841.
PRR	15-MAR-2000;	2000W0-US006884.
PRR	20-MAR-2000;	2000W0-US007377.
PRR	30-MAR-2000;	2000W0-US008439.
PRR	15-MAY-2000;	2000W0-US01358.
PRR	17-MAY-2000;	2000W0-US01370.
PRR	22-MAY-2000;	2000W0-US014042.
PRR	30-JUN-2000;	2000W0-US014941.
PRR	02-JUN-2000;	2000W0-US012464.
PRR	28-JUL-2000;	2000W0-US020710.
PRR	11-AUG-2000;	2000W0-US020331.
PRR	23-AUG-2000;	2000W0-US025228.
PRR	24-AUG-2000;	2000W0-US023328.
PRR	08-NOV-2000;	2000W0-US030952.
PRR	01-DEC-2000;	2000W0-US034678.
PRR	28-FEB-2001;	2001W0-US005520.
PRR	01-JUN-2001;	2001W0-US018700.
PRR	20-JUN-2001;	2001W0-US018992.
PRR	29-JUN-2001;	2001W0-US021066.
PRR	09-AUG-2001;	2001W0-US0241735.
PRR	28-AUG-2001;	2001US-00941992.

BETH) GENENTECH INC.
Akhkenazi AJ, Baker KP, Botstein D, Deanoeyers L, Eaton DL,
Goddowski PJ, Gerritsen MB, Goddard A,
Gorniak NP, Gurney AL, Kjavin LJ, Napier MA, Pan J,
Pancioli NP, Stewart TA, Tumas D, Watanabe CR,
Wood WI;

new secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184, PRO0361 or PRO846) useful as targets for therapeutic intervention in cancers (e.g. lung or breast cancer), or for diagnosing these cancers.

Claim 2: Fig 299; 64pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides comprising a sequence without signal peptide and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. The PRO polypeptides or polynucleotides are also useful as pharmaceuticals, diagnostics, biosensors or bioreactors, for detecting or treating e.g. tumours in mammals, e.g. humans, dogs, cats, cattle, horses, sheep, pigs, goats or rabbits as targets for therapeutic intervention in certain cancers (e.g. colon, lung or breast cancer) and diagnostic determination of the presence of these cancers. The PRO polypeptides are also useful as molecular weight markers or for chromosome identification. The PRO genes are useful as hybridisation probes or for screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequences

Db	901	AAAGTCAGCCAATAAGTCTTTCTTATTTGTGACTTTTACTAATAAAAATAATC7GCCT	960
QY	961	GTAATTACCTGAGTCCTTACCTGGAACAGCACTCCPTTTCACCACATAGTT	1020
Db	961	GTAATTACCTGAGTCCTTACCTGGAACAGCACTCCPTTTCACCACATAGTT	1020
QY	1021	AACITGACTTCAAGATAATTTCAGGTTTCAACTGGTTTGTGTTGTTTGTGTT	1080
Db	1021	AACITGACTTCAAGATAATTTCAGGTTTCAACTGGTTTGTGTTGTTTGTGTT	1080
QY	1081	TTCGTGGAGAGGGGACCGTGGAGGGTAAACACTTTTCAAGTCACTTA	1140
Db	1081	TTCGTGGAGAGGGGACCGTGGAGGGTAAACACTTTTCAAGTCACTTA	1140
QY	1141	CTAAACAAACTTTGTAATAAGACCTTACCTCTTATTTGAGTTCAATTATTTGC	1200
Db	1141	CTAAACAAACTTTGTAATAAGACCTTACCTCTTATTTGAGTTCAATTATTTGC	1200
QY	1201	AGCTTAGGCCATCAAGGCTGACTCTGACTCTGACTTGAATTGACTGACTGTT	1260
Db	1201	AGCTTAGGCCATCAAGGCTGACTCTGACTCTGACTTGAATTGACTGACTGTT	1260
QY	1261	ATCGGGATCTGCTGACTCTGACTCTGACTCTGACTCTGACTCTGACTGCT	1320
Db	1261	ATCGGGATCTGCTGACTCTGACTCTGACTCTGACTCTGACTCTGACTGCT	1320
QY	1321	TTCACAAAAGAGATTTCCTCATGTACTTGATCTGATGCAATGATCTGAGAC	1380
Db	1321	TTCACAAAAGAGATTTCCTCATGTACTTGATCTGATGCAATGATCTGAGAC	1380
QY	1381	AAACTGGCCATTGCTACTTTACTCTAAAGACTAAACTAGCTTGTGCTT	1440
Db	1381	AAACTGGCCATTGCTACTTTACTCTAAAGACTAAACTAGCTTGTGCTT	1440
QY	1441	ACTCATCTCTAGTACCTTAAAGCAATCCTAAAGGACTGGACACTGAAATAAGAA	1500
Db	1441	ACTCATCTCTAGTACCTTAAAGCAATCCTAAAGGACTGGACACTGAAATAAGAA	1500
QY	1501	ATTTTATTTAACCCAGCCCTCCCTGATGATAATAACACATTGCACTTC	1560
Db	1501	ATTTTATTTAACCCAGCCCTCCCTGATGATAATAACACATTGCACTTC	1560
QY	1561	CGGTCTGGTGTGAGGGCCTGTTGAGCTCCATAATGCAAGCTTGAATAGGCTGG	1620
Db	1561	CGGTCTGGTGTGAGGGCCTGTTGAGCTCCATAATGCAAGCTTGAATAGGCTGG	1620
QY	1621	GGTTGTGGTGCCTCTTGAAAGGCTAACATTATTGATAACTGGCTTTCTCC	1680
Db	1621	GGTTGTGGTGCCTCTTGAAAGGCTAACATTATTGATAACTGGCTTTCTCC	1680
QY	1681	TATGTCCTTCTTGAAATTAACATAATAATTGAAACATCA	1728
Db	1681	TATGTCCTTCTTGAAATTAACATAATAATTGAAACATCA	1728

GenCore version 5.1.6
 Copyright (c) 1993 - 2004 Compugen Ltd.

score greater than or equal to the score of the result being printed,
 and is derived by analysis of the total score distribution.

SUMMARIES

OM nucleic - nucleic search, using sw model		Result No.				% Query Match Length DB ID Description			
Run on:	April 20, 2004, 01:58:41 ; Search time 6718 Seconds (without alignments)	Score:	Score:	Score:	Score:	Score:	Score:	Score:	Score:
Title:	US-09-989-725-417	1	1728	100.0	1728	6	AR252653	Sequence	AR252653 Sequence
Perfect score:	1728	2	1728	100.0	1728	6	AX05468	Sequence	AX05468 Sequence
Sequence:	1 cagcgggtccaaaggctgt.....aaaaatttgaaacatcaa 1728	3	1728	100.0	1728	6	AX055716	Sequence	AX055716 Sequence
Scoring table:	IDENTITY_NUC	4	1728	100.0	1728	6	AX077037	Sequence	AX077037 Sequence
Gapop 10.0 , Gapext 1.0	5	1728	100.0	1728	6	AK103530	Sequence	AK103530 Sequence	
Searched:	3470272 seqs, 21671516995 residues	6	1728	100.0	1728	9	AY335909	Human sapi	AY335909 Human sapi
Total number of hits satisfying chosen parameters:	6940544	7	1690.4	97.8	1772	9	BC040124	Human sapi	BC040124 Human sapi
Minimum DB seq length: 0		8	1685.4	97.5	1834	6	BD222662	Human sapi	BD222662 Human sapi
Maximum DB seq length: 2000000000		9	1672.2	96.8	1694	6	BD127721	Primer fo	BD127721 Primer fo
Post-Processing: Minimum Match 0%		10	AK074677	90.0					
Maximum Match 100%		11	1649.2	95.4	1734	6	AR352701	Sequence	AR352701 Sequence
Listing First 45 summaries		12	1649.2	95.4	1734	6	BD15646	70 human	BD15646 70 human
Database :	GenSymbol*	13	1589.6	92.0	1772	6	AR352639	Sequence	AR352639 Sequence
	1: gb_ba:*	14	1589.6	92.0	1772	6	BD195584	70 human	BD195584 70 human
	2: gb_hhg:*	15	1589.6	92.0	1772	6	BD218614	71 human	BD218614 71 human
	3: gb_in:*	16	1514.8	87.7	1669	9	BC015884	Human sapi	BC015884 Human sapi
	4: gb_cm:*	17	1498	86.7	1498	6	BD170617	NF-kappa	BD170617 NF-kappa
	5: gb_cv:*	18	1498	86.7	1498	9	AB097017	Human sapi	AB097017 Human sapi
	6: gb_pat:*	19	1494.4	86.5	1500	6	BD233471	Human pro	BD233471 Human pro
	7: gb_ph:*	20	1402.2	81.1	1626	6	BD218547	71 human	BD218547 71 human
	8: gb_P1:*	21	1183.4	68.5	224761	9	AC026894	Human sapi	AC026894 Human sapi
	9: gb_pr:*	22	1181.8	68.4	256164	9	RSA100877	Human sapi	RSA100877 Human sapi
	10: gb_ro:*	23	1159.4	67.1	160849	2	AC011219	Human sapi	AC011219 Human sapi
	11: gb_sts:*	24	1159.4	67.1	163126	9	AC124658	Human sapi	AC124658 Human sapi
	12: gb_sy:*	25	974.8	56.4	209573	2	AC100761	Human sapi	AC100761 Human sapi
	13: gb_un:*	26	903.8	52.3	1720	6	BD269862	Tine poly	BD269862 Tine poly
	14: gb_vl:*	27	901.4	52.2	1686	10	BC002208	Mus muscu	BC002208 Mus muscu
	15: em_da:*	28	594	34.4	594	6	BD0233461	Human pro	BD0233461 Human pro
	16: em_da:*	29	584	33.8	589	6	BD124761	Primer fo	BD124761 Primer fo
	17: em_hum:*	30	584	33.8	589	6	BD126776	Primer fo	BD126776 Primer fo
	18: em_in:*	31	532.8	30.8	231883	2	AC132584	Mus muscu	AC132584 Mus muscu
	19: em_ph:*	32	532.8	30.8	234169	10	MNU0400878		MNU0400878
	20: em_p1:*	33	502	29.1	502	6	AX397151	Sequence	AX397151 Sequence
	21: em_pr:*	34	502	29.1	502	6	AX397171	Sequence	AX397171 Sequence
	22: em_ro:*	35	376.6	21.8	61820	2	AC120026	Human sapi	AC120026 Human sapi
	23: em_vl:*	36	337.4	19.5	339	11	G38653	SGC-64019	G38653 SGC-64019
	24: em_da:*	37	312.2	18.1	1054	5	BC050159	Danio rer	BC050159 Danio rer
	25: em_hum:*	38	280.6	16.2	437	11	CG1187	human STS W	CG1187 human STS W
	26: em_in:*	39	279.4	16.2	207364	2	AC120564	Rattus no	AC120564 Rattus no
	27: em_ph:*	40	279.4	16.2	266766	2	AC094770	Rattus no	AC094770 Rattus no
	28: em_p1:*	41	257.6	14.9	61820	2	AC120026	Human sapi	AC120026 Human sapi
	29: em_vl:*	42	208	12.0	70553	2	AC120030	Human sapi	AC120030 Human sapi
	30: em_sts:*	43	202.6	11.7	15652	6	BD170687	NF-kappa	BD170687 NF-kappa
	31: em_cv:*	44	196.8	11.4	1495	6	AX136089	Sequence	AX136089 Sequence
	32: em_cv:*	45	196.8	11.4	1499	6	BD093294	Amyloid b	BD093294 Amyloid b

ALIGNMENTS

RESULT 1	AR252653	1728 bp	DNA	linear	PAT 20-DEC-2002
LOCUS	Sequence 417 from patent US 6478825.				
DEFINITION					
ACCESSION	AR252653				
VERSION	AR252653.1				
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unclassified.				
REFERENCE	1 (bases 1 to 1728)				
AUTHORS	Winterbottom, J.M., Shimp, L., Boyce, T.M. and Kaeo, D.				
TITLE	Implant, method of making same and use of the implant for the treatment of bone defects				
JOURNAL	Patent : US 6478825-A 417 12-NOV-2002;				

Pred. No. is the number of results predicted by chance, to have a

FEATURES	Location/Qualifiers
source	1..1728 /organism="Unknown" /mol_type="Genomic DNA"
ORIGIN	
Query Match	100.0%; Score 1728; DB 6; Length 1728;
Best Local Similarity	100.0%; Pred. No. 0;
Matches 1728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Cy	1 CAGCGGGTCCAAAGCCTGCCCCTGCCCCCTGAGCCCTGAGCCCTGAGCCGCC 60
Db	1 CAGCGGGTCCAAAGCCTGCCCCTGCCCCCTGAGCCCTGAGCCCTGAGCCGCC 60
Cy	61 GGTGCGGGGGGCGTCGGGGCTGGGGACCGCTGGGGACCCCTGGGG 120
Db	61 GGCGGGGGGCGTCGGGGCTGGGGACCGCTGGGGACCCCTGGGG 120
Qy	121 AGGCCTTCCTGGCTTCAGCTGGCTTCAGCTGGCTTCAGCTGGCTTCAGCTGGCT 180
Db	121 AGGCCTTCCTGGCTTCAGCTGGCTTCAGCTGGCTTCAGCTGGCTTCAGCTGGCT 180
Qy	181 GCTGGCGAGCTGTCAGCGCCGCGCAAGAATTGCGAGTCATGATCTG 240
Db	181 GCTGGCGAGCTGTCAGCGCCGCGCAAGAATTGCGAGTCATGATCTG 240
Qy	241 CCTCCCTATAAGCAAAATTCTGGCAATTATAAGACATATCTGAAAGATG 300
Db	241 CCTCCCTATAAGCAAAATTCTGGCAATTATAAGACATATCTGAAAGATG 300
Qy	301 TGATTGCTTCATTTGTGAGGCCATCTTGCGGGCCTGATGAGAGCATCTG 360
Db	301 TGATTGCTTCATTTGTGAGGCCATCTTGCGGGCCTGATGAGAGCATCTG 360
Qy	361 TCTACGCTTGTAATGCAATGAGAAACTCTCTGAGGTTACATTAT 420
Db	361 TCTACGCTTGTAATGCAATGAGAAACTCTCTGAGGTTACATTAT 420
Qy	421 AATTATTCCTCATTGGCCCTCTACTCTGATATCTCTGTTGA 480
Db	421 AATTATTCCTCATTGGCCCTCTACTCTGATATCTCTGTTGA 480
Qy	481 GCCCATATCTGAAGGGCCCTCTTGGACATGACAGGTGATGATGAT 540
Db	481 GCCCATATCTGAAGGGCCCTCTTGGACATGACAGGTGATGATGAT 540
Qy	541 TGGGATCAACGAGCTTGCACATGCAAGGAAATGCAAGGAAAGCTCAAGGCA 600
Db	541 TGGGATCAACGAGCTTGCACATGCAAGGAAATGCAAGGAAAGCTCAAGGCA 600
Qy	601 CAACTGTGAACAGGTAGAAATGCAAGGAACTGGCTGAAAGCA 660
Db	601 CAACTGTGAACAGGTAGAAATGCAAGGAACTGGCTGAAAGCA 660
Cy	661 CGAAAGCTGTGCTTGAACGGGATGTTCTCCCTCAGTAATTGGGATGATTCAAGT 720
Db	661 CGAAAGCTGTGCTTGAACGGGATGTTCTCCCTCAGTAATTGGGATGATTCAAGT 720
Cy	721 GACTGAAGAAAAGCCAGACAACACTGGAAAGACTGCTGGGTTCTCATTT 780
Db	721 GACTGAAGAAAAGCCAGACAACACTGGAAAGACTGCTGGGTTCTCATTT 780
Qy	781 TTAAATACCTGTGTTGATTCACCAACTGTGCTGGAAAGTTCAAACCTGGGAAAGCT 840
Db	781 TTAAATACCTGTGTTGATTCACCAACTGTGCTGGAAAGTTCAAACCTGGGAAAGCT 840
Qy	841 TGCTTGATTTTCTGTAACTGAAATTAAGACAGATTTTAAAGAACACAGCTC 900
Db	841 TGCTTGATTTTCTGTAACTGAAATTAAGACAGATTTTAAAGAACACAGCTC 900
Qy	901 AAATCGCCAATAGCTTCTTCTATGTGACTTTACTATAATAATAATCTGCCT 960
Db	901 AAATCGCCAATAGCTTCTTCTATGTGACTTTACTATAATAATAATCTGCCT 960
Qy	961 GTAAATTATCTTGAAAGCTTACCTGGAAACAGCACCTCTCTTACCCACATAGTTT 1020
Db	961 GTAAATTATCTTGAAAGCTTACCTGGAAACAGCACCTCTCTTACCCACATAGTTT 1020
Qy	1021 AACCTGACTTCTCAGATAATTTCAGGGTTTCTGCTGGTTCTGTTGTTGTTGTT 1080
Db	1021 AACCTGACTTCTCAGATAATTTCAGGGTTTCTGCTGGTTCTGTTGTTGTTGTT 1080
Cy	1081 TTGGGGGAGGGGGGGATGCCCTGAGCTGGGGAGCTACACCTTCAAGCCTTA 1140
Db	1081 TTGGGGGAGGGGGGGATGCCCTGAGCTGGGGAGCTACACCTTCAAGCCTTA 1140
Qy	1141 CTAAACAAACTTTGTAATAGACCTTACCTCTTATTCGAGTTTCATTATTTGTC 1200
Db	1141 CTAAACAAACTTTGTAATAGACCTTACCTCTTATTCGAGTTTCATTATTTGTC 1200
Qy	1201 AGTGAAGCCCTGAACTGACTGACTTCAATTGACTGACTGACTGTT 1260
Db	1201 AGTGAAGCCCTGAACTGACTGACTTCAATTGACTGACTGACTGTT 1260
Qy	1261 ATCCTGGTATCTGGTGTGCTGACTTCAATTGACTGACTGACTGTT 1320
Db	1261 ATCCTGGTATCTGGTGTGCTGACTTCAATTGACTGACTGACTGTT 1320
Qy	1321 TTTCRCAAAAGCAGATTCTCTCATGACTGTCATGTCATCTGATCAGAC 1380
Db	1321 TTTCRCAAAAGCAGATTCTCTCATGACTGTCATGTCATCTGATCAGAC 1380
Qy	1381 AAACCTGGCCATTCTGCTAGTTACCTTAAGACTAAACATAGCTTGGTGTGCTT 1440
Db	1381 AAACCTGGCCATTCTGCTAGTTACCTTAAGACTAAACATAGCTTGGTGTGCTT 1440
Qy	1441 ACTCTCTCTAGTACCCCTTAAGCAAACTCTGGAGACTGACACTGCAATAAGAA 1500
Db	1441 ACTCTCTCTAGTACCCCTTAAGCAAACTCTGGAGACTGACACTGCAATAAGAA 1500
Qy	1501 ATTATTTAAACCAAGCCTCTGATTGATAATATACACATTGTCAGCATTTC 1560
Db	1501 ATTATTTAAACCAAGCCTCTGATTGATAATATACACATTGTCAGCATTTC 1560
Qy	1561 CGGTGTCGGAGAGCAGACTGTTGAGTCCCAATATGCAACTTGAACTGGCTGG 1620
Db	1561 CGGTGTCGGAGAGCAGACTGTTGAGTCCCAATATGCAACTGGCTGG 1620
Qy	1621 GGTTGGGGCCCTCTGAAACGCTTAATTGGATAACTGGTTTTCTTCC 1680
Db	1621 GGTTGGGGCCCTCTGAAACGCTTAATTGGATAACTGGTTTTCTTCC 1680
REF ID: AX055468	RESULT 2
LOCUS	AX055468
DEFINITION	Sequence 98 from Patent WO0073452.
VERSION	AX055468
KEYWORDS	GI:12228731
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Butheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	Ashkenazi A.J., Baker, K.P., Chan, B., Goddowski, P.J., Gurney, A.L., Hebert, C., Henzel, W., Kabakoff, R.C., Tumas, D., Watanabe, C.K. and Wood, W.I., Compositions and methods for the treatment of immune related diseases
AUTHORS	
TITLE	Patent: WO 0073452-A 98-07-DEC-2000; Genentech, Inc. (US)
JOURNAL	

FEATURES	source	location/Qualifiers	
	1:..1728	/organism="Homo sapiens"	
	/mol_type="unaligned DNA"	/db_xref="taxon:9606"	
ORIGIN			
Query Match		Score 1728; DB 6; Length 1728;	
Best Local Similarity	100.0%	Pred. No. 0;	
Matches 1728; Conservative	0;	Indels 0;	Gaps 0;
QY	1 CAGCCGGTCCDAAGCCTGACCTGAGCCGCGGCC 60		
DB	1 CAGCCGGTCCCAAGCCTGACCTGAGCCGCGGCC 60		
QY	61 GGTGCGGGGGCTCGGCGCTGTGGGACCGCCCC 120		
DB	61 GTGCGGGGGCTCGGCGCTGTGGGACCGCCCC 120		
QY	121 AGACCTTTTCGCTGGCTCTGGCTGCTGGCT 180		
DB	121 AGACCTTTTCGCTGGCTCTGGCTGCTGGCT 180		
QY	181 GCTGGCGAGGTCTAGCGCCCAAAGAATTGGGATGTCAGATGTAATGATCTG 240		
DB	181 GCTGGCGAGGTCTAGCGCCCAAAGAATTGGGATGTCAGATGTAATGATCTG 240		
QY	241 CCCCTCCATAAAGAAAMTTCTGGCATATTATAAAGACATTCGAGAGATG 300		
DB	241 CCCCTCCATAAAGAAAMTTCTGGCATATTATAAAGACATTCGAGAGATG 300		
QY	301 TGAATTGCCTCATGTTGGAGCCATTCCTTGCGGGGGCTGATGAGAGCATCTG 360		
DB	301 TGATTCCTCATGTTGGAGCCATTCCTTGCGGGGGCTGATGAGAGCATCTG 360		
QY	361 TCTACGCTGTGAATGCAATGAGAGAGCTGTGTCATGAGGTACCTATT 420		
DB	361 TCTACGCTGTGAATGCAATGAGAGAGCTGTGTCATGAGGTACCTATT 420		
QY	421 AATTATTCCTCCATTGGGCCCTCPACTCTGTGATGGPATACTCTGGTGA 480		
DB	421 AATTATTCCTCCATTGGGCCCTCPACTCTGTGATGGPATACTCTGGTGA 480		
QY	481 GCCCATACTGAAGGGCCCTCTTGCACATGCACATGATGATGATGATAT 540		
DB	481 GCCCATACTGAAGGGCCCTCTTGCACATGCACATGATGATGATGATAT 540		
QY	541 TGGGATCACCGCCCTTGCACATGTCGCGCTCCCGAGTGAGC 600		
DB	541 TGGGATCACCGCCCTTGCACATGTCGCGCTCCCGAGTGAGC 600		
QY	601 CAACGGCTGACAGGTAGAAATGCAAGCAGGCTGAGCTCAAGAGCA 660		
DB	601 CAACGGCTGACAGGTAGAAATGCAAGCAGGCTGAGCTCAAGAGCA 660		
QY	661 GCGAAAGTCTGCTTGCCTTGCACGGCATGTCCTCAGTAATTGGGATTAAGGT 720		
DB	661 GCGAAAGTCTGCTTGCCTTGCACGGCATGTCCTCAGTAATTGGGATTAAGGT 720		
QY	721 GACTGAAGAAAAGGGAGAACACTGGAAAGACTGCTGCTGGTTTCATT 780		
DB	721 GACTGAAGAAAAGGGAGAACACTGGAAAGACTGCTGCTGGTTTCATT 780		
QY	781 TTAAATACCTGTGATTCACCAACTGTGCTGGAAAGTCAAAACTGGANGCAAACCT 840		
DB	781 TTAAATACCTGTGATTCACCAACTGTGCTGGAAAGTCAAAACTGGANGCAAACCT 840		
QY	841 TGCTGTGATTTCCTTGCTGTGATTAATAGAGCAATTTAAAGGACAGCTC 900		
DB	841 TGCTGTGATTTCCTTGCTGTGATTAATAGAGCAATTTAAAGGACAGCTC 900		
QY	901 AAAGTCAGCCAATTAAGTCTTCCATTGTGACTTTACTATAAAATAATCTGCT 960		
RESULT	3		
AX055716			
LOCUS	AX055716	From Patent WO007348.	
DEFINITION	Sequence 31		
ACCESSION	AX055716		
VERSION	AX055716.1	GI:12228841	
KEYWORDS			
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Butheria; Primates; Catarrhini; Hominidae; Homo.		
REFERENCE	1 Baker, K.P., Goddard, A., Hebert, A.L., Henzel, W., Kabakoff, R.C., Shelton, D.L., Smith, V., Watanabe, C.K. and Wood, W.I.		
AUTHORS			
TITLE	Methods and compositions for inhibiting neoplastic cell growth		
JOURNAL	Patent: WO 007348-A 31-07-DEC-2000; Genentech, Inc. (US)		
FEATURES	Location/Qualifiers		

source 1..1728
 organism="Homo sapiens"
 /mol type="unassigned DNA"
 /db_xref="taxon:9606"

RIGIN

Query Match 100.0%; Score 1728; DB 6; Length 1728;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

1 CAGCGGGTCCCCAAGCTGTGCTGAGCCTGAGCTGAGCCGAGCCGGAGGCC 60
1 CAGCGGGTCCCCAAGCTGTGCTGAGCCTGAGCTGAGCCGAGCCGGAGGCC 60
61 GTCGGGGGGCTCGGGCTGGGGCTGGGGATGGGGAAAGTGTTAACACTT 1140
61 GTCGGGGGGCTCGGGCTGGGGCTGGGGATGGGGAAAGTGTTAACACTT 1140
121 AGGCCTTCCTGGCTTCGGCTTCGGCTGGGGCTGGGGATGGGGAAAGTGCT 1200
121 AGGCCTTCCTGGCTTCGGCTGGGGCTGGGGATGGGGAAAGTGCT 1200
181 GCTGGCGAGCTGCAAGCGCCCAAAATTGGAGATGTCAGATGTAATGATCG 240
181 GCTGGCGAGCTGCAAGCGCCCAAAATTGGAGATGTCAGATGTAATGATCG 240
241 CCCCTCCATAAAGAAATTCTGGCATATTATAAGACATATCTGAAACATG 300
241 CCCCTCCATAAAGAAATTCTGGCATATTATAAGACATATCTGAAACATG 300
301 TGATTCGCTTCAGTTGGAGCCATGGGGCTGATGAGCATACTG 360
301 TGATTCGCTTCAGTTGGAGCCATGGGGCTGATGAGCATACTG 360
361 TCTACGCTGTAATGCAATCAATCAAGGGTACATTAT 420
361 TCTACGCTGTAATGCAATCAATCAAGGGTACATTAT 420
361 TCTACGCTGTAATGCAATCAATCAAGGGTACATTAT 420
421 AATTATCTCCATTGGCCTTCTACTCTGGPATATCTACTCTGGTGA 480
421 AATTATCTCCATTGGCCTTCTACTCTGGPATATCTACTCTGGTGA 480
481 GCCCATATGAAAGGGCCCTTGGCATGGACAGITGATACAGTGATGATAT 540
481 GCCCATATGAAAGGGCCCTTGGCATGGACAGITGATACAGTGATGATAT 540
541 TGGGATACCAAGCCTTGCALAAATGCAAGGGTACATTGTGATGATAT 600
541 TGGGATACCAAGCCTTGCALAAATGCAAGGGTACATTGTGATGATAT 600
601 CAACGTGAAACAGGTAGAAATTGCAAGGGCAGCTTCAAGTCAGAGCA 660
601 CAACGTGAAACAGGTAGAAATTGCAAGGGCAGCTTCAAGTCAGAGCA 660
661 GCGAAAGTCCTGCTTGGACGGCATGTTGCTTCAGTAATGGGAATGATTCAAGGT 720
661 GCGAAAGTCCTGCTTGGACGGCATGTTGCTTCAGTAATGGGAATGATTCAAGGT 720
721 GACTGAAAGAAACGGAGACAACCTGGAAAGAAACTGCTGCTGGTTTCATT 780
721 GACTGAAAGAAACGGAGACAACCTGGAAAGAAACTGCTGCTGGTTTCATT 780
781 TTAATACCTGTTGTTGTTTACCAACTGCTGCTGGAAAGTTCAACACTGAGCAAAACT 840
781 TTAATACCTGTTGTTGTTACCAACTGCTGCTGGAAAGTTCAACACTGAGCAAAACT 840
841 TGCTGTGATTTTTTCTGTTACGTATAATAGAGCATTTAACGGCACAGCTC 900
841 TGCTGTGATTTTTTCTGTTACGTATAATAGAGCATTTAACGGCACAGCTC 900
901 AAAGTCGCCAAATAGTCCTTCTGCTTACGTATAATAGAGCATTTAACGGCACAGCTC 960
901 AAAGTCGCCAAATAGTCCTTCTGCTTACGTATAATAGAGCATTTAACGGCACAGCTC 960

```

RESULT 4
 AX077037
 LOCUS Sequence 25 from Patent
 DEFINITION WO0105972.
 ACCESSION AX077037
 VERSION AX077037.1 GI:13121664
 KEYWORDS Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 Ashkenzi A.J., Baker K.P., Pong, S., Goddard A., Godowski, P.J.,
 Gurney A.L., Hilian, K.J., Mark, M.R., Marsters, S.A., Pitti, R.M.,
 Tomas, D., Watanae, C.K. and Wood, W...
 Compositions and methods for the treatment of immune related
 diseases
 Genentech, Inc. (US) Patient : WO 0105972-A 25-JAN-2001
 JOURNAL

FEATURES		Location/Qualifiers				
1..1728	source	1..1728	Score 100.0%; Best Local Similarity 100.0%; Matches 1728; Query Match	Db	901 AAATCAGCCAAATAGCTTCTATTGTGACTTTACTAATAAAATAATTGCTT 960	
/organism="Homo Sapiens"		0..0	Conservative 0; Mismatches 0; Gaps 0;	Qy	961 GTAAATTATCTTGAAAGTCCTTACCTGGAAACAAGCACTCCTTTT CACCATAGTTT 1020	
/mol type="unassigned DNA"				Db	961 GTAAATTATCTTGAAAGTCCTTACCTGGAAACAAGCACTCCTTTT CACCATAGTTT 1020	
PRIGIN						
1	CAGCGCGGCTCCAGGCGCTGCGCCCTTAAGCCTGAGCCCTGAGCCGGCGAGGC 60	1	CAAGCGGCTCCAAAGCTGTGCCCTGAAGCTTGAGCTGAGCCGGAGGC 60	Qy	1021 AACTGACTTCAGATAATTTCAGGGTTTGTGTTGTTGTTGTTGTT 1080	
b	61	GGTCGCGGGGCTCCGGGTGTGAGACCGTGCCCCCGCGATGGCAGAACCTGAGCCGGAGGC 60	1	GGTGGGGAGAGGGGGATGGCTGGAGTGTTAACACTTTCAAGTCCTTA 1140	Db	1081 TTGGGGAGAGGGGGATGGCTGGAGTGTTAACACTTTCAAGTCCTTA 1140
b	61	GGTCGCGGGGCTCCGGGTGTGAGACCGTGCCCCCGCGATGGCAGAACCTGAGCCGGAGGC 60	61	CTAAACAAACTTTGTAATAAGACCTTACCCCTPATTTGAGTTTCAATTATTTGTC 1200	Qy	1141 CTAAACAAACTTTGTAATAAGACCTTACCCCTPATTTGAGTTTCAATTATTTGTC 1200
b	61	GGTCGCGGGGCTCCGGGTGTGAGACCGTGCCCCCGCGATGGCAGAACCTGAGCCGGAGGC 60	61	CTAAACAAACTTTGTAATAAGACCTTACCCCTPATTTGAGTTTCAATTATTTGTC 1200	Db	1141 CTAAACAAACTTTGTAATAAGACCTTACCCCTPATTTGAGTTTCAATTATTTGTC 1200
b	121	AGGCCCTCTTCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG 180	121	AGGCCCTCTTCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG 180	Qy	1201 AGTGTAGCCAGGCTTCATCAAAAGAGTGACTTACCTAATGACTTTGCACTGCTGCTATT 1260
b	121	AGGCCCTCTTCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG 180	121	AGTGTAGCCAGGCTTCATCAAAAGAGTGACTTACCTAATGACTTTGCACTGCTGCTATT 1260	Db	1201 AGTGTAGCCAGGCTTCATCAAAAGAGTGACTTACCTAATGACTTTGCACTGCTGCTATT 1260
b	181	GCTGGCGAGCTGTGAGACCCGCCAAAGATTTCAGGATGTCAGATGPAATAATGTTATCTG 240	181	GCTGGCGAGCTGTGAGACCCGCCAAAGATTTCAGGATGTCAGATGPAATAATGTTATCTG 240	Qy	1261 ATCTGGTATCTGGTGTGACTTCATGGTAACGGGATCTCAAAATGCTGGCTGCT 1320
b	181	GCTGGCGAGCTGTGAGACCCGCCAAAGATTTCAGGATGTCAGATGPAATAATGTTATCTG 240	181	GCTGGCGAGCTGTGAGACCCGCCAAAGATTTCAGGATGTCAGATGPAATAATGTTATCTG 240	Db	1261 ATCTGGTATCTGGTGTGACTTCATGGTAACGGGATCTCAAAATGCTGGCTGCT 1320
b	241	CCCTCCCTAAAGAAAAATTCTGGCATATTATAAAACACATATCAGAAAGATG 300	241	CCCTCCCTAAAGAAAAATTCTGGCATATTATAAAACACATATCAGAAAGATG 300	Qy	1321 TTTCACAAAAGAGCATTTCTCATGATCTGTGATGATGATCTGTGATGATG 1380
b	241	CCCTCCCTAAAGAAAAATTCTGGCATATTATAAAACACATATCAGAAAGATG 300	241	CCCTCCCTAAAGAAAAATTCTGGCATATTATAAAACACATATCAGAAAGATG 300	Db	1321 TTTCACAAAAGAGCATTTCTCATGATCTGTGATGATGATCTGTGATG 1380
b	301	TGATTCCTCATGTTGTGAGCCCATGGCTTGTGGGGCCCTGATGAAAGCTACTC 360	301	TGATTCCTCATGTTGTGAGCCCATGGCTTGTGGGGCCCTGATGAAAGCTACTC 360	Qy	1381 AAATGGCCATTGGTAGTTACTCTAAAGCTAACTTCATGGACTCTGCTT 1440
b	301	TGATTCCTCATGTTGTGAGCCCATGGCTTGTGGGGCCCTGATGAAAGCTACTC 360	301	TGATTCCTCATGTTGTGAGCCCATGGCTTGTGGGGCCCTGATGAAAGCTACTC 360	Db	1381 AAATGGCCATTGGTAGTTACTCTAAAGCTAACTTCATGGACTCTGCTT 1440
b	361	TCTACCGCTGTAATGCAAATAATGAAAGAAAGCTGTGATCAATCAAGTTACATTAT 420	361	TCTACCGCTGTAATGCAAATAATGAAAGAAAGCTGTGATCAATCAAGTTACATTAT 420	Qy	1441 ACTCATCTCTAGTACCTTAAGGACAAATCCTAGAATCTGGCTGCTT 1500
b	361	AATTATCTCTCCATTGGCCCTCTACTCTGTACATGGTATCTCTACTCTGGTGA 420	361	AATTATCTCTCCATTGGCCCTCTACTCTGTACATGGTATCTCTACTCTGGTGA 420	Db	1441 ACTCATCTCTAGTACCTTAAGGACAAATCCTAGAATCTGGCTGCTT 1500
b	421	AATTATCTCTCCATTGGCCCTCTACTCTGTACATGGTATCTCTACTCTGGTGA 480	421	AATTATCTCTCCATTGGCCCTCTACTCTGTACATGGTATCTCTACTCTGGTGA 480	Qy	1501 ATTATTTAAACCCAGCTCCCTGGATTGATAATACTACATGCTGGCTT 1560
b	421	AATTATCTCTCCATTGGCCCTCTACTCTGTACATGGTATCTCTACTCTGGTGA 480	421	AATTATCTCTCCATTGGCCCTCTACTCTGTACATGGTATCTCTACTCTGGTGA 480	Db	1501 ATTATTTAAACCCAGCTCCCTGGATTGATAATACTACATGCTGGCTT 1560
b	481	GCCCCATACGTGAAAGGGCCCTCTGGACATGCAAGTGTGATGATGATGAT 540	481	GCCCCATACGTGAAAGGGCCCTCTGGACATGCAAGTGTGATGATGATGAT 540	Qy	1561 CGGTGTGGTGGCCCTCTCTGAAAGGTCTAACCTATTGGATAACTGGCTTTCTCC 1620
b	481	GCCCCATACGTGAAAGGGCCCTCTGGACATGCAAGTGTGATGATGATGAT 540	481	GCCCCATACGTGAAAGGGCCCTCTGGACATGCAAGTGTGATGATGATGAT 540	Db	1561 CGGTGTGGTGGCCCTCTCTGAAAGGTCTAACCTATTGGATAACTGGCTTTCTCC 1620
b	541	TGGGATCACAGCCCTTGTGAAAGGACCCGATGCTGCTGCCCTCCGGCAGTCGAC 600	541	TGGGATCACAGCCCTTGTGAAAGGACCCGATGCTGCTGCCCTCCGGCAGTCGAC 600	Qy	1621 GGTTGGTGGCCCTCTCTGAAAGGTCTAACCTATTGGATAACTGGCTTTCTCC 1680
b	541	TGGGATCACAGCCCTTGTGAAAGGACCCGATGCTGCTGCCCTCCGGCAGTCGAC 600	541	TGGGATCACAGCCCTTGTGAAAGGACCCGATGCTGCTGCCCTCCGGCAGTCGAC 600	Db	1621 GGTTGGTGGCCCTCTCTGAAAGGTCTAACCTATTGGATAACTGGCTTTCTCC 1680
b	601	CAACGTGCTGAAAGGTGAAATAACCAAGCAGTCGCTGCCCTCCGGCAGTCGAC 660	601	CAACGTGCTGAAAGGTGAAATAACCAAGCAGTCGCTGCCCTCCGGCAGTCGAC 660	Qy	1681 TATGTCCTTGTGAAATAAAATAATTGTGAAACATCAA 1728
b	601	CAACGTGCTGAAAGGTGAAATAACCAAGCAGTCGCTGCCCTCCGGCAGTCGAC 660	601	CAACGTGCTGAAAGGTGAAATAACCAAGCAGTCGCTGCCCTCCGGCAGTCGAC 660	Db	1681 TATGTCCTTGTGAAATAAAATAATTGTGAAACATCAA 1728
Y	661	GCGAAAGTGTGCTTGTGACCGCGATTTGTCTCATGGGAATTCAATTCAAGGT 720	661	GCGAAAGTGTGCTTGTGACCGCGATTTGTCTCATGGGAATTCAATTCAAGGT 720	RESULT 5	
b	661	GCGAAAGTGTGCTTGTGACCGCGATTTGTCTCATGGGAATTCAATTCAAGGT 720	661	GCGAAAGTGTGCTTGTGACCGCGATTTGTCTCATGGGAATTCAATTCAAGGT 720	AX403530	
b	721	GACTGAAAGAAACGGCAACAACTGGAAAGRACTGACGGGTTTGTGGTTCAATT 780	721	GACTGAAAGAAACGGCAACAACTGGAAAGRACTGACGGGTTTGTGGTTCAATT 780	LOCUS	1728 bp
b	721	GACTGAAAGAAACGGCAACAACTGGAAAGRACTGACGGGTTTGTGGTTCAATT 780	721	GACTGAAAGAAACGGCAACAACTGGAAAGRACTGACGGGTTTGTGGTTCAATT 780	DEFINITION	Sequence 417 from Patent WO0073454.
b	781	TTAATACCTTGTGATTCAACACTGTTGAGGATCAAAACTGGAAAGAAACT 840	781	TTAATACCTTGTGATTCAACACTGTTGAGGATCAAAACTGGAAAGAAACT 840	ACCESSION	AX403530
b	781	TTAATACCTTGTGATTCAACACTGTTGAGGATCAAAACTGGAAAGAAACT 840	781	TTAATACCTTGTGATTCAACACTGTTGAGGATCAAAACTGGAAAGAAACT 840	VERSION	AX403530.1
b	841	TGCTTGTATTTTTGTGAACTGTTGAACTTAATAGAGACATTAAAGCAAGCTC 900	841	TGCTTGTATTTTTGTGAACTGTTGAACTTAATAGAGACATTAAAGCAAGCTC 900	KEYWORDS	GI:21437007
b	841	TGCTTGTATTTTTGTGAACTGTTGAACTTAATAGAGACATTAAAGCAAGCTC 900	841	TGCTTGTATTTTTGTGAACTGTTGAACTTAATAGAGACATTAAAGCAAGCTC 900	ORGANISM	Homo sapiens
b	901	AAAGTCAGCACAATAAGCTTCTCTTGTGACTTTACTAATAAAATAATTGCTT 960	901	AAAGTCAGCACAATAAGCTTCTCTTGTGACTTTACTAATAAAATAATTGCTT 960	SOURCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Eutheria; Primates; Hominoidea; Homo sapiens (human)
Y	1..1728	Score 100.0%; Best Local Similarity 100.0%; Matches 1728; Query Match	Db	901 AAATCAGCCAAATAGCTTCTATTGTGACTTTACTAATAAAATAATTGCTT 960	REFERENCE	1. Ashkenazi, A.J., Baker, K.P., Botstein, D., Desnoyers, L., Eaton, D., Ferraris, N., Gerber, R., Gerritsen, M., Goddard, A., Godowski, P., Grimaldi, C.L., Gunney, A.L., Klagsbrun, I., Napier, M.A., Pan, J., Pioni, N.P., Roy, M., Stewart, T.A., Tomas, D., Watanabe, C.K., Williams, P., Wood, W.I. and Zhang, Z. Secreted and transmembrane polypeptides and nucleic acids encoding
Y	1..1728	Score 100.0%; Best Local Similarity 100.0%; Matches 1728; Query Match	Db	961 GTAAATTATCTTGAAAGTCCTTACCTGGAAACAAGCACTCCTTTT CACCATAGTTT 1020	AUTHORS	2. Ferraris, N., Gerber, R., Gerritsen, M., Goddard, A., Godowski, P., Grimaldi, C.L., Gunney, A.L., Klagsbrun, I., Napier, M.A., Pan, J., Pioni, N.P., Roy, M., Stewart, T.A., Tomas, D., Watanabe, C.K., Williams, P., Wood, W.I. and Zhang, Z. Secreted and transmembrane polypeptides and nucleic acids encoding

JOURNAL	the same	Patent: WO 0073454-A 417 07-DEC-2000;
FEATURES	Genentech Inc. (US)	
Source	1..1728	
	/organism="Homo sapiens"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:9606"	
ORIGIN		
Query Match	100.0%	Score 1728; DB 6; Length 1728;
Best Local Similarity	100.0%	Pred. No. 0;
Matches 1728; Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
Qy	1	CAGCGGGTCCCAGCCCTGCCCCGAGCGGCC 60
Db	1	CAGCGGGTCCCAGCCCTGCCCCGAGCGGCC 60
Qy	61	GTCGGGGGGCTCGGGCTCGGGCTGGGGACCCCTGGGGATGGGGACCCCTGGGG 120
Db	61	GTCGGGGGGCTCGGGCTGGGGACCCCTGGGG 120
Qy	121	AGGCCTTCITCCTGGCTTCAGCTTGCTGCCCCGGCTGAGCCCTGGGG 180
Db	121	AGGCCTTCITCCTGGCTTCAGCTTGCTGCCCCGGCTGAGCCCTGGGG 180
Qy	181	GCTGGCGAGCTGTCAGGGCGCAAGAATTGGAGATGICAAGANGTAATGTATCG 240
Db	181	GCTGGCGAGCTGTCAGGGCGCAAGAATTGGAGATGICAAGANGTAATGTATCG 240
Qy	241	CCCPCCCTATAAAGRAAAATTCTGGCATATTATAATAGAACATATCTCAGAAAGATG 300
Db	241	CCCPCCCTATAAAGRAAAATTCTGGCATATTATAATAGAACATATCTCAGAAAGATG 300
Qy	301	TGATTCCTCATGTTGAGGCCATGGCGCAAGAATTGGAGATGICAAGANGCATACTG 360
Db	301	TGATTCCTCATGTTGAGGCCATGGCGCAAGAATTGGAGATGICAAGANGCATACTG 360
Qy	361	TCTAGCTGTAATGAAATAATGAGAAAAGCTCTCACATCAAGGGTACCAATT 420
Db	361	TCTAGCTGTAATGAAATAATGAGAAAAGCTCTCACATCAAGGGTACCAATT 420
Qy	421	AATTATTCCTCCATTTCGGCTCTACTCTGGTATATCTACTCTGGTGA 480
Db	421	AATTATTCCTCCATTTCGGCTCTACTCTGGTATATCTACTCTGGTGA 480
Qy	481	GCCCCATGAAAGGGCGCTCTGGAGATGACAAGTGATGATGATGATAT 540
Db	481	GCCCCATGAAAGGGCGCTCTGGAGATGACAAGTGATGATGATGATAT 540
Qy	541	TGGGGATCACCAGCTTTCGAAATGCAACAGATGTCGCTAGCCGGCTCCGAGTCAGC 600
Db	541	TGGGGATCACCAGCTTTCGAAATGCAACAGATGTCGCTAGCCGGCTCCGAGTCAGC 600
Qy	601	CAACGTGCTAACAGGTCAAATGCAACAGATGTCGCTAGCCGGCTCCGAGTCAGC 660
Db	601	CAACGTGCTAACAGGTCAAATGCAACAGATGTCGCTAGCCGGCTCCGAGTCAGC 660
Qy	661	GCGAAAGTCGTCCTGGCTTGGACGGCATGTCAGTCAGTGAATTGAAATGCAAGGT 720
Db	661	GCGAAAGTCGTCCTGGCTTGGACGGCATGTCAGTCAGTGAATTGAAATGCAAGGT 720
Qy	721	GACTGAAAGAACAGGAGAACAGAACAGTGGAAAGACTGACTGGGTTTCCTGGGTTTCCT 780
Db	721	GACTGAAAGAACAGGAGAACAGAACAGTGGAAAGACTGACTGGGTTTCCTGGGTTTCCT 780
Qy	781	TAAATACCTGGTGGATTCAACACTGGAGATTCAAACACTGGAAACTAACTGGTTTCACT 840
Db	781	TAAATACCTGGTGGATTCAACACTGGAGATTCAAACACTGGAAACTAACTGGTTTCACT 840
Qy	841	TGCTGTGATTTCTTCAGTAAATAGAGAACATTTAACAGCACACAGCTC 900
Db	841	TGCTGTGATTTCTTCAGTAAATAGAGAACATTTAACAGCACACAGCTC 900
RESULT	6	
LOCUS	AY359069	1728 bp mRNA linear
DEFINITION	Homo sapiens clone DNA67004	Cliforf15 (UNQ712) mRNA, complete cds.
VERSION	AY359069_1	
KEYWORDS	FLI CDNA, Homo sapiens (human)	
ORGANISM	Homo sapiens	
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.		
REFERENCE	1 (bases 1 to 1728)	
AUTHORS	Clark, H.F., Gurney, A.L., Abaya, B., Baker, K., Baldwin, D., Brush, J., Chen, J., Chow, B., Chui, C., Crowley, C., Currell, B., Deuel, B., Dowd, P., Eaton, D., Foster, J., Grimaldi, C., Gu, Q., Hass, P.E.,	

					source	
Db	1561	CGGTCGTGCTGGTGAAGGGCTGGCTTGACTCCGATATGGAGCTTGAACTAGGGCTGG	1620			
QY	1621	GGTTGCTGGCTCTTGTGAAGGTCAACCTATTGGTAACTGGCTTTCCTCC	1680			
Db	1621	GGTTGCTGGCTCTTGTGAAGGTCAACCTATTGGTAACTGGCTTTCCTCC	1680			
QY	1681	TATGTCCTTGTGAATGACATATAATTGGACATCA	1728			
Db	1681	TATGTCCTTGTGAATGACATATAATTGGACATCA	1728	gene		
		1. .1772				
		/organism="Homo sapiens"				
		/mol_type="mRNA"				
		/db_xref="MGC_9606"				
		/clone="MGC_48749 IMAGE:6553804"				
		tissue type="Pancreas, epithelioid carcinoma"				
		/clone.Lib="NIH MGC_70"				
		/lab_host="DH10B"				
		/note="vector: PCMV-SPORT6"				
		1. .1772				
		/gene="IC11orf15"				
		/db_xref="LocusID: 56674"				
		143. .739				
		/codon_start=1				
		/product="chromosome 11 open reading frame 15"				
		/protein_id="AAH40124.1"				
		/db_xref="GT: 25304.015"				
		/db_xref="LocusID: 56674"				
		/translation="MRLWGGILRLGLSLSCLALSVLLIAQLSDAARNPVEDVRKC				
		VPPYKENSIGHLYNKNISQKDCCDCLVPEPMVRGDVEAYLCRCKYKEFRSSVT				
		VPIIYLISLGLLMLMMVYLTVBPLKRRFHQAOLIQSDDDIGHOPFANAHDLVA				
		RSSRANVLNKVEYAQWRKLUQVQEORKSVPDRHVLIS				
				ORIGIN		
				Query Match	97.8%	Score 1690.4;
				Best Local Similarity	99.5%	DB 9; Length 1772;
				Matches 1719; Conservative	0;	Pred. No. 0;
				Matches 1719; Mismatches	1;	Indels 8; Gaps 2;
			1	CAGCGGGTCCCAAGCCCTGGCTAGCTGACCTGAGCTGAGCCCTGAGCCCTGAGCC	60	
			40	CAGCGGGTCCCAAGCCCTGGCTAGCTGAGCTGAGCCCTGAGCCCTGAGCC	99	
			61	GGTCGGGGGGCTCTGGGGGTGGACGCCATGGGATGCCATGGGACCCCTGTGGG	120	
			100	GTTGGGGGGGGCTGGGGTTGGGACCCCTGGGCCCCAGCTGGGACCCCTGTGGG	159	
			121	AGCCCTTCCTCGCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGG	180	
			160	AGGCCTTCCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCT	219	
			181	GCTGGCGAGCTGAGAGCGCCAGAATTTCGAGATGTCAGATGAAATCTATCTG	240	
			220	GCTGGCGAGCTGAGAGCGCCAGAATTTCGAGATGTCAGATGAAATCTATCTG	279	
			241	CCCTCCCTATAAAAATAATTCTGGCATATTATAATAAGAACATATCTCAGAAAGATTG	300	
			280	CCCTCCCTATAAAAATAATTCTGGCATATTATAATAAGAACATATCTCAGAAAGATTG	339	
			QY	301	TGATGCCCTCATGTTGTGAGCCATGCTGCGGGGCTGATGAGAGCTACTG	360
			Db	340	TGATGCCCTCATGTTGTGAGCCATGCTGCGGGGCTGATGAGAGCTACTG	399
			QY	361	TCTAGGCTGTAATGAAATAATGAAAGAAAGCTGTCACATCAGGTACCATAT	420
			Db	400	TCTAGGCTGTAATGAAAGAAAGCTGTCACATCAGGTACCATAT	459
			QY	421	AATTATCTCTCCATTTCGGCTTACTCTCTACATGGTATACTCTGTGTTGA	480
			Db	460	AATTATCTCTCCATTTCGGCTTACTCTCTACATGGTATACTCTGTGTTGA	519
			QY	481	GCCCATACTGAGAGGGCCCTCTGGACATGCACTGATGATGATGATGAT	540
			Db	520	GCCCATACTGAGAGGGCCCTCTGGACATGCACTGATGATGATGATGAT	579
			QY	541	TGGGATCACAGCTGGCTTGGCAAATGACACAGATGCTGGCTGGCTGGCT	600
			Db	580	TGGGATCACAGCTGGCTTGGCAAATGACACAGATGCTGGCTGGCTGGCT	639
			QY	601	CAACGTGCTGAACTGGTAGAATATGACAGCAGGCTGGAAAGCTCAAGTCAAAGCA	660
			Db	640	CAACGTGCTGAACTGGTAGAATATGACAGCAGGCTGGCTGGCTGGCT	699
			QY	661	GCAGAAGTCGCTGCTTGAACGGCATGTTGCTCAGCTTAATGGGAATGAACTCAAGGT	720
			FEATURES			
			Location/Qualifiers			

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LINL: <http://image.lnl.gov>

Series: IMAK Plate: 84 Row: O Column: 11

This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 11034854.

Sequence Data							
DDB	700	GCGAAAGTGTGCTTTGACGGCATGTTGCTCAGTAATTGGAAATTGAATTCAAGGT	759				
QY	721	GAATGAGAAGAACGGGACAACAGGAAAGACTGAAAGACTGACTGGTTTGTGTTGTTCAAT	780				
DDB	760	TAATACCTTGATTTTTCAGTGTGATTGATGAAAGACTGACTGGAAAGACTGACTGGTTCTAT	819				
DY	781	TAAATACCTTGATTTTTCAGTGTGATTGATGAAAGACTGACTGGAAACAAACT	840				
DDB	820	TAATACCTTGATTTTTCAGTGTGATTGATGAAAGACTGACTGGAAACAACT	879				
DY	841	TGCTGTGATTTTTTCAGTGTGATTGATGAAAGACTGACTGGAAACACAGCTC	900				
DDB	880	TGCTGTGATTTTTTCAGTGTGATTGATGAAAGACTGACTGGAAACACAGCTC	938				
DY	901	AAAGTCAGGCAATAAGTGTGACTTTCTATTTGTGACTTTCTATTAATCTGCCT	960				
DDB	939	AAAGTCAGGCAATAAGTGTGACTTTCTATTTGTGACTTTCTATTAATCTGCCT	998				
DY	961	GTAATTATCTGAAGTCTTACCTGAAACAGCACTCTCTCTTTGACACATAGTTT	1020				
DDB	999	GTAATTATCTGAAGTCTTACCTGAAACAGCACTCTCTCTTTGACACATAGTTT	1058				
DY	1021	AACCTGACTTCAGATAATTTCAGGTTTTCAGGTTTTCAGGTTTTCAGGTTT	1080				
DDB	1059	AACCTGACTTCAGATAATTTCAGGTTTTCAGGTTTTCAGGTTTTCAGGTTT	1118				
DY	1081	TTCGTTGGAGAGGGAGGATGCCAGCTGGAAAGTGTAAACACTTTCAGTCACTTA	1140				
DDB	1119	TTCGTTGGAGAGGGAGGATGCCAGCTGGAAAGTGTAAACACTTTCAGTCACTTA	1178				
DY	1141	CTAAACACACTTTGTAAAATGACCTTACCTCTTATTTCAGTTCAATTATTTGCC	1200				
DDB	1179	CTAAACACACTTTGTAAAATGACCTTACCTCTTATTTCAGTTCAATTATTTGCC	1238				
DY	1201	AGCTTAGCCAGCTCATCAAAGAGCTGACTTCTCATTCAGTTTCACMCACITGTT	1260				
DDB	1239	AGCTTAGCCAGCTCATCAAAGAGCTGACTTCTCATTCAGTTTCACMCACITGTT	1298				
DY	1261	ATCTGGTATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	1320				
DDB	1299	ATCTGGTATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	1358				
DY	1321	TTCACAAAAAGGAGATTCTCATGACTGATGATGATGATGATGATGATGAAAC	1380				
DDB	1359	TTCACAAAAAGGAGATTCTCATGACTGATGATGATGATGATGATGATGAAAC	1418				
DY	1381	AAACTGGCCTTGTGCTACTTCTCATGACTTAAAGGAACTACATTCCTGTTGCTCT	1440				
DDB	1419	AAACTGGCCTTGTGCTACTTCTCATGACTTAAAGGAACTACATTCCTGTTGCTCT	1478				
DY	1441	ACTCATCTCTCTGACTCTTAAGGACAATCTTAAGGACTCTGACACTTGCATLAGAA	1500				
DDB	1479	ACTCATCTCTCTGACTCTTAAGGACAATCTTAAGGACTCTGACACTTGCATLAGAA	1538				
DY	1501	ATTATTTAAACCCAGCCCTCTGAACTTATACATTCAGTGTGCTGCTGCTGCT	1560				
DDB	1539	ATTATTTAAACCCAGCCCTCTGAACTTATACATTCAGTGTGCTGCTGCTGCT	1598				
DY	1561	CGGTGCTGCTGAGGCGCCTGTTGAGCTCCAATATGCACTTGAATCTAGGCTGG	1620				
DDB	1599	CGGTGCTGCTGAGGCGCCTGTTGAGCTCCAATATGCACTTGAATCTAGGCTGG	1658				
DY	1621	CGGTGCTGCTGCTCTGAAAGGCTTAACCTTATGGATAACTCTGGCTTTCTTC	1680				
DDB	1659	CGGTGCTGCTGCTCTGAAAGGCTTAACCTTATGGATAACTCTGGCTTTCTTC	1715				
DY	1681	TATGTCCTCTTGGAACTAACATTAATTTGAACTATCA	1728				
DDB	1716	---TCCTCTTGGAACTAACATTAATTTGAACTATCA	1759				
DY	1745	TAATGAAATTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1798				
DDB	1781	TAATGAAATTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1836				
DY	1816	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	1874				
DDB	1854	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	1902				
DY	1882	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	1939				
DDB	1920	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	1977				
DY	1958	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	2015				
DDB	1996	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	2053				
DY	2034	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	2091				
DDB	2072	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	2129				
DY	2110	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	2167				
DDB	2148	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	2205				
DY	2186	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	2243				
DDB	2224	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	2281				
DY	2262	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	2319				
DDB	2300	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	2357				
DY	2338	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	2395				
DDB	2376	TCATGTTGTGAGGCCATGCCATGCCATGCCATGCCATGCCATGCCATGCCAT	2433				

Db	121	CTAGCCCTGCGCCCTCGCCTTCGGCTTCTGGCTGGCGAGCTGGTGACGCC 180	Db	1201	TGACTTACTCATTTGACTTTGACTGATTACTGGATCTGCTGTGAC 1260
Qy	206	AAGAATTGAGGATGTAAGATGTAATGTAATCTGCTCCCTATAAGAAAATTCTGG 265	Qy	1286	TTCATGTTAAACCGGATCTTAAATGCTGGCTGCTTCAACAAAAGAGATTTCCTCA 1345
Db	181	AAGAATTGAGGATGTAAGATGTAATCTGCTCCCTATAAGAAAATTCTGG 240	Db	1261	TTCATGTTAAACCGGATCTTAAATGCTGGCTGCTTCAACAAAAGAGATTTCCTCA 1320
Db	266	CATATTATAATAAGAACATATTCAGAAAGATTGTGAATGCCCTCATGTAATG 325	Qy	1346	TGFACTGCTATGCTGCTGATGCTGAACTTCAAGGCACTTCAAGATCTGGCTGCTTACTC 1405
Qy	241	CATATTATAATAAGAACATATTCAGAAAGATTGTGAATGCCCTCATGTAATG 300	Db	1321	TGACTGCTATGCTGATGCTGATGCTGAACTTCAAGATCTGGCTGCTTACTTACTC 1380
Db	326	ATGCCCTGTGCGGGGGCTGATGTAAGAGCATACTGTACCGTGTGAAATGCAAATATGAA 385	Qy	1406	TAAGACTAACATAGCTTGCTGGTGTGGCTTACTACATCTTACCTTTAAGGA 1465
Qy	301	ATGCCCTGTGCGGGGGCTGATGTAAGAGCATACTGTACCGTGTGAAATGCAAATATGAA 360	Db	1381	TAAGACTAACATAGCTTGCTGGTGTGGCTTACTACATCTTACCTTTAAGGA 1440
Db	386	GAAAGAACCTCTTCACATCAAGGTACCAATTATTTTCACTCTGCTGCCCT 445	Qy	1466	CAAACTCTTAAAGGACTGGACACTGCTAACAAATTATTTAACCCAGCTCC 1525
Qy	361	GAAAGAACCTCTTCACATCAAGGTACCAATTATTTTCACTCTGCTGCCCT 420	Db	1441	CAAACTCTTAAAGGACTGGACACTGCTAACAAATTATTTAACCCAGCTCC 1500
Qy	446	CTACTCTGTACATGGTATCTTACTCTGTTGAGCCATACTGAGAGGGCTCTTT 505	Qy	1526	TGGATTGATAATATACATTTGAGCTTCTGCTGCTGAGGAGCTGTT 1585
Db	421	CTACTCTGTACATGGTATCTTACTCTGTTGAGCCATACTGAGAGGGCTCTTT 480	Db	1501	TGGATTGATAATATACATTTGAGCTTCTGCTGCTGAGGAGCTGTT 1560
Qy	506	GGACATGACAGTGTGATGAGCTAGGTGATGATGATGATGGATATGGATCACAGCCTTTGCAAAT 565	Qy	1586	GAGCTCCATATGTCAGGTTGAGCTAGGCTTGCCTCTCTGAAAG 1645
Db	481	GGACATGACAGTGTGATGAGCTAGGTGATGATGATGGATATGGATCACAGCCTTTGCAAAT 540	Db	1561	GAGCTCCATATGTCAGGCTTGCCTCTCTGAAAG 1620
Qy	566	GCAACAGTGTGCTGCTGCGTCCGZGATGCTGCAAGCTGTAATGATAAT 625	Qy	1646	TCTTACCACTTATTGGATAACTGGCTTCTCTCTGAAATGTAACAT 1705
Db	541	GCAACAGTGTGCTGCGTCCGZGATGCTGCAAGCTGTAATGATAAT 600	Db	1621	TCTTACCACTTATTGGATAACTGGCTTCTCTCTGAAATGTAACAT 1673
Qy	626	GCACAGCACCGCTGGAAAGCTTCAGTCAGGCAAGCTGCTGTTGACCGCAT 685	Qy	1706	AAATAATTTTGAACATC 1726
Db	601	GCACAGCACCGCTGGAAAGCTTCAGTCAGGCAAGCTGCTGTTGACCGCAT 660	Db	1674	AAAATAATTTTGAACATC 1694
RESULT 10					
		AK074677	AK074677	AK074677	AK074677
		LOCUS	Hom sapiens cDNA FLJ90196	1694 bp	mRNA
		DEFINITION	clone MAMMA101344.		linear
		ACCESSION	AK074677		PRI 03-SEP-2002
		VERSION	AK074677.1	GI:22760273	
		KEYWORDS	oligo capping; fis (full insert sequence).		
		SOURCE	Hom sapiens (human)		
		ORGANISM	Hom sapiens		
		AUTHORS	Bukaryota; Eutheria; Primates; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
		REFERENCE	1		
		AUTHORS	Isogai,T., Ota,T., Nishikawa,T., Hayashi,K., Otsubo,T., Sugiyama,T., Suzuki,Y., Nagai,K., Sugano,S., Itoh,S., Kawai,H., Saito,K., Yamamoto,J., Wakamatsu,Y., Kojima,S., Nagahari,K., Masuho,Y., Ono,T., Okano,K., Yoshikawa,Y., Aotsuka,S., Sasaki,N., Hattori,A., Okumura,K., Niinomiya,K.		
		TITLE	NEDO human cDNA sequencing project		
		JOURNAL	unpublished		
		AUTHORS	Isogai,T. and Otsubo,T.		
		TITLE	Direct Submission.		
		JOURNAL			
		COMMENT	Submitted (25-MAR-2002) Takao Isogai, Helix Research Institute, Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan (E-mail:genomics@ri.co.jp), Tel: +81-43-8-52-3975, Fax: +81-43-8-52-3966.		
		FEATURES	NEDO human cDNA sequencing project supported by Ministry of Economy, Trade and Industry of Japan; cDNA full insert sequencing; Research Association for Biotechnology; cDNA library construction; Institute of Medical Science, University of Tokyo, Laboratory of Genome Structure, Human Genome Center; cDNA 5' & 3'-end one pass sequencing and clone selection; Helix Research Institute (supported by Japan Key Technology Center etc.).		
		LOCATION/Qualifiers	Location		
		source	1 . 1694		
		/organism="Homo sapiens"			
		/mol_type="mRNA"			
		/db_xref="taxon:9606"			

TITLE		JOURNAL		DOCUMENT		PATENT NUMBER		INVENTOR(S)		PUBLICATION DATE		CROSS-REFERENCED PATENTS		
OS	Unidentified	PN	JP 200519990-A/107	PD	02-JUL-2002	PP	06-MAR-1998	JP 1998538875	PR	07-MAR-1997	US	60/040162,07-MAR-1997	US	60/040333 PR
Bednarik, D.P., Endress, G.A., Yu, G.L., N.J., Feng, P., Young, P.E., Green, J.M., Ferrie, A.M., Duan, R., Hu, J.S., Florence, K.A., Olsen, H.S., Ebner, R., Brewer, L.A., Moore, P.A., Shi, Y., Lafleur, D.W., Li, Y., Zeng, Z., and Kyaw, H.	70 human secreted proteins													
HUMAN GENOME SCIENCES INC	Unidentified	PN	JP 200519990-A/107	PD	02-JUL-2002	PP	06-MAR-1998	JP 1998538875	PR	07-MAR-1997	US	60/040162,07-MAR-1997	US	60/040333 PR
							60/038621,07-MAR-1997	US	07-MAR-1997	US	60/040626,07-MAR-1997	US	60/040161 PR	
							60/040336,07-MAR-1997	US	07-MAR-1997	US	60/040334,07-MAR-1997	US	60/040163 PR	
							60/0403580,11-APR-1997	US	11-APR-1997	US	60/043568,11-APR-1997	US	60/043569 PR	
							60/040331,11-APR-1997	US	11-APR-1997	US	60/043311,11-APR-1997	US	60/043671 PR	
							60/040332,11-APR-1997	US	11-APR-1997	US	60/043321,11-APR-1997	US	60/043669 PR	
							60/0403672,11-APR-1997	US	11-APR-1997	US	60/043315,11-APR-1997	US	60/043315 PR	
							60/040378,11-APR-1997	US	11-APR-1997	US	60/043576,11-APR-1997	US	60/043576 PR	
							60/0403670,23-MAY-1997	US	23-MAY-1997	US	60/047600,23-MAY-1997	US	60/047600 PR	
							60/047615,23-MAY-1997	US	23-MAY-1997	US	60/047597,23-MAY-1997	US	60/047597 PR	
							60/047502,23-MAY-1997	US	23-MAY-1997	US	60/047633,23-MAY-1997	US	60/047633 PR	
							60/047583,23-MAY-1997	US	23-MAY-1997	US	60/047617,23-MAY-1997	US	60/047617 PR	
							60/047612,23-MAY-1997	US	23-MAY-1997	US	60/047503,23-MAY-1997	US	60/047503 PR	
							60/047592,23-MAY-1997	US	23-MAY-1997	US	60/047581,23-MAY-1997	US	60/047581 PR	
							60/047584,23-MAY-1997	US	23-MAY-1997	US	60/047500,23-MAY-1997	US	60/047500 PR	
							60/047587,23-MAY-1997	US	23-MAY-1997	US	60/047492,23-MAY-1997	US	60/047492 PR	
							60/047598,23-MAY-1997	US	23-MAY-1997	US	60/047613,23-MAY-1997	US	60/047613 PR	
							60/047582,23-MAY-1997	US	23-MAY-1997	US	60/047596,23-MAY-1997	US	60/047596 PR	
							60/047601,23-MAY-1997	US	23-MAY-1997	US	60/047632,23-MAY-1997	US	60/047632 PR	
							60/047599,23-MAY-1997	US	23-MAY-1997	US	60/047595,23-MAY-1997	US	60/047595 PR	
							60/047585,23-MAY-1997	US	23-MAY-1997	US	60/047587,23-MAY-1997	US	60/047587 PR	
							60/047590,23-MAY-1997	US	23-MAY-1997	US	60/047589,23-MAY-1997	US	60/047589 PR	
							60/047589,23-MAY-1997	US	23-MAY-1997	US	60/047594,23-MAY-1997	US	60/047594 PR	
							60/047612,23-MAY-1997	US	23-MAY-1997	US	60/047593,23-MAY-1997	US	60/047593 PR	
							60/047584,23-MAY-1997	US	23-MAY-1997	US	60/047630,23-MAY-1997	US	60/047630 PR	
							60/048974,06-JUN-1997	US	06-JUN-1997	US	60/048964,06-JUN-1997	US	60/048964 PR	
							60/056886,22-AUG-1997	US	22-AUG-1997	US	60/056877,22-AUG-1997	US	60/056877 PR	
							60/056889,22-AUG-1997	US	22-AUG-1997	US	60/056893,22-AUG-1997	US	60/056893 PR	
							60/056630,22-AUG-1997	US	22-AUG-1997	US	60/056878,22-AUG-1997	US	60/056878 PR	
							60/056666,22-AUG-1997	US	22-AUG-1997	US	60/056872,22-AUG-1997	US	60/056872 PR	
							60/056631,22-AUG-1997	US	22-AUG-1997	US	60/056637,22-AUG-1997	US	60/056637 PR	
							60/056634,22-AUG-1997	US	22-AUG-1997	US	60/056888,22-AUG-1997	US	60/056888 PR	
							60/056689,22-AUG-1997	US	22-AUG-1997	US	60/056632,22-AUG-1997	US	60/056632 PR	
							60/056654,22-AUG-1997	US	22-AUG-1997	US	60/056876,22-AUG-1997	US	60/056876 PR	
							60/056881,22-AUG-1997	US	22-AUG-1997	US	60/056911,22-AUG-1997	US	60/056911 PR	
							60/056636,22-AUG-1997	US	22-AUG-1997	US	60/056874,22-AUG-1997	US	60/056874 PR	
							60/056910,22-AUG-1997	US	22-AUG-1997	US	60/056864,22-AUG-1997	US	60/056864 PR	
							60/056631,22-AUG-1997	US	22-AUG-1997	US	60/056845,22-AUG-1997	US	60/056845 PR	
							60/056892,22-AUG-1997	US	22-AUG-1997	US	60/056630,22-AUG-1997	US	60/056630 PR	
							60/056880,22-AUG-1997	US	22-AUG-1997	US	60/056877,22-AUG-1997	US	60/056877 PR	
							60/056889,22-AUG-1997	US	22-AUG-1997	US	60/056883,22-AUG-1997	US	60/056883 PR	
							60/056884,22-AUG-1997	US	22-AUG-1997	US	60/056889,22-AUG-1997	US	60/056889 PR	
							60/056887,22-AUG-1997	US	22-AUG-1997	US	60/056890,22-AUG-1997	US	60/056890 PR	
							60/056888,22-AUG-1997	US	22-AUG-1997	US	60/057761,22-AUG-1997	US	60/057761 PR	
PI STEVEN M RUBEN, CRAIG A ROSEN, CARRIE L FISCHER, DANIEL R SOPPE, PI KENNETH C CARTER, DANIEL P BEDNARIK, GREGORY A ENDRESS, GUO LIANG, PI YU-JIANG NI, PI PING FENG, PAUL E YOUNG, JOHN M GREENE, ANN M FERRIE, ROXANNE DUAN, PI JING SHAN HU, KIMBERLY A FLORENCE, HENRIK S OLSEN, REINHARD EBNER, PI LAURIE A BREWER, PAUL A MOORE, YANGGU SHI, DAVID W LAFLEUR, PI YI LI, ZHIZHEN ZENG, PI HUA KYAW, PC C12N15/1, C12N5/10, C12N1/21, C07K14/47, C07K16/18, C12Q1/68, PC C12N33/50, G01N33/53, G01N33/68, G01K3B/17, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N33/36, G01N33/40, G01N33/44, G01N33/48, G01N33/52, G01N33/56, G01N33/60, G01N33/64, G01N33/68, G01N33/72, G01N33/76, G01N33/80, G01N33/84, G01N33/88, G01N33/92, G01N33/96, G01N33/00, G01N33/04, G01N33/08, G01N33/12, G01N33/16, G01N33/20, G01N33/24, G01N33/28, G01N33/32, G01N														

D b	1645	AGGGCTGGGTGCGTCCTCTGAAGGTAAACCAATTATGGATAACTGCTTT	1704
Q y	1673	TTCCTTCCATGCTCTTGGAAATGAACTAAATTTGAAACATCA	1728
	1705	TTTCTCTTGGAAATGAACTAAATTTGAAACATCA	1754

Search completed: April 20, 2004, 05:58:36
Job time : 6725 secs

Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2004, 02:12:11 ; Search time 4580 Seconds
(without alignments)
11266.779 Million cell updates/sec

Title: US-09-989-725-417

Perfect score: 1728

Sequence: 1 cagcggtccaaaggctgt.....aaataattttgaaacatcaa 1728

Scoring table: IDENTITY_NUC

Gapop 10- , Gapext 1.0

Searched: 27513289 seqs, 14931090276 residues

Total number of hits satisfying chosen parameters: 55026578

Post-processing: Maximum Match 0%
Listing first 45 summaries

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Database : EST:*

1: em_estba:*

2: em_esthum:*

3: em_estin:*

4: em_estmu:*

5: em_estov:*

6: em_estpl:*

7: em_estco:*

8: em_htc:*

9: cb_est1:*

10: qb_est2:*

11: qb_htc:*

12: qb_est3:*

13: qb_est4:*

14: qb_sts5:*

15: em_estfun:*

16: em_eston:*

17: em_gss_hum:*

18: em_gss_inv:*

19: em_gss_pln:*

20: em_gss_vrt:*

21: em_gss_fun:*

22: em_gss_mam:*

23: em_gss_mus:*

24: em_gss_pro:*

25: em_gss_rid:*

26: em_gss_phg:*

27: em_gss_vrl:*

28: qb_gss1:*

29: qb_gss2:*

30: qb_gss3:*

31: qb_gss4:*

32: qb_gss5:*

33: qb_gss6:*

34: qb_gss7:*

35: qb_gss8:*

36: qb_gss9:*

37: qb_gss10:*

38: qb_gss11:*

39: qb_gss12:*

40: qb_gss13:*

41: qb_gss14:*

42: qb_gss15:*

43: qb_gss16:*

44: qb_gss17:*

45: qb_gss18:*

46: qb_gss19:*

47: qb_gss20:*

48: qb_gss21:*

49: qb_gss22:*

50: qb_gss23:*

51: qb_gss24:*

52: qb_gss25:*

53: qb_gss26:*

54: qb_gss27:*

55: qb_gss28:*

56: qb_gss29:*

57: qb_gss30:*

58: qb_gss31:*

59: qb_gss32:*

60: qb_gss33:*

61: qb_gss34:*

62: qb_gss35:*

63: qb_gss36:*

64: qb_gss37:*

65: qb_gss38:*

66: qb_gss39:*

67: qb_gss40:*

68: qb_gss41:*

69: qb_gss42:*

70: qb_gss43:*

71: qb_gss44:*

72: qb_gss45:*

73: qb_gss46:*

74: qb_gss47:*

75: qb_gss48:*

76: qb_gss49:*

77: qb_gss50:*

78: qb_gss51:*

79: qb_gss52:*

80: qb_gss53:*

81: qb_gss54:*

82: qb_gss55:*

83: qb_gss56:*

84: qb_gss57:*

85: qb_gss58:*

86: qb_gss59:*

87: qb_gss60:*

88: qb_gss61:*

89: qb_gss62:*

90: qb_gss63:*

91: qb_gss64:*

92: qb_gss65:*

93: qb_gss66:*

94: qb_gss67:*

95: qb_gss68:*

96: qb_gss69:*

97: qb_gss70:*

98: qb_gss71:*

99: qb_gss72:*

100: qb_gss73:*

101: qb_gss74:*

102: qb_gss75:*

103: qb_gss76:*

104: qb_gss77:*

105: qb_gss78:*

106: qb_gss79:*

107: qb_gss80:*

108: qb_gss81:*

109: qb_gss82:*

110: qb_gss83:*

111: qb_gss84:*

112: qb_gss85:*

113: qb_gss86:*

114: qb_gss87:*

115: qb_gss88:*

116: qb_gss89:*

117: qb_gss90:*

118: qb_gss91:*

119: qb_gss92:*

120: qb_gss93:*

121: qb_gss94:*

122: qb_gss95:*

123: qb_gss96:*

124: qb_gss97:*

125: qb_gss98:*

126: qb_gss99:*

127: qb_gss100:*

128: qb_gss101:*

129: qb_gss102:*

130: qb_gss103:*

131: qb_gss104:*

132: qb_gss105:*

133: qb_gss106:*

134: qb_gss107:*

135: qb_gss108:*

136: qb_gss109:*

137: qb_gss110:*

138: qb_gss111:*

139: qb_gss112:*

140: qb_gss113:*

141: qb_gss114:*

142: qb_gss115:*

143: qb_gss116:*

144: qb_gss117:*

145: qb_gss118:*

146: qb_gss119:*

147: qb_gss120:*

148: qb_gss121:*

149: qb_gss122:*

150: qb_gss123:*

151: qb_gss124:*

152: qb_gss125:*

153: qb_gss126:*

154: qb_gss127:*

155: qb_gss128:*

156: qb_gss129:*

157: qb_gss130:*

158: qb_gss131:*

159: qb_gss132:*

160: qb_gss133:*

161: qb_gss134:*

162: qb_gss135:*

163: qb_gss136:*

164: qb_gss137:*

165: qb_gss138:*

166: qb_gss139:*

167: qb_gss140:*

168: qb_gss141:*

169: qb_gss142:*

170: qb_gss143:*

171: qb_gss144:*

172: qb_gss145:*

173: qb_gss146:*

174: qb_gss147:*

175: qb_gss148:*

176: qb_gss149:*

177: qb_gss150:*

178: qb_gss151:*

179: qb_gss152:*

180: qb_gss153:*

181: qb_gss154:*

182: qb_gss155:*

183: qb_gss156:*

184: qb_gss157:*

185: qb_gss158:*

186: qb_gss159:*

187: qb_gss160:*

188: qb_gss161:*

189: qb_gss162:*

190: qb_gss163:*

191: qb_gss164:*

192: qb_gss165:*

193: qb_gss166:*

194: qb_gss167:*

195: qb_gss168:*

196: qb_gss169:*

197: qb_gss170:*

198: qb_gss171:*

199: qb_gss172:*

200: qb_gss173:*

201: qb_gss174:*

202: qb_gss175:*

203: qb_gss176:*

204: qb_gss177:*

205: qb_gss178:*

206: qb_gss179:*

207: qb_gss180:*

208: qb_gss181:*

209: qb_gss182:*

210: qb_gss183:*

211: qb_gss184:*

212: qb_gss185:*

213: qb_gss186:*

214: qb_gss187:*

215: qb_gss188:*

216: qb_gss189:*

217: qb_gss190:*

218: qb_gss191:*

219: qb_gss192:*

220: qb_gss193:*

221: qb_gss194:*

222: qb_gss195:*

223: qb_gss196:*

224: qb_gss197:*

225: qb_gss198:*

226: qb_gss199:*

227: qb_gss200:*

228: qb_gss201:*

229: qb_gss202:*

230: qb_gss203:*

231: qb_gss204:*

232: qb_gss205:*

233: qb_gss206:*

234: qb_gss207:*

235: qb_gss208:*

236: qb_gss209:*

237: qb_gss210:*

238: qb_gss211:*

239: qb_gss212:*

240: qb_gss213:*

241: qb_gss214:*

242: qb_gss215:*

243: qb_gss216:*

244: qb_gss217:*

245: qb_gss218:*

246: qb_gss219:*

247: qb_gss220:*

248: qb_gss221:*

249: qb_gss222:*

250: qb_gss223:*

251: qb_gss224:*

252: qb_gss225:*

253: qb_gss226:*

254: qb_gss227:*

255: qb_gss228:*

256: qb_gss229:*

257: qb_gss230:*

258: qb_gss231:*

259: qb_gss232:*

260: qb_gss233:*

261: qb_gss234:*

262: qb_gss235:*

263: qb_gss236:*

264: qb_gss237:*

265: qb_gss238:*

266: qb_gss239:*

267: qb_gss240:*

268: qb_gss241:*

269: qb_gss242:*

270: qb_gss243:*

271: qb_gss244:*

272: qb_gss245:*

273: qb_gss246:*

274: qb_gss247:*

275: qb_gss248:*

276: qb_gss249:*

277: qb_gss250:*

278: qb_gss251:*

279: qb_gss252:*

280: qb_gss253:*

281: qb_gss254:*

282: qb_gss255:*

283: qb_gss256:*

284: qb_gss257:*

285: qb_gss258:*

286: qb_gss259:*

287: qb_gss260:*

288: qb_gss261:*

289: qb_gss262:*

290: qb_gss263:*

291: qb_gss264:*

292: qb_gss265:*

293: qb_gss266:*

294: qb_gss267:*

295: qb_gss268:*

296: qb_gss269:*

297: qb_gss270:*

298: qb_gss271:*

299: qb_gss272:*

300: qb_gss273:*

301: qb_gss274:*

302: qb_gss275:*

303: qb_gss276:*

304: qb_gss277:*

305: qb_gss278:*

306: qb_gss279:*

307: qb_gss280:*

308: qb_gss281:*

309: qb_gss282:*

310: qb_gss283:*

311: qb_gss284:*

312: qb_gss285:*

313: qb_gss286:*

314: qb_gss287:*

315: qb_gss288:*

316: qb_gss289:*

317: qb_gss290:*

318: qb_gss291:*

319: qb_gss292:*

320: qb_gss293:*

321: qb_gss294:*

322: qb_gss295:*

323: qb_gss296:*

324: qb_gss297:*

325: qb_gss298:*

326: qb_gss299:*

327: qb_gss300:*

328: qb_gss301:*

329: qb_gss302:*

330: qb_gss303:*

331: qb_gss304:*

332: qb_gss305:*

333: qb_gss306:*

334: qb_gss307:*

335: qb_gss308:*

336: qb_gss309:*

337: qb_gss310:*

338: qb_gss311:*

339: qb_gss312:*

340: qb_gss313:*

341: qb_gss314:*

342: qb_gss315:*

343: qb_gss316:*

344: qb_gss317:*

345: qb_gss318:*

346: qb_gss319:*

347: qb_gss320:*

348: qb_gss321:*

349: qb_gss322:*

350: qb_gss323:*

351: qb_gss324:*

352: qb_gss325:*

353: qb_gss326:*

354: qb_gss327:*

355: qb_gss328:*

356: qb_gss329:*

357: qb_gss330:*

358: qb_gss331:*

359: qb_gss332:*

360: qb_gss333:*

361: qb_gss334:*

362: qb_gss335:*

363: qb_gss336:*

364: qb_gss337:*

365: qb_gss338:*

366: qb_gss339:*

367: qb_gss340:*

368: qb_gss341:*

369: qb_gss342:*

370: qb_gss343:*

371: qb_gss344:*

372: qb_gss345:*

373: qb_gss346:*

374: qb_gss347:*

375: qb_gss348:*

376: qb_gss349:*

377: qb_gss350:*

378: qb_gss351:*

379: qb_gss352:*

380: qb_gss353:*

381: qb_gss354:*

382: qb_gss355:*

383: qb_gss356:*

384: qb_gss357:*

385: qb_gss358:*

386: qb_gss359:*

387: qb_gss360:*

388: qb_gss361:*

389: qb_gss362:*

390: qb_gss363:*

391: qb_gss364:*

392: qb_gss365:*

393: qb_gss366:*

394: qb_gss367:*

395: qb_gss368:*

396: qb_gss369:*

397: qb_gss370:*

398: qb_gss371:*

399: qb_gss372:*

400: qb_gss373:*

401: qb_gss374:*

402: qb_gss375:*

403: qb_gss376:*

404: qb_gss377:*

405: qb_gss378:*

406: qb_gss379:*

407: qb_gss380:*

408: qb_gss381:*

409: qb_gss382:*

410: qb_gss383:*

411: qb_gss384:*

412: qb_gss385:*

413: qb_gss386:*

414: qb_gss387:*

415: qb_gss388:*

416: qb_gss389:*

417: qb_gss390:*

418: qb_gss391:*

419: qb_gss392:*

420: qb_gss393:*

421: qb_gss394:*

422: qb_gss395:*

423: qb_gss396:*

424: qb_gss397:*

425: qb_gss398:*

426: qb_gss399:*

427: qb_gss400:*

428: qb_gss401:*

429: qb_gss402:*

430: qb_gss403:*

431: qb_gss404:*

432: qb_gss405:*

433: qb_gss406:*

434: qb_gss407:*

435: qb_gss408:*

436: qb_gss409:*

437: qb_gss410:*

438: qb_gss411:*

439: qb_gss412:*

440: qb_gss413:*

441: qb_gss414:*

442: qb_gss415:*

443: qb_gss416:*

444: qb_gss417:*

445: qb_gss418:*

446: qb_gss419:*

447: qb_gss420:*

448: qb_gss421:*

449: qb_gss422:*

450: qb_gss423:*

451: qb_gss424:*

452: qb_gss425:*

453: qb_gss426:*

454: qb_gss427:*

455: qb_gss428:*

456: qb_gss429:*

457: qb_gss430:*

458: qb_gss431:*

459: qb_gss432:*

460: qb_gss433:*

461: qb_gss434:*

462: qb_gss435:*

463: qb_gss436:*

464: qb_gss437:*

465: qb_gss438:*

466: qb_gss439:*

467: qb_gss440:*

468: qb_gss441:*

469: qb_gss442:*

470: qb_gss443:*

471: qb_gss444:*

472: qb_gss445:*

473: qb_gss446:*

474: qb_gss447:*

475: qb_gss448:*

476: qb_gss449:*

477: qb_gss450:*

478: qb_gss451:*

479: qb_gss452:*

480: qb_gss453:*

481: qb_gss454:*

482: qb_gss455:*

483: qb_gss456:*

484: qb_gss457:*

485: qb_gss458:*

486: qb_gss459:*

487: qb_gss460:*

488: qb_gss461:*

489: qb_gss462:*

490: qb_gss463:*

491: qb_gss464:*

492: qb_gss465:*

493: qb_gss466:*

494: qb_gss467:*

495: qb_gss468:*

496: qb_gss469:*

497: qb_gss470:*

498: qb_gss471:*

499: qb_gss472:*

500: qb_gss473:*

501: qb_gss474:*

502: qb_gss475:*

503: qb_gss476:*

504: qb_gss477:*

505: qb_gss478:*

506: qb_gss479:*

507: qb_gss480:*

508: qb_gss481:*

509: qb_gss482:*

510: qb_gss483:*

511: qb_gss484:*

512: qb_gss485:*

513: qb_gss486:*

514: qb_gss487:*

515: qb_gss488:*

516: qb_gss489:*

517: qb_gss490:*

518: qb_gss491:*

519: qb_gss492:*

520: qb_gss493:*

521: qb_gss494:*

522: qb_gss495:*

523: qb_gss496:*

524: qb_gss497:*

525: qb_gss498:*

526: qb_gss499:*

527: qb_gss500:*

528: qb_gss501:*

529: qb_gss502:*

530: qb_gss503:*

531: qb_gss504:*

532: qb_gss505:*

533: qb_gss506:*

534: qb_gss507:*

535: qb_gss508:*

536: qb_gss509:*

537: qb_gss510:*

538: qb_gss511:*

539: qb_gss512:*

540: qb_gss513:*

541: qb_gss514:*

542: qb_gss515:*

543: qb_gss516:*

544: qb_gss517:*

545: qb_gss518:*

546: qb_gss519:*

547: qb_gss520:*

548: qb_gss521:*

549: qb_gss522:*

550: qb_gss523:*

551: qb_gss524:*

552: qb_gss525:*

553: qb_gss526:*

554: qb_gss527:*

555: qb_gss528:*

556: qb_gss529:*

557: qb_gss530:*

558: qb_gss531:*

559: qb_gss532:*

560: qb_gss533:*

561: qb_gss534:*

562: qb_gss535:*

563: qb_gss536:*

564: qb_gss537:*

565: qb_gss538:*

566: qb_gss539:*

567: qb_gss540:*

568: qb_gss541:*

569: qb_gss542:*

570: qb_gss543:*

571: qb_gss544:*

572: qb_gss545:*

573: qb_gss546:*

574: qb_gss547:*

575: qb_gss548:*

576: qb_gss549:*

577: qb_gss550:*

578: qb_gss551:*

579: qb_gss552:*

580: qb_gss553:*

581: qb_gss554:*

582: qb_gss555:*

583: qb_gss556:*

584: qb_gss557:*

585: qb_gss558:*

586: qb_gss559:*

587: qb_gss560:*

588: qb_gss561:*

589: qb_gss562:*

590: qb_gss563:*

591: qb_gss564:*

592: qb_gss565:*

593: qb_gss566:*

594: qb_gss567:*

595: qb_gss568:*

596: qb_gss569:*

597: qb_gss570:*

598: qb_gss571:*

599: qb_gss572:*

600: qb_gss573:*

601: qb_gss574:*

602: qb_gss575:*

603: qb_gss576:*

604: qb_gss577:*

605: qb_gss578:*

606: qb_gss579:*

607: qb_gss580:*

608: qb_gss581:*

609: qb_gss582:*

610: qb_gss583:*

611: qb_gss584:*

612: qb_gss585:*

613: qb_gss586:*

614: qb_gss587:*

615: qb_gss588:*

616: qb_gss589:*

617: qb_gss590:*

618: qb_gss591:*

619: qb_gss592:*

620: qb_gss593:*

621: qb_gss594:*

622: qb_gss595:*

623: qb_gss596:*

624: qb_gss597:*

625: qb_gss598:*

626: qb_gss599:*

627: qb_gss600:*

628: qb_gss601:*

629: qb_gss602:*

630: qb_gss603:*

631: qb_gss604:*

632: qb_gss605:*

633: qb_gss606:*

634: qb_gss607:*

635: qb_gss608:*

636: qb_gss609:*

637: qb_gss610:*

638: qb_gss611:*

639: qb_gss612:*

640: qb_gss613:*

641: qb_gss614:*

642: qb_gss615:*

643: qb_gss616:*

644: qb_gss617:*

645: qb_gss618:*

646: qb_gss619:*

647: qb_gss620:*

648: qb_gss621:*

649: qb_gss622:*

650: qb_gss623:*

651: qb_gss624:*

652: qb_gss625:*

653: qb_gss626:*

654: qb_gss627:*

655: qb_gss628:*

656: qb_gss629:*

657: qb_gss630:*

658: qb_gss631:*

659: qb_gss632:*

660: qb_gss633:*

661: qb_gss634:*

662: qb_gss635:*

663: qb_gss636:*

664: qb_gss637:*

665: qb_gss638:*

666: qb_gss639:*

667: qb_gss640:*

668: qb_gss641:*

669: qb_gss642:*

670: qb_gss643:*

671: qb_gss644:*

672: qb_gss645:*

673: qb_gss646:*

674: qb_gss647:*

675: qb_gss648:*

676: qb_gss649:*

677: qb_gss650:*

678: qb_gss651:*

679: qb_gss652:*

680: qb_gss653:*

681: qb_gss654:*

682: qb_gss655:*

683: qb_gss656:*

684: qb_gss657:*

685: qb_gss658:*

686: qb_gss659:*

687: qb_gss660:*

688: qb_gss661:*

689: qb_gss662:*

690: qb_gss663:*

691: qb_gss664:*

692: qb_gss665:*

693: qb_gss666:*

694: qb_gss667:*

695: qb_gss668:*

696: qb_gss669:*

697: qb_gss670:*

698: qb_gss671:*

699: qb_gss672:*

700: qb_gss673:*

701: qb

FEATURES	Source	Query Match	Best Local Similarity	Score	Length	DB	Location/Qualifiers
		http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue Genoscope sequence ID : CSODE010DG04P1.	95.2%	947.4;	DB 9;	1045	
		1. . 1045					
		/organism="Homo sapiens"					
		/mol_type="mRNA"					
		/db_xref="Taxon:9606"					
		/clone="CSODE010Y0N08"					
		/issue_type="PLACENTA"					
		/clone_id="Homo sapiens PLACENTA"					
		/note="Vector: pCMVSPORT 6; 1st strand cDNA was primed with a NorI-oligo (D) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR sites of the pCMVSPORT 6 vector. Library was not normalized."					
ORIGIN							
		54.8%: Score 947.4; DB 9; Length 1045;					
		Best Local Similarity 95.2%; Pred. No. 1.6e-169; Mismatches 40; Indels 6; Gaps 2;					
		Matches 949; Conservative 949;					
		Qy 20 TGCCTGAGCCCTGAGCTGAGCTGAGCTGGCGCGGCCGCGGCCGCTTCGGCTTGGC 79					
		Db 50 TCCCGATCATCGSSGTGAGCTGGCGCGGCCGCGGCCGCTTCGGCTTGGC 109					
		Qy 80 TGTGGACCGCTGGGCCACCGATGGCGACCCCTGGGAGGGCTTCGGCTTGGC 139					
		Db 110 TGTGGACCGCTGGCGCGGCCAACCGATGGCGACCCCTGGGAGGGCTTCGGCTTGGC 169					
		Qy 140 TCCCTGGTAGCGCTGGCTGGCTGGCTGGCTGGCTGGCGCGCTGCAAGAC 199					
		Db 170 TCCCTGGTAGCGCTGGCTGGCTGGCTGGCGCTTGCGTGGCTGGCGCGCTGCAAGAC 228					
		Qy 200 GCGCCAAAGAATTTCGAGGATCTCAAGTGTAAATGATCTGCCTCCATTAAGAAAT 259					
		Db 229 GSCGCCAGAAATTSGGAGATTSAGATGAAATGATCTGCCTCCATTAAGAAAT 288					
		Qy 260 TCTGGCCATTATTATAAGAACATATCTCAGAAAGATTTGATGCTCTCATGTTGTG 319					
		Db 289 TCTGGCCATTATTATAAGAACATATCTCAGAAAGATTTGATGCTCTCATGTTG 348					
		Qy 320 GAGGCCATGCGCTGGGGCTGTGATGCTAGCTAGCTAGCTGTAATGCTGAAAAA 379					
		Db 349 GAGCSCATGCCCTGGCGGGCTGTGATGCTAGCTAGCTAGCTGAAATCAA 408					
		Qy 380 TATGAAGAAAGAGCTGTCTCAATCAAGTTACCATTAATTATCTCTCCATTGT 439					
		Db 409 TATGAAGAAAGAGCTGTCTGTSACATCAAGTTACCATTAATTATCTCTCCATTGT 468					
		Qy 440 GGCTCTTCACTTGATGATGTTACTCTGTTGATGCTGCTGCTGCTGCTGCTG 499					
		Db 469 GGCTCTTCACTTGATGATGTTACTCTGTTGATGCTGCTGCTGCTGCTGCTG 528					
		Qy 500 CTCTTGGACATSCACAGTTGATACAGATGATGATGATGATGATGATGATGATG 559					
		Db 529 CTCTTGGACATGACAGTTGATACAGATGATGATGATGATGATGATGATGATG 588					
		Qy 560 GCAAATGGACACGATGCTGCTAGCCGCTCCCGCAGTGAGCCAACTGCTGAAACAGGTA 619					
		Db 589 GSAATGGACACGATGCTGCTAGCCGCTCCCGCAGTGAGCCAACTGCTGAAACAGGTA 648					
		Qy 620 GAATATGGACACGAGCTGGAGC-TTCAATCTCAAGGAGCTGCTGCTGCTGCTG 678					
		Db 649 GAATATGGACACGAGCTGGAGC-TTCAATCTCAAGGAGCTGCTGCTGCTGCTG 708					
		Qy 679 CGCGCATGTTGCTCACTTAATTGGMATTGAGTCAAGTGGCTGAAAGAAAGGC 738					
		Db 709 CGCGCATGTTGCTCACTTAATTGGMATTGAGTCAAGTGGCTGAAAGAAAGGC 768					
		Qy 739 AGACAACCTGAAAGAAACTGACTCGGGTTGCTGGGTTCAATTAACTTGTGTGATT 798					
		Db 769 AGACAACCTGAAAGAAACTGACTCGGGTTGCTGGGTTCAATTAACTTGTGTGATT 828					
		Qy 750 AAGAATGACTGAGCTGGGTTGCTGGGTTCAATTAACTTGTGTGATT CACCAACTGT 808					
		Query Match 54.3%; Score 938; DB 9; Length 1180;					
		Best Local Similarity 94.6%; Pred. No. 9.7e-168;					
		Matches 1004; Conservative 24; Mismatches 26; Indels 7; Gaps 6					
		Qy 630 AGCAGGGCTGGAAAGCTTCAAGTCTGGCTGGCTGGCTGGCTGGCTGGCTGG 689					
		Db 1058 ACMGAGCCTGARSTGAGCGTCTKTC-TTRMCGGCTGTTG 1000					
		Qy 690 TCTCTAGCTTAATTGGGAAATGTAATTCAAGGTGACTAGAAGAAACAGGAGCAACTGG 749					
		Db 999 CCCTCAGCTTAATTGGGAAATGTAATTCAAGGTGACTAGAAGAAAGGAGCAACTGG 941					
		Qy 750 AAGAATGACTGAGCTGGGTTGCTGGGTTCAATTAACTTGTGTGATT CACCAACTGT 808					

		source	
Db	555	COATATGAAAGGGCCCTTGTGACATCACAGTTGATACTAGTGATGATATG	614
OY	543	GGGATCAACCAGCCTTTGCAAATGACATGATGCTTACGGCTCCGAGGCCA	602
Db	615	GGGATCAACCACCTTGTGAAATGACATGCTAACGGCTCCAGGGGCCA	674
QY	603	ACGTGCTGAAAGGTGAATGAAATGACAGGCTCAAGTCAGAGGCAGC	662
Db	675	ACGTGCTGAAAGGTGAATGAAATGACAGGCTCAAGTCAGAGGCAGC	734
QY	663	GAAGACTGCTTGTGACGGCATGTTGCTCAGTGATTGGGATTGAATGAGTGA	722
Db	735	GAAAAGCTGTGCTTGTGACGGCATGTTGCTCAGTGATTGGGATTGAATGAGTGA	794
QY	723	CTAGAGAAACAGGGAAACAGTGGAAAGAACAGTGGCTTGTGTTGTTCAATT	782
Db	795	CTAGAGAAACAGGGAAACAGTGGAAAGAACAGTGGCTTGTGTTGTTCAATT	854
QY	783	AATACCTGTGATTCAACACTTGCTGGAGATTCAAAATCGGAGCAAATCTG	842
Db	855	AATACCTGTGATTCAACACTTGCTGGAGATTCAAAATCGGAGCAAATCTG	914
QY	843	CTTGAA-TTTTTTTCTGTTAACGTTAATATAGAACATTTTAAAGCAACAGCTCA	901
Db	915	CTTGATT-TTTTTCTGTTAACGTTAATATAGAACATTAAAGCAACAGCTCA	973
QY	902	AAGTCAGCCAAATAAGCTTCTCTTCTCTTCTGTTAACACTTAAATCTGCTG	961
Db	974	AAGTCAGCCAAATAAGCTTCTCTTCTGTTAACACTTAAATCTGCTG	1032
QY	962	TAAATTATCTGAACTTACCTGAAAGACTCTTCTTACACATAGTTTA	1021
Db	1033	TAAATTATCTGAACTTACCTGAAAGCMYCTCTTAA---OCACATAGTTAA	1087
QY	1022	ACTTGACTTCAAGATAATTTCAGGGTTGGTGTGTTTGTGTTTTTTT	1081
Db	1088	MTTGTGCTTCAAGA---WAWTTTCAGGT---TTGGCTGTGTGTTTGTGTT	1139
QY	1082	TGGTGGAGAGGGGGAGCTGGGAGCTGGTAAACACTTTCAAGTCACIT	1139
Db	1140	TGTGGGGAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	1197
RESULT	4		
LOCUS	BX425270	BX425270	1201 bp mRNA linear EST 15-MAY-2003
DEFINITION		BX425270	Homo sapiens NEUROBLASTOMA Homo sapiens cDNA clone CLOBB007ZAI 5'-PRIME.
ACCESSION		BX425270	mRNA Sequence.
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
		Homo sapiens	
		Bukaryota; Metazoa; Chordata; Craniata; Vertebrates; Euteleostomi;	
		Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
REFERENCE		1 (bases 1 to 1201)	
AUTHORS		Li, W., Gruber, C., Jesse, J. and Polayes, D.	
TITLE		Pull-length cDNA libraries and normalization	
JOURNAL		Unpublished (2001)	
COMMENT		Contact: Genoscope Genoscope - Centre National de Sequencing BP 191 91006 EVRY cedex - France Email: seq@genoscope.cns.fr	
		more information about this cluster, see http://www.genoscope.cns.fr/seq/cluster.cgi?seq=CLOBB007ZAI1RP1cluster=6242.f . For	
		Invitrogen. This sequence was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to this cluster, see http://www.genoscope.cns.fr/seq/cluster.cgi?seq=CLOBB007ZAI1RP1cluster=6242.f . Contact :	
		Feng Liang Email: fliang@lifepeaks.com URL : http://fulllength.invitrogen.com/InvitroGenCorporation1600	
FEATURES		Parady Avenue Genoscope Sequence ID : CLOBB007ZAI1RP1.	
		Location/Qualifiers	817 AATACTTGTGATTCAACACTGTTGCTCAAACTGAAACTGGCTAAACTG

KEYWORDS	Homo sapiens (human)
SOURCE	Homo sapiens
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiridae; Homo.
REFERENCE	1 (bases 1 to 1201)
AUTHORS	Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
TITLE	Full-length cDNA libraries and normalization
JOURNAL	Unpublished (2001)
COMMENT	Contact: Genoscope Genoscope - Centre National de Séquençage BP 191 91006 EVRY Cedex - France Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr Library was constructed by Life Technologies, a division of csg-bin/clustter.cgi?seq=CS0DF012BC07Q1&cluster=6242.f. Contact : Invitrogen. This sequence belongs to sequence cluster 6242.f. For more information about this cluster, see http://www.genoscope.cns.fr/cgi-bin/clustter.cgi?seq=CS0DF012BC07Q1&cluster=6242.f. For more information about this cluster, see http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue Genoscope sequence ID : CS0DF012BC07Q1.
FEATURES	Location/Qualifiers 1..1201 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone="CS0DF012YE14" /issue_type="FETAL BRAIN" /dev_stage="fetal" /clstrn_lib="Homo sapiens FETAL BRAIN" /note="Organ: brain; Vector: PCMVSPORT 6; 1st strand cDNA was primed with a Not I-oligo (DR) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoRV sites of the pcMVSport 6 vector. Library was not normalized."
ORIGIN	Query Match Score 904; DB 13; Length 1201; Best Local Similarity 93.8%; Pred. No. 2.7e-16; Matches 951; Conservative 20; Mismatches 36; Indels 7; Gaps 3;
Qy	113 CTGTGGGGAGGCCCTCTGGTTGGTCCCTGCTAACCTGTCGCTCGGCCTTCC 172
Db	61 CTGTGGGGAGGCCCTCTGGTTGGTCCCTGCTAACCTGTCGCTCGGCCTTCC 120
Qy	173 GTGCTGCTGCTGCGCAGCTGTCAGACGCCCAAGAAATTGAGGATGTCAGATGAA 232
Db	121 GTCTGCTGCTGCGCAGCTGTCAGACGCCCAAGAAATTGAGGATGTCAGATGAA 179
Qy	233 TGTATCTGCCCTCATTAAGAAAATTCTGGCCATTATAATAAGGACATATCTAG 292
Db	180 TGTATCTGCCCTCATTAAGAAAATTCTGGCCATTATAATAAGGACATATCTAG 239
Qy	293 AAAGATGTTGATTGCTCTCATTTGGAGGCCATGCTGCTGGCCCTGATGAGAA 352
Db	240 AAAGATGTTGATTGCTCTCATTTGGAGGCCATGCTGCTGGCCCTGATGAGAA 299
Qy	353 GCATACTGCTCAAGCTGCTGTAATGAGAAGACTCTACATCAGTT 412
Db	300 GCATACTGCTCAAGCTGCTGTAATGAGAAGACTCTACATCAGTT 359
Qy	413 ACCATTATAATTATCTCCATTGCTGCTACTACATGTTATCTACT 472
Db	360 ACCATTATAATTATCTCCATTGCTGCTACTACATGTTATCTACT 419
Qy	473 CTGGTTAGCCATTACTGAAAGGGCCTCTTGGACATGTCAGAGTGT 532
Db	420 CTGGTTAGCCATTACTGAAAGGGCCTCTTGGACATGTCAGAGTGT 479
Qy	533 GATGATATTGGGATCACAGCTTGTCAATGACAGAATGCTGTA 592
Db	480 GATGATATTGGGATCACAGCTTGTCAATGACAGAATGCTGTA 539
RESULT	7 AL550557/c
LOCUS	AL550557 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA clone CS0DI058YJ16 3'-PRIME, mRNA sequence.
DEFINITION	AL550557
ACCESSION	AL550557.2
VERSION	GI:31272374
KEYWORDS	EST.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens Eukaryota; Eutheria; Primates; Catarrini; Hominidae; Homo.
COMMENT	1 (bases 1 to 1201) Contact: Genoscope - Centre National de Séquençage BP 191 91006 EVRY cedex - France Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 6173.r Contact : Feng Liang Email : fliang@ifeitech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue Genoscope sequence ID : CS0DI058D08NP1.
FEATURES	Source 1..1201 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone="CS0DI058YJ16" /issue_type="PLACENTA COT 25-NORMALIZED" /clone_id="Homo sapiens PLACENTA COT 25-NORMALIZED" /note="3' last strand cDNA was primed with a Not I-oligo (dr) primer. Five prime end enriched, double-strand cDNA was

							/note="1st strand cDNA was primed with a NotI-oligo (dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and Eco R sites of the pCMVSPORT 6 vector. Library was normalized."
Db	501	AAUTTATCTCCATTTCGCTTGGACATCAGTTGATGTGATGATAAT	540				
Qy	481	GCCCATCTGAAAGGCCCTTGGACATCAGTTGATGTGATGATAAT	540				
Db	561	GCCCCATCTGAAAGGCCCTTGGACATCAGTTGATGTGATGATAAT	620				
Qy	541	TGGGATTAACCAAGCTTGTCAAATGGACACGATGTCATGCCGTCG	600				
Db	621	TGGGATTAACCAAGCTTGTCAAATGGACACGATGTCATGCCGTCG	680				
Qy	601	CAACGGCTGTGAAAGGGTAGAATGGACAGGGCTGGAAACTGCAAG	650				
Db	681	CAACGGCTGTGAAAGGGTAGAATGGACAGGGCTGGAAACTGCAAG	740				
Qy	661	GCGAAAGTGTGCTTGGACGGGATTTGTCCTTCAGCTTAATGGAAAT	720				
Db	741	GCGAAAGTGTGCTTGGACGGGATTTGTCCTTCAGCTTAATGGAAAT	800				
Qy	721	GACTGAGAAACAGGGAGAACAGCAGGAAGAACGACTGAGGGTTTG	780				
Db	801	GACTGAGAAACAGGGAGAACGACTGAGGGTTTG	860				
Qy	781	TTATATACCTTGTGATTGATTCACCAACACTTGTGGAAAGTCAAAC	840				
Db	861	TTATATACCTTGTGATTGATTCACCAACACTTGTGGAAAGTCAAAC	920				
Qy	841	TGCTTGATTTTTCTTGTGATTGATTCACCAACACTTGTGGAAAGTCAA	900				
Db	921	TGCTTGATTTTTCTTGTGATTGATTCACCAACACTTGTGGAAAGTCAA	979				
Qy	901	AAAGTCAGCCAAATAAGCTTTCTATTGTGACTTTTACTAATAAAAT	950				
Db	980	-ARKACGCCAAATAATC-TTCCATTGTGACTTTACTAATAAAAT	1027				
RESULT 1.3							
LOCUS	AL552032	1190 bp mRNA linear EST 31-MAY-2003					
DEFINITION	AL552032	Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA clone CSIRO06YL12 5'-PRIME, mRNA sequence.					
ACCESSION	AL552032						
VERSION	AL552032.2	GT:31273848					
KEYWORDS							
SOURCE	Homo sapiens (human)						
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.						
REFERENCE	Li, W.B., Gruber, C., Jesse, J. and Polayes, D.						
AUTHORS							
TITLE	Full-length cDNA libraries and normalization						
JOURNAL	Unpublished (2001)						
COMMENT	On Feb 15, 2001 this sequence version replaced gi:12890542.						
	Contact: Genoscope						
	Genoscope - Centre National de Sequecage						
	BP 191 91006 EVRY Cedex - France						
	Email: www.genoscope.cnrs.fr						
	Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 6242.f. For more information about this Cluster, see http://www.genoscope.cnrs.fr/cgi-bin/cluster.cgi?seq=CS0D1060DF06QP1&cluster=6242.f .						
	Feng Liang Email : filiang@lifetech.com URL : http://fulllength.invitrogen.com/ InvitroGen Corporation 1600 Faraday Avenue Genoscope Sequence ID : CS0D1060DF06QP1.						
FEATURES	Location/Qualifiers						
source	1..1190						
	/organism="Homo sapiens"						
	/mol_type="mRNA"						
	/db_xref="taxon:9606"						
	/clone_id="CS0D1060Y12"						
	/issue_type="PLACENTA COT 25-NORMALIZED"						
	/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"						
	950 GTCTTTCCTATTTGACTTTACTAAWAAAATCTGCTSTAATAW-----CTGGAA 1003						

Qy	977	TCTTTPACTGGAACAGGACTCTCTTTACCAACATTTAACCTTAACTTGACTTTCAAGA	1036	1002	TTTTTACCATAGTTAACTTGACTTTCAAGAATTTCAGGTTTGTGTTGTT	1061	
Db	1004	GTCYTAACCTGACMCGCCTCTT	:-----CAGCATAGTTAACGTTCA-----	689	TTTTTACCATAGTTAACTTGACTTTCAAGAATTTCAGGTTTGTGTTGTT	630	
Db	1037	TAATTTTCAAGGTTTTGTTGTTG-TTGTGTTGTTGTTGTTGAGGG	1094	1062	TGTTTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT	1121	
Qy	1056	-AWATTCAGSKTTGCGTGTGTTGKGTGTTGCGGAGGG	1114	629	TGTTTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT	570	
Db	1095	GAGGGATGCTCGGAAGTGGTTAACACTTTAACGTTAACGTTACTT	1139	1122	TTTTTCAAGTCACTTAACAAACTTGTAAATAGACCTTACCTTCACTT	1181	
Qy	1115	ARTGGTAAMTTTCARTMTMMAAAACCTTGTAAWRCCTMCTT	1159	569	TTTTTCAAGTCACTTAACAAACTTGTAAATAGACCTTACCTTCACTT	510	
Db	RESULT 14			Qy	1182	AGTTTCATTATATTGCACTGTAAGCAGCTCACAAAGAGTCACCTTGTGAA	1241
LOCUS	AL576084/C	AL576084 Homo sapiens mRNA	1201 bp	Db	509	AGTTTCATTATATTGCACTGTAAGCAGCTCACAAAGAGTCACCTTGTGAA	450
DEFINITION		AL576084 Homo sapiens PLACENTA COT 25-NORMALIZED		Qy	1242	CTTTTGCACTGACTGTATTATCTGGTATCTGGTCTGACTCTCATGTAACGGGA	1301
ACCESSION	AL576084	CSOD101YY103	3-PRIME, mRNA sequence.	Db	449	CTTTTGCACTGACTGTATTATCTGGTATCTGGTCTGACTCTCATGTAACGGGA	390
VERSION	AL576084.2	GI:31314380		Qy	1302	TCTAAATGCCCTGGGGTTTCACAAAAGAGAATTTCATGACTGTGATCTG	1361
KEYWORDS	EST.			Db	389	TCTAAATGCCCTGGGGTTTCACAAAAGAGAATTTCATGACTGTGATCTG	330
SOURCE	Homo sapiens (human)			Qy	1362	ATGCAATGCTACTCATCTTCAAGCATACTCCCTAAGGACTATGAACTAATAG	1421
ORGANISM	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			Db	329	ATGAAATGATCTGACAAACTGCAACTGCACTTACTCTAAAGCTAACTATG	270
	Mammalia; Butheria; Primates;			Qy	1422	TCTTGTCCTGTTGCTTACTCATCTTCAAGCATACTCCCTAAGGACTATGAACTAATAG	210
REFERENCE	BP 191 9106 EVRY cedex - France			Db	269	TCTTGTCCTGTTGCTTACTCATCTTCAAGCATACTCCCTAAGGACTATGAACTAATAG	1541
AUTHORS	Li W.B., Gruber, C., Jesse, J. and Polayes, D.			Qy	1482	GGCACTGCAATAAGAAATTTTAAACCCAGCCCTCCCTGATTGATAATAT	1541
TITLE	Full-length cDNA libraries and normalization			Db	209	GGCACTGCAATAAGAAATTTTAAACCCAGCCCTCCCTGATTGATAATAT	150
JOURNAL	Unpublished (2001)			Qy	1542	ACACATTGTCAAGTTTCCGGTCGTTGCTGAGAACAGCTTGTGAGTCATGTCGTC	1601
COMMENT	On Feb 16, 2001 this sequence version replaced gi:12937876.			Db	149	ACACATTGTCAAGTTTCCGGTCGTTGCTGAGAACAGCTTGTGAGTCATGTCGTC	90
	Contact: Genoscope			Qy	1602	AGCTTGAACTAGGGCTCTGGGTGCTCTCTGAAAGCTPAACCAATTATGGA	1661
	Genoscope - Centre National de Sequenage			Db	89	AGCTTGAACTAGGGCTCTGGGTGCTCTCTGAAAGCTPAACCAATTATGGA	30
	BP 191 9106 EVRY cedex - France			Qy	1662	TAACTGGCTTTCTCTTC	1679
	Email: secref@genoscope.cns.fr			Db	29	TAACTGGCTTTCTCTTC	12
	Web : www.genoscope.cns.fr						
	Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 6173.r						
	Contact: Feng Liang Email: fliang@litech.com URL :						
	http://fulllength.invitrogen.com/ Invitrogen Corporation 1600						
	Paraday Avenue Genoscope sequence ID : CSOD1071BB04NP1.						
FEATURES	Location/Qualifiers						
source	1..1201	/organism="Homo sapiens"					
/mol_type="mRNA"		/db_xref="taxon:9606"					
/clone="CSOD1071YY106"		/tissue_type="PLACENTA COT 25-NORMALIZED"					
/clone_id="Homo sapiens PLACENTA COT 25-NORMALIZED"		/note="1st strand cDNA was primed with a 5'Nci-oligo (dT) primer. Five prime end enriched double-strand cDNA was digested with Not I and cloned into the Not I and Eco R V sites of the pCMVSPORT 6 vector. Library was normalized."					
ORIGIN		RESULT 15					
Query Match	Score 884; DB 9; Length 1201;	LOCUS AL540345	953 bp	mRNA	linear	EST 12-MAY-2003	
Best Local Similarity 97.9%; Conservative Matches 899;	Prcd: No. 1, 7e-157; Mismatches 14; Indels 1; Gaps 1;	DEFINITION AL540345	Homo sapiens PLACENTA	Homo sapiens	Chordata; Craniata; Vertebrata; Euteleostomi;		
Db		ACCESSION AL540345.2	5'-PRIME,		Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
		VERSION AL540345	5-PRIME,		Mammalia; Buteraria; Primates; Catarrhini; Hominidae; Homo		
		KEYWORDS EST.	SEQUENCE				
		ORGANISM Homo sapiens	EST.				
		REFERENCE Li, W.B., Gruber, C., Jesse, J. and Polayes, D.					
		AUTHORS					
		TITLE					
		JOURNAL					
		COMMENT					
		Contact: Genoscope					
		Genoscope - Centre National de Sequenage					
		BP 191 9106 EVRY cedex - France					
		Email: secref@genoscope.cns.fr					
		Web : www.genoscope.cns.fr					
		Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 6173.r					
		Contact: Genoscope					
		Genoscope - Centre National de Sequenage					
		BP 191 9106 EVRY cedex - France					
		Email: secref@genoscope.cns.fr					
		Web : www.genoscope.cns.fr					
		Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 6173.r					

Contact : Feng Liang Email : fliang@lifetech.com URL :
<http://fulllength.invitrogen.com/> Invitrogen Corporation 1600
 Parady Avenue Genoscope Sequence ID : CSODE001A9QPI.

FEATURES
source

1..953

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="9065"

/clone="CSODE001C017"

/tissue_type="PLACENTA"

/clone.Lib="Homo sapiens PLACENTA"
 note="Vector: PCMVSPORT 6; 1st strand cDNA was primed
 with NtI-Oligo(dT) Primer. Five prime end enriched,
 double-strand cDNA was digested with Not I and cloned into
 the Not I and EcoRV sites of the PCMVSPORT 6 vector.
 Library was not normalized."

ORIGIN

QY	785	TACCTTGTTGATTGCCAACTGGAGATCAAACCTGGAGAAAAACTTGTG	844
Db	844	TACCTTGTTGATTGCCAACTGGAGATCAAACCTGGAGAAAAACTTGTG	903
QY	845	TGATTTTTCTCTGTTAACGTAATAAGAGACATTAAAGCACA	894
Db	904	TGATTTTTCTCTGTTAACGTAATAAGCACA	953
		Search completed: April 20, 2004, 07:15:07	
		Job time : 4587 secs	
Query Match	50 3%	Score 869 2; DB 9; Length 953;	
Best Local Similarity	98.5%	Pred. No. 1..1e-154; Indels 1; Gaps 1;	
Matches	877; Conservative	8; Mismatches 4; Indels 1; Gaps 1;	
QY	5	CGGGTCCAGCCTCTGGCTGAGCTGAGCTGAGCTGAGCTGAGCCGGAGCGAGCCGGAGCGCGTC	64
Db	65	CGGATCCAGCCTCTGGCTGAGCTGAGCTGAGCTGAGCTGAGCCGGAGCGAGCCGGAGCGCGTC	124
QY	65	GCGGGGGCTCGGGGTGTGGGACCCCTGGGCCCTGGCTGAGCTGAGCTGAGCCGGAGCGAGCG	124
Db	125	GCGGGGGCTCGGGGTGTGGGACCCCTGGGCCCTGGCTGAGCTGAGCCGGAGCGAGCG	184
QY	125	CCTCTTGGGTTGGCT	184
Db	185	MTTCCTGGGTTGGCT	244
QY	185	GCGAGCTGTAAGGCCAGAGATTGAGATGAGATGAGATGAGATGAGATGAGATGAGATGAGCT	244
Db	245	GCGAGCTGTAAGGCCAGAGATTGAGATGAGATGAGATGAGATGAGATGAGATGAGATGAGCT	303
QY	245	CCCTATAAGAAAATTCTGGCAATTATAATAGACATACTCAGAAAGATTGCTATGCTGCT	304
Db	304	CYWATAAGAAAATTCTGGCAATTATAATAGACATACTCAGAAAGATTGCTATGCTGCT	363
QY	305	TGCCCTCATGTTGGGGCCATGCCTGCTGCGGGGGCCCTGATCTAGAACGACATCTGCTA	364
Db	364	TGCHPTCATGTTGGCTGAGCCATGCCTGCGGGGCTGATCTAGAACGACATCTGCTA	423
QY	365	CGCTGTCATGCCATTAGGAAAGACTCTCTCACATCACGTTAACCTTATT	424
Db	424	CGCTGTCATGCCATTAGGAAAGACTCTCTCACATCACGTTAACCTTATT	483
QY	425	TATCTCTCATTTGGCCCTCTACTCTGTTACATGGTATCTTACTCTGTTGAGCC	484
Db	484	TATCTCTCATTTGGCCCTCTACTCTGTTACATGGTATCTTACTCTGTTGAGCC	543
QY	485	ATACTGAAGGGCGCTTGGCATGACAGTGTATAGAGTATGATGATATGG	544
Db	544	ATACTGAAGGGCGCTTGGCATGACAGTGTATAGAGTATGATGATATGG	603
QY	545	GATCACAGCCCTTTCGAAATGACAGATGCTGCCAGCTCCGAGTCAGCCAC	604
Db	604	GATCACAGCTTTCGAAATGACAGATGCTGCCAGCTCCGAGTCAGCCAC	663
QY	605	GTGCTGAAACAGGTAGATAATGACAGACAGCTGAGCTTCAAGTCAGTCAGCG	664
Db	664	GTGCTGAAACAGGTAGATAATGACAGACAGCTGAGCTTCAAGTCAGTCAGCG	723
QY	665	AAGTCCTCTTGTACGGCATGTTCTCAGTAATTGGAAATTGAAATTCAAGGTGCT	724
Db	724	AAGTCCTCTTGTACGGCATGTTCTCAGTAATTGGAAATTGAAATTCAAGGTGCT	783
QY	725	AGAAAGAACAGGACACACTGGAAAGACTGACTGCTGTTCTGGTTTCAATTAA	784
Db	784	AGAAAGAACAGGACACACTGGAAAGACTGACTGCTGTTCTGGTTTCAATTAA	843